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1 
Introduction 
1.1 Cancer and economic evaluation 
Cancer is an important cause of illness and death, accounting for a high percentage of 
mortality in Western countries. In the Netherlands, about 30% of all deaths is due to 
cancel' and the prevalence, an indicator of the present burden of illness to society, is 
clearly rising (Coebergh, 1991). In the last decades cancer treatment has shown a rapid 
evolution. It is now a multidisciplinary treatment strategy incorporating surgery, radio-
therapy, chemotherapy and immunotherapy. The high incidence and prevalence of cancer 
make this disease a major economic issue. The direct medical costs are considerable and 
are still rising due to the increased use of expensive dlUgs, radiotherapy equipment, the 
growing attention to various kinds of palliative interventions and survival success. In the 
Netherlands, the total direct medical costs of malignant cancer amounted to 1052 million 
dollars in 1988, that is 4.8% of total health care costs. About 60% of this expenditure 
was produced by inpatient hospital care, about 30% by outpatient hospital care and about 
10% by non-hospital care (Koopmanschap et al., 1994). It is expected that in 2020, as a 
result of ageing, these costs will have increased much more rapidly than total health care 
costs. Finally, the high prevalence of morbidity, mortality and the consequent loss in 
production also cause high indirect costs. 
As health care budgets have grown, an increasing emphasis is being placed on identifying 
and improving value for money. Therefore, efficacy can no longer be the only criterion 
that determines whether or not a technology should be used in caring for patients in 
general and cancer patients in specific. This is tlUe at the level of public health policy as 
well as at the level of clinical practice. For example the Health Insurance Executive 
Board has concluded that cost-effectiveness should be taken into account when approving 
insurance coverage for new treatment modalities. Practising oncologists, faced with 
pressures to control health care costs, are increasingly being asked to incorporate 
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considerations of cost into their decisions regarding the care they provide to their patients. 
Note that although economic evaluations could provide important information to decision-
makers, it addresses only one dimension of health care programme decisions. Economic 
evaluation is most useful and appropriate when preceded by evaluation of the efficacy and 
effectiveness (Drummond, 19871). 
The first part of this thesis deals with methodological and practical issues of economic 
evaluation in general and in cancer treatment in specific. As cancer treatment may have 
important side effects, not only life years gained, but also the quality of the life years 
gained are at issue. Because of this trade-off between the adverse effects of treatment 
against the adverse effects of the disease itself, quality of life measurement deserves 
special attention in economic evaluations of cancer treatment. 
1.2 Cancer and new treatment modalities 
During the last few decades, patients with cancer can benefit from new therapeutic 
approaches, including autologous bone marrow transplantation (ABMT), the administra-
tion of haematopoietic growth factors (HOFs) and peripheral blood progenitor cell 
(PBPC) transplantation. Stem cell transplantation (SCT), both ABMT and PBPC trans-
plantation alike, has significantly improved remission rates and survival in the treatment 
of malignant lymphomas and acute leukaemias. However, the costs of SCT are high and 
the additional burden that it places on hospital budget raises concerns (Dufoir et al., 
1992; Welch and Larson, 1989). 
Transplantations with stem cells derived either from bone marrow or from peripheral 
blood, are performed to hasten neutrophil recovery. PBPC transplantation is increasingly 
used in the treatment of malignancies to alleviate bone marrow toxicity resulting from 
high-dose chemotherapy. It is introduced as an alternative to ABMT, in patients with 
haematological- and oncological malignancies. Although SCT could improve treatment 
outcome, the treatment associated risk of fatal complications is high and the patients' 
morbidity can be serious due to pancytopenia. HGFs make it possible to accelerate 
haematopoietic recovery after an SCT and thereby reduce the therapy-related toxicity. 
Several HOFs have been cloned, such as granulocyte colony-stimulating factor (O-CSF) 
and granulocyte-macrophage colony-stimulating factor (OM-CSF). However, patients 
receiving HGFs still had a median duration of severe neutropenia for two weeks and had 
more than three weeks of thrombocytopenia (Nemunaitis et al., 1991). 
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The second part of this thesis deals with the costs of SCT, including ABMT, ABMT with 
HGF and PBPC transplantation. The results are based on retrospective studies of detailed 
patient records. The first cost study focuses on ABMT in the treatment of patients with 
malignant lymphoma and acute leukaemia. In the Netherlands, little is known about the 
cost of ABMT. This kind of information is important for the reimbursement policy. This 
study aims at calculating the average costs of ABMT in the Netherlands. The costs of 
ABMT in relation to PBPC transplantation are compared in the second study. The patients 
received ABMT without the colony stimulating factor G-CSF (filgrastim), ABMT with G-
CSF or PBPC transplantation mobilised by G-CSF. The patient popUlation consisted of 
solid tumour patients and patients with malignant lymphomas. The last cost study focuses 
on the costs associated with the treatment of patients with multiple myeloma. The 
treatment modalities are high-dose melphalan with and without G-CSF on the one hand 
and G-CSF mobilised PBPC transplantation following high-dose melphalan on the other 
hand. 
Furthermore, three prospective economic evaluations concerning ABMT and HGFs have 
been carried out. These studies are cost-effectiveness analyses and include a quality of life 
measurement. The first study addresses the question whether patients with non-Hodgkin's 
lymphoma who show only partial response to initial chemotherapy will benefit from early 
high-dose chemo-radiotherapy and ABMT. The aim of this study is to assess the effecti-
veness, quality of life and cost implications of autologous bone marrow transplantation 
(ABMT) versus standard chemotherapy. 
The second study concerned the treatment of patients with acute myeloid leukaemia 
(AML). AML is mainly seen in elderly patients. The generally reduced tolerance of older 
patients to the toxicity of chemotherapy and the increased preleukaemic conditions may 
require special treatment strategies for AML in the elderly. Only few studies especially 
dealt with therapy development of AML in elderly patients. The advent of HGFs which 
on the one hand may improve the response and on the other shorten hand the neutrophil 
regeneration after chemotherapy might be especially important in improving the outcome 
of the older category of AML patients. The aim of this analysis was to compare the costs 
and effectiveness of GM-CSF (molgramostim) as an adjunct to intensive remission 
induction chemotherapy. Specific attention has been given to both the short- and long-
term quality of life of the patients. 
The third study focuses on patients with chemotherapy-related fever and neutropenia. 
Neutropenia is a frequent and serious complication of cancer chemotherapy. When 
neutropenia is complicated by fever, infection is usually assumed to be present. So, 
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neutropenic fever represents an indication for empiric antibiotic therapy, requmng 
additional health care resources. HGFs reflect a new and effective means of treating 
chemotherapy patients to prevent fever and neutropenia. The use of HGFs may reduce the 
duration andlor severity of neutropenia. Also, the administration of HGFs may lead to 
significant cost savings, by reducing the stay in hospital, and may improve quality of life. 
As resources are limited, the implementation of ABMT and HGFs in clinical practice may 
have major macro- and microeconomic consequences. Concerning ABMT, the 
macroeconomic consequences of introducing ABMT in terms of the additional resources 
required to finance ABMT for patients with non-Hodgkin's lymphoma (NHL) and AML 
are studied. 
The final paper describes the implementation of HGFs in the daily hospital practice by 
means of a hospital economic model. The economic model deals with all relevant direct 
costs and savings in relation to chemotherapy-induced fever and neutropenia. In this 
model, a distinction is made between patients receiving intensive and standard chemo-
therapy schedules. The latter is subdivided in prophylactic administrations and administra-
tions in patients with chemotherapy-induced fever and neutropenia. By means of a 
literature review, default values have been estimated for a number of cases. Furthermore, 
sensitivity analyses have been carried out and a Markov model is specified. 
1.3 COlllellls 
Part I deals with methodological and practical issues concerning economic evaluation of 
cancer treatments. Chapter 2 briefly discusses basic methods of economic evaluation, the 
way of measuring and valuing effectiveness and resources. Also, the current practice of 
economic evaluation is described by reviewing screening and lung cancer. Chapter 3 also 
concerns methodological and practical aspects, but it focllses on economic evaluation 
alongside cancer trials. Chapter 4 describes how to measure and value quality of life in 
economic evaluation. 
In part II, the results of several costs analyses are presented. Chapter 5 considers the 
costs of ABMT in lymphoma and acute leukaemia patients. It is the first study concerning 
the costs of ABMT in the Netherlands. An alternative to ABMT is PBPC transplantation. 
In Chapter 6, ABMT is compared with PBPC transplantation in patients with 
haematological as well as oncological malignancies. Furthermore, PBPC transplantation in 
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combination with high-dose chemotherapy may be a treatment alternative to high-dose 
chemotherapy alone. Chapter 7 considers SCT in patients with multiple myeloma. 
Part III presents the results of tlu'ee cost-effectiveness studies. The first study concerns 
patients with NHL, who had a partial response and NHL free bone marrow after tlu'ee 
cycles with conventional chemotherapy (Chapter 8). The patients received either ABMT 
or CHOP chemotherapy. The other two studies deal with the haematopoietic growth 
factor GM-CSF. Chapter 9 describes the results of a study comparing the costs and 
effects of GM-CSF as an adjunct to intensive chemotherapy in elderly patients with AML. 
Chapter 10 deals with the administration of GM-CSF in patients with chemotherapy-
related fever and neutropenia. 
Part IV considers the implementation of ABMT and HGFs in the clinical practice. 
Chapter 11 describes the costs of introducing ABMTs in the Netherlands from a 
macroeconomic perspective. In Chapter 12 the cost consequences of introducing HGFs in 
the daily hospital practice are described by means of a hospital economic model. 
Chapter 13 concludes with a discussion and with recommendations for further research. 
Chapter 14 and 15 summarises the previous parts in English and Dutch, respectively. The 
appendix presents the meaning of abbreviations, bibliographic references, quality of life 
questionnaires and unit prices. 
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Part I 
Methodological and practical issues 

2 
Cost-effectiveness in cancer care 
2.1 llllrodllclioll 
The aim of this chapter is to examine the need for economic evaluation of cancer care and 
to stress the importance that any such evaluation is carried out in a rigorous and effective 
manner. As pressures on health care budgets have grown worldwide, an increasing 
emphasis is being placed on identifying and improving value for money: that is, maximi-
sing the health gain from resources committed to health care by concentrating on 
interventions of proven effectiveness and cost-effectiveness. 
To date, the cost-effectiveness literature across all areas of health care remains fairly 
small, despite strong growth in recent years: between 1960 and 1992 a total of 636 
economic evaluations combining cost and outcome data were published, or less than two a 
month (Backhouse el 01., 1992). Another survey identified an annual average of 247 
studies containing some fonn of evaluation between 1979 and 1990 (Elixhauser el 01., 
1993). The quality of these studies is known to be highly variable. Although more studies 
have been published with timc, this has only kept pace with the increasing number of 
clinical trials. 
This chapter will briefly discuss basic methods of economic evaluation. This will be 
followed by a section discussing current methods of mcasuring and valuing the effective-
ness of care. Measuring and valuing of resources is covered in the next section. Current 
practice of economic evaluation is covered in a section which reviews the gcneral 
situation in medicine and then discusses two areas of cancer care - lung cancer and 
screening. The penultimate section discusses the use of results of economic evaluations. 
The final part consists of a serics of reconmlendations applicable to a wide variety of 
individuals involved in all aspects of cancer care. 
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2,2, Methods of economic evaluation 
This section briefly introduces concepts and techniques used in economic evaluation, For 
in depth discussion readers are referred to the following references: Department of 
Health, 1992; DlUmmond et ai" 19871 and 1987II; Luce and Elixhauer, 1990, 
2,2,1 Techniques of analysis 
Economics offers a range of techniques for the evaluation of health care activities, Each 
has its place, but it is imp0l1ant to ensure that the appropriate method is being used in 
any particular context. 
Cost-minimisation analysis (CMA): The least complicated approach to economic evaluati-
on is to judge between alternatives on the basis of minimum cost. In doing this it is 
essential to establish a priori that the treatment options being compared are identical in 
their effectiveness and risk of complications and side-effects, i.e, that resource cost is the 
only significant difference between the options, Good examples of such studies can be 
found in the literature (e,g, Lawson et ai" 1981) on long-term domiciliary oxygen 
therapy, but the approach is likely to have limited applicability in the cancer field because 
of the variable impact of treatments on patient survival and quality of life, 
Nevertheless, this approach can be useful for comparing different treatment techniques 
with similar patient outcome. In radiotherapy treatment for instance, one can choose 
between off-line or on-line in vivo dosimetry and portal imaging techniques, For each of 
them, a choice can be made on the basis of cost information (Kesteloot et ai" 19931 and 
1993II), since the patient outcomes are very similar with both techniques, For another 
quality assurance technique, the use of fixation masks, no difference in patient outcome 
(i.e, reproducibility of the patient set-up) could be detected, implying that the choice 
between PVC (plastic) and thermoplastic (Orfit) masks can be based on cost data (Weltens 
et ai" 1993), 
Cost-effectiveness analysis (CEA): This is the commonest approach to economic evaluati-
on in health care, enabling the comparison of alternatives with both differing cost and 
differing effectiveness: the latter being measured in natural units such as life years saved 
(e,g, Ludbrooke (1981) compared treatments for renal failure in this way), New medical 
treatments may be more effective and are often more costly and their impact can be 
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clearly expressed using the cost-effectiveness ratio, i.e. the extra cost of each extra life 
year gained by switching to the new treatment. 
C, - C, 
" CE 
E, - E, 
where I is the new 
treatment and 2 is 
the current treatment 
Cost-effectiveness is a relative concept, the ratio must always be calculated in the context 
of a comparison with existing or potentially competing treatments. Thus, new treatments 
for teratoma will concentrate on potential further improvement in survival over existing 
chemotherapy, whereas in advanced non-small cell lung cancer improved palliation will 
be sought. 
Cost-utility analysis (CUA): The limitation of CEA is that it requires a single measure of 
effectiveness by which to compare procedures. Often treatments will have a range of 
outcomes and these outcomes will be valued differently by different patient groups. 
Recent developments in economic evaluation have attempted to measure multi-dimensional 
outcomes and to incorporate preferences in the assessment of the effectiveness of health 
care. Thus, an attempt is made to measure the effect of health care on the lives of 
patients (in economic terms its utility to them), rather than just its impact on clinical 
variables. For example, to judge the success of chemotherapy in terms of tumour control 
may miss thc aspects of the treatment which have most impact on patients. The most 
common utility measure used is the quality adjusted life year (QALY), which combines 
the benefits of survival and quality of life during the survival period. The results of CVA 
are also presented in ratio form as the cost per QAL Y gained from the adoption or 
expansion of a health care programme. As well as being a beller measure of effective-
ness, CVA also enables comparisons to be made between progranmles for different 
patient groups as the utility measures are not disease specific. 
Cost-benefit analysis (CBA): The three approaches to economic evaluation described 
above are designed to answer specific questions regarding the choice between competing 
health care interventions when a decision has already been made to do something. CEA 
and CVA can therefore be useful in allocating limited budgets between competing 
services. They do not address the more fundamental question of whether some health care 
activities are worth doing at all. The economic technique designed to deal with such 
questions is CBA. This differs from CEA and CVA in that it calculates the benefits in 
monetary terms as well as the costs. Thus, if some of the benefits are not directly 
purchased by people as consumers (as in the majority of health care), then proxy 
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measures of monetaIY benefits must be calculated. The danger with using this approach is 
that items which are too difficult or too controversial to apply monetalY values may be 
ignored, although they are important. The advantage of CBA is that it provides a measure 
of the rate of return to investment in health care which can be compared with the rates of 
return from other public and also private investments. 
Early CBA studies in health care were often limited to those factors most easily quantified 
and used poor proxies for the value of improved survival and length of life. More 
recently renewed interest in CBA in health care has been generated by the successful use 
of the teclmique in other areas such as environmental economics. The monetary value of 
health benefits can be estimated by measuring the patients' willingness-to-pay through 
questionnaire surveys (Johanssen and Jonsson, 1991). This approach is the subject of 
much debate amongst economists and is unlikely to become routinely applied in the near 
future (Hutton, 1992). 
2.2.2 Studies of economic analysis 
Whatever the method of economic evaluation chosen, the analysis must follow the same 
framework. The basic stages are: 
a. problem definition; 
b. identification of options; 
c. identification of relevant costs and outcomes; 
d. measurement of costs and effectiveness of each option; 
e. allowance for differential timing of costs and benefits; 
f. assessment of risk and uncertainty; 
g. presentation of results. 
a. Problem definition,' This is a crucial stage as it dictates the subsequent conduct of the 
analysis. A key factor is to determine the perspective from which the analysis is being 
conducted. This governs which costs and outcomes are considered. For example, if the 
perspective of the health service is taken then costs falling on other government agencies, 
such as social services, and patients may be ignored. An analysis carried out from the 
perspective of society as a whole would include these costs. The scope of the problem 
will determine the economic evaluation technique to be used. Thus, selecting the most 
appropriate imaging technique to make a given diagnosis may require CEA and the choice 
between chemotherapy or surgery in the treatment of cancer requires CVA. 
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b. Identification oj options: An economic study will only be valid if comparison is made 
between a new procedure and the best available alternative. In the case of new therapies 
where no effective treatment currently exists, the assessment of costs and outcomes must 
be made against current patterns of care, however ineffective. 
c. Idelllification oj costs and all/comes: The relevant costs and outcome measures will be 
influenced by the study perspective, the economic method and the health care procedure 
under analysis. 
d. Measllremelll oj costs and effectiveness: Good evidence of clinical effectiveness (or 
lack of it) is essential for stages of economic analysis. This should come from a control-
led clinical trial if possible. Prospectively collected cost data is also preferable, but 
caution should be taken in using cost data from clinical trials, as the care given is dictated 
by the trial protocol and may not match subsequent care delivered in routine situations. 
e. Allowance Jor diJferelllial timing oj costs and olltcomes: When comparing alternative 
health care programmes the pattern of costs and benefits may differ significantly between 
options under review. For example, health promotion and preventive health care program-
mes incur immediate costs, but the main health benefits will only be realised many years 
into the future. Acute surgical treatment has a high immediate cost, but, if successful, 
gives immediate benefits to the patient. Long-term maintenance drug therapy (e.g. for 
hypertension or peptic ulcer) may have a relatively low annual cost, but builds-up to a 
substantial amount over a lifetime. Simply adding total costs and benefits over time is not 
adequate because people have distinct preferences for delaying costs and bringing forward 
benefits, the flow through time matters as well as the absolute size of costs and benefits. 
To take into account this "time preference it in the economists' parlance, discounting of 
costs and benefits is necessary. In essence this process reflects the declining importance 
in individuals' decision making of outcomes occurring further and further into the future, 
by reducing their value (for analytical purposes) by a given percentage for each year 
ahead they are expected to occur. This produces estimates of costs and benefits valued at 
a single point in time, i.e. their present value. Thus, Illost decisions in lung cancer will 
not be discounted since their outcome occurs rapidly. In breast cancer discounting may be 
necessary for preventative or screening strategies, whilst it becomes less necessary the 
more advanced the disease. 
In the context of cancer the importance of the timing of benefit flows would be seen in an 
evaluation of strategies to reduce the loss of quantity and quality of life from, for 
example, lung cancer. Health promotion activities to reduce smoking by young people 
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could have a major impact, but the benefits would not be seen for many years. On the 
other hand marginal improvements in the effectiveness of radiotherapy could give small 
but immediate benefits. The complexity of such analyses is further complicated, since the 
data can be looked at from the standpoint of society as a whole or from that of the 
patient. 
f Assessmelll oj risk and uncertainty: In the absence of firm data it is often necessary to 
make assumptions in estimating the costs of health care. Clinical effectiveness data may 
also be subject to uncertainty. This must be explicitly recognised and tested using 
sensitivity analysis. This will identify the key variables and assumptions, which, if 
changed will alter the conclusions of the study. 
g. Presentation oj results: This should be done in a way which clearly shows whether the 
original problem defined has been solved. Where uncertainty has been shown to be 
present, ranges rather than point estimates should be presented. The results should be 
placed in their context, indicating the possibility of generalisation to other sellings. For 
those studies designed to help health service decision makers to allocate limited budgets 
the marginal costs and benefits should in particular be shown. 
2.2.3 Areas oj debate 
The above brief review of methods of economic evaluation and the framework within 
which such evaluations should be conducted is designed to give the reader an overall per-
spective on the process. Subsequent sections will discuss the development of methods in 
more detail. Needless to say while the above broad framework is generally accepted by 
economists there is intense debate on many specific points. 
For example, there are many different approaches to the measurement of quality of life 
and the utilities to be allached to different health states. This makes the interpretation of 
cost per QALY results very difficult (Gerard, 1992). Although economists lay great 
emphasis on the need for strong evidence of clinical effectiveness (though effectiveness 
may differ in the community selling) from randomised controlled trials they are ambiva-
lent about the desirability of collecting economic data in the same way (Dnmunond and 
Davies, 1991). Some economists also question the appropriateness of discounting health 
benefits (as opposed to costs) as time preference may not apply to non-monetary costs and 
benefits. Amongst those who agree that discounting of benefits should take place there is 
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debate as to whether the current Treasury recommended rate of 6 % is appropriate 
(Parsonage and Neuberger, 1992; Cairns, 1992). 
On the cost side the general view is that the main focus should be on direct costs of 
health care, rather than the indirect costs of illness to society through the loss of working 
days. This remains a much debated area and recent work has shown that even if lost 
working time is to be included as a cost, the value placed on it should be much lower 
than that used in earlier studies (Koopmanschap and Van Ineveld, 1992). 
Despite the healthy debate on these and other issues, methods of economic evaluation are 
sufficiently well established to provide an essential contribution to the debate on the 
development of health care services. This applies equally to cancer care as to other areas. 
Checklist: 
Problelll definition,' Clear definition of problem, statement of perspective of analysis and 
analytical technique, 
Options,' There must be a comparison of at least two options (including the status quo). 
Identification of costs and outcomes: All costs and outcomes relevant to the study 
perspective must be identified, 
Measurement of costs and outcomes: The best possible source of cost and outcome data should 
be used e,g, randomised controlled trials may provide this though it is important to note that 
they may vary from the costs in the community, 
Differential timing of cost alld benefit flows: Future costs and outcomes must be discounted at a 
rate appropriate to the study perspective, 
Uncertainty: The impact of this should be demonstrated through the use of sensitivity analysis, 
which analyses the impact of different cost and/or outcome estimates on the final results. 
Presentation of results,' These should show the marginal impact on cost and effectiveness of 
each option, 
15 
I Methodological and practical issues 
The above checklist serves as a guide to the key points for those assessing the quality of a 
completed evaluation or for those planning a new study. 
2.3. Measuring and evaluating outcome 
Although this section, for brevity, concerns itself solely with randomised clinical trials 
(RCTs), evidence of treatment outcome is often derived from other data. Whilst RCTs 
remain the "gold standard", where data from such trials is not available, useful informati-
on can be gleaned from non RCT sources. The same problems, noted below, of RCTs, of 
course, still apply and are sometimes amplified. It should be emphasised that, whenever 
possible, expensive new therapies should be assessed in RCTs large enough to provide a 
clear result. 
2.3.1 Data from current ReTs 
RCTs have become the "gold standard" by which medical care is evaluated (Sacks et al., 
1982). Despite many thousands of RCTs, many questions remain unanswered and 
apparently open. Even more damaging may have been the failure of the medical commu-
nity to identify therapies that do work and acceptance of treatments of little or no 
efficacy. Systematic reviews and consensus meetings based on such data will help to 
overcome the problem of RCTs which are too small to give a reliable answer. 
The basic reason for our failure to come up with clear answers to questions has been the 
small size of most RCTs. For example, an ongoing systematic review of all chemotherapy 
trials including a no chemotherapy control (published and unpublished) in non-small cell 
lung cancer has only found 70 such RCTs. These include about 10000 patients in all 
(non-small cell lung cancer overview Collaborators' conference, Cambridge, 24-26 
September 1993). Some trials had more than two arms, so that the mean number of 
patients per arm is about 100. During the time period of these trials several million 
people died of lung cancer - less than 1 % of patients with non-small cell lung cancer are 
entered into chemotherapy trials. 
It has taken cancer clinicians a long time to realise that large therapeutic gains are 
unlikely to be achieved by current therapies. Only now are large scale trials being 
contemplated. An alternative, currently available, is the tool of systematic review 
(overview or meta analysis). Such a systematic review may be based on an exhaustive 
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analysis of individual patient data from all published and unpublished RCTs. This 
approach is likely to be more accurate than such an exercise simply carried out on 
published data. Publication bias, patient exclusion, length of follow-up and rigour of the 
original analysis are all potential sources of error in a systematic review of published 
trials. Preliminary data from Stewart and Parmar (1993) suggests that such reviews may 
overestimate treatment effects when compared to individual patient data overviews. 
The utility of systematic review of individual patient data has been clearly demonstrated. 
Lau and his colleagues (1992) examined all of the RCTs for the therapy of myocardial 
infarction. These were looked at in a cumulative fashion, so that the evidence (or lack of 
it) for each treatment could be examined over time. As an example, they found 33 RCTs 
(36974 patients) of intravenous streptokinase carried out between 1959 and 1988. When 
examined in a cumulative fashion there was initial evidence of a favourable treatment 
effect after 8 trials (1973, 2432 patients, p=0.007) even though the majority of individual 
trials were negative. By 1977 the p-value was less than 0.001 (14 trials, 4314 patients). 
Despite these clinical trials continued to be published up to 1988, large scale trials (such 
as ISIS) are being demanded before clinicians would accept this approach. Similarly, the 
recent individual systematic review of early breast cancel' management has shown 
unexpected survival benefit for a therapy discarded two decades ago - oophorectomy in 
premenopausal women (Early Breast Cancel' Trialists' Collaborative Group, 1992). 
As well as providing data to answer questions, systematic reviews often show up the need 
for new large scale trials and it is to be hoped that genuinely large trials that provide 
answers and data with tight confidence intervals will be carried out. Systematic reviews 
are likely to be seen increasingly often and the Cochrane Collaboration will act as a 
coordinator stimulating, supporting and making data available from systematic reviews 
(Herxheimer, 1993). The Cochrane Collaboration is an international network which will 
provide databases of all past and ongoing RCTs as well as past and present systematic 
reviews. They will provide, on line, updated systematic reviews of individual questions. 
The activities will encompass the whole of medicine - a truly monumental task. 
When carrying out an economic evaluation it is essential that there is reliable data on 
efficacy. In the absence of a large definitive trial (the usual case) selection of specific 
trials or a cursory examination of the literature is likely to lead to a biased result. The 
difficulty of obtaining reliable data and avoiding bias is demonstrated by the finding that 
computerised searches of databases like MEDLINE only identify 50% of published RCTs 
found by hand searching the literature (Dickenson et al., 1985). 
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Additional problems with the current literature include the use of inappropriate controls 
(for instance trials of chemotherapy in non-small cell lung cancer comparing chemothera-
py regimes when the benefit of chemotherapy was unproved) and the failure to measure 
appropriate end points. Although survival is highly important, concentration on this has 
meant that there is little or no data on the outcome of therapy on symptom control or 
quality of life - even when treatment is entirely palliative. 
2.3.2 Measuring and valuing quality of life 
Cancer is an important cause of illness and accounts for a high percentage of crude 
mortality in Western countries. In the last decades cancer treatment has developed 
rapidly. It is now multidisciplinary, incorporating surgery, radiotherapy, chemotherapy 
and lor inununotherapy. Treatment may have major side effects, particularly radio- and 
chemotherapy. Consequently, patients and those involved in their care have wondered 
whether improved probability of survival, if it exists, outweigh the burden of these severe 
side effects in all cases. Therefore, not only life years gained, but also the quality of 
those years is an important issue. 
The usual objective of carrying out quality of life research is to gain insight into the 
reaction of patients to cancer and its treatment and the interrelations of these different 
reactions with the overall quality of life. Furthermore, data concerning the impact of a 
certain therapy on the quality of life may increase knowledge about the effectiveness of 
such therapy (De Haes and Knippenberg, 1985). 
Quality of life studies generally give a description of the health status. Depending on the 
type of study, they deal with more or less objective features of health. Most studies 
incorporate the physical and psychological aspects of life, sometimes complemented by 
the aspect of social functioning. From the economic perspective the objective of studying 
quality of life is to determine the contribution of changes in quality of life to a summary 
measure for the outcome of an intervention. When there is more than one effect parame-
ter (e.g. survival and health status improvement) or when outcome is measured in more 
dimensions of quality of life, a value judgement (e.g. utility weight) should be given to 
each of these parameters or quality of life dimensions in order to arrive at such a 
sununary measure. This makes it possible to make comparisons across different technol-
ogies and across different disease categories. The importance of different outcome 
parameters will depend on the disease type. Quality of life assumes greater importance in 
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advanced breast cancer, whereas survival is of paramount importance in malignant 
teratoma. 
Measurement instruments for description and valuation of quality of life: Descriptive 
insttUments can be divided into two main categories: the generic instlUments and disease-
specific questionnaires (Patrick and Deyo, 1989). Generic instmments are developed to 
measure all health dimensions. They can be used over a wide range of disease categories 
and are therefore suited to function as generally applicable descriptive instmments for 
measuring quality of life improvement in economic evaluation. In this respect they 
provide a reference for quantitative assessment of quality of life changes in economic 
evaluation and have been used in many economic appraisals. Generic instmments most 
frequently used are: the Nottingham Health Profile (NHP), the Sickness Impact Profile 
(SIP), the abbreviated RAND-Medical Outcome Study questionnaire (RAND-MOS 20) 
and the newly developed Short Form-36 (SF-36) (Uyl-de Groot et al., 1994III). 
Disease-specific instl1lments measure health problems specific for an illness or disease 
category. These instmments measure specific quality of life aspects typical of a particular 
disease, and are therefore more sensitive to changes in the health states of patients with 
that disease. Using cancer as an example, these instl1lments can be divided into cancer 
specific questionnaires (for all cancers) and specific cancer questionnaires (for one type of 
cancer). The following cancer specific instl1lments are often used: the Functional Living 
Index for Cancer (FLIC) , Spitzer QL index, European Organisation for Research and 
Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30), Cancer 
Rehabilitation Evaluation System-Short Form (CARES-SF) and the Rotterdam Symptom 
Checklist (RSCL). Examples of specific cancer instmments are: the breast Cancer 
Chemotherapy Questionnaire, the Performance Parameters for head and neck cancer and 
the Linear Analog Self-Assessment (LASA) of Voice Quality for laryngeal cancer (Uyl-de 
Groot et 01., 1994III). 
For the description of quality of life in economic evaluation, generic instl1lments suffice 
for overall comparison and testing, but the inclusion of specific instl1lments may be 
advisable, particularly for reasons of explanation if changes in dimensions are small or 
conflicting. By using generic instmments it is not always possible to gain insight into how 
changes in health have taken place. 
When strategies score differently on different dimensions and when one needs a summary 
measure of outcome comparable across a range of interventions, it is necessary to get 
valuation of health states in one single dimension representing an overall judgement of 
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quality of life of a health state. This then would allow the calculation of "quality adjusted 
life years" (QALYs), where a life year gained is "adjusted" using this value judgement 
for quality of life. To acquire valuations, respondents are requested to value health states. 
These states are derived from a set of health state descriptors. The values are usually 
ranging from 0 to 1 (0 = "worst imaginable health state", and 1 = "best imaginable 
health state"). By means of modelling techniques a multi attribute utility function may be 
derived to predict values of any composition of health states. Methods of acquiring 
valuations are: direct rating (e.g. determining a point on a line with clearly defined 
endpoints), standard gamble (choosing between options under uncertainty) and time 
trade-off (choosing between options with different durations of a particular health status) 
(Drummond et al., 1989; Torrance, 1987). 
Furthermore, there are different basic approaches to measuring the utility of health status. 
One approach is to find people with the particular health state and solicit their valuation 
of such health states in terms of a utility. Using such subjective utility assessments is most 
in line with welfare theory, Another approach is to describe the condition, usually by an 
abbreviated written scenario, to people who do not have the condition and ask them to 
make the appropriate valuation (Drununond et al., 1989). These people are thought to 
represent public opinion. Other approaches include for instance the patients family or 
health professionals opinions. 
Which approach is preferable, depends on the viewpoint of the study. When a study is 
conducted from the societal viewpoint and is pertinent to public policy decision making, 
the appropriate utilities are those of the general public. If a fixed set of utility values is 
available and if a generic instrument is used to measure health outcomes in an economic 
evaluation, this adds to the comparability of results from economic evaluations and fits 
with the public sector context of decision making supported by results from an economic 
evaluation. The problem with soliciting value judgements from persons without relevant 
disease experience is that the person should truly understand what the described health 
state is like. For some of the generic health measurement instruments (e.g. the EuroQol) 
such a set of utility values is known allowing the calculation of QALYs gained when such 
a generic instrument is used to assess health outcomes. Available valuation instruments 
are EuroQol, the Quality of Well-being Scale (QWB-Scale), the McMaster Utility 
Measurement Questionnaire (MUMQ), the Torrance's Health State Classification System 
and the Rosser & Kind-index (Uyl-de Groot et al., 1994III). 
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Choice of measurement instrumellls: In clinical trials the choice of measurement instru-
ment depends on criteria such as psychometric features (internal consistency, reliability, 
validity, etc.), specific patient features, feasibility and on the possibility of gaining insight 
into the quality of life aspects of the disease itself and into the side-effects of treatment. 
Quality of life measurement in economic evaluation should allow comparison across 
different technologies and diseases. This requires the inclusion of a generic, a cancer 
specific measurement instrument and a valuation instrument. The precise combination of 
instruments depends on the required psychometric and specific patient features and on 
feasibility. (See Chapter 4, Table 4.1 for an overview). 
Interview schedule alld follow-up time: Ideally the data collected should describe quality 
of life of patients before, during and after treatment. The choice of time scale depends on 
the natural history of the disease and on the timing and pattern of treatment. During 
intensive treatment periods it may be important to have frequent measurement of quality 
of life, occasionally intervals of I or 2 days may be desirable (Fayers and Jones, 1983). 
If there is a survival benefit it is important to take into account quality of life during life 
years gained. In this respect, it is necessary to make a distinction between curative and 
palliative treatment modalities. In both modalities quality of life measurement is very 
important, but the outcome indicators differ. In palliative treatment modalities, quality of 
life is the single most important outcome indicator. For curative treatment modalities the 
most important indicator is the assessment of quality of life of life years gained, which is 
estimated by a separate observation of survival and quality of life. 
As economic evaluation generally requires lifelong follow-up, a modelling approach may 
be necessary to predict lifelong consequences. By specifying a simulation model or a 
MARKOV model defining various states characterised by heallh status and lor specific 
treatment (associated with a cost-profile) the follow-up period of the actual clinical trial 
may be reduced. It will be assumed that each state can be characterised by a unique 
quality of life. The following disease states may be distinguished: disease-free, partial 
remission, relapse (symptom free), relapse (symptoms) and terminal state. The measure-
ment and valuation of quality of life of patients in the terminal phase of cancer may be 
difficull, because these patients may be "off protocol" and difficull to approach. Accept-
able compliance rates require motivation of the patient, sophistication of the procedure 
and a permissive attitude towards the ideal interview schedule. 
It should be obvious from the above discussion that quality of life measurements are not 
easy to perform nor to interpret. Drummond (1991) e.g. includes a thorough discussion of 
the (dis)advantages of such measurements; e.g. the quality of life estimates can only be as 
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reliable as the underlying mortality and morbidity data, when different measurement 
methods may yield different results, and QALYs value quantity (life years) and quality of 
life in an identical way. Despite the methodological and practical difficulties of outcome 
measurement, such measures can clearly contribute to improved resource allocations 
decisions, if applied and interpreted correctly. 
2.4 Measuring and valuing resources 
2.4.1 Introduction 
The basic idea of economic evaluations is that resources are limited and have an alternati-
ve use. Resources used for a specific cancer treatment, e.g. radiation for breast cancer 
patients, could be used in other cancer treatments, in non-cancer treatments within the 
health care sector or even outside the health care sector. The true economic cost for a 
rcsource is the value this resource would have in its best alternative use, i.e. the opportu-
nity cost. The monetary cost is made up of two components: volume (quantity) times unit 
price (valuation). In most cases the market price of a resource is the relevant value in 
monetary terms, but in some cases the price does not correctly reflect the value of the 
alternative use; sometimes market prices do not even exist. However, a non-existing 
market price does not mean that the cost is zero; a "shadow price" which reflects the 
value of the resource in it's best alternative use has to be used. 
When valuing and reporting the costs it is useful to identify the quantity of the resources 
used, and the price separately, before reporting the cost (quantity times unit price). 
2.4.2 Types oj costs 
In identifying the relevant costs, it is useful to make a distinction between direct and 
indirect costs. Traditionally, direct costs are defined as the resources involved in the 
treatment of the disease. Typical direct medical costs include costs of staff time, drugs, 
equipment and buildings. However, usually more resources are associated with the 
treatment than pure medical costs controlled by the health care sector. Direct nonmedical 
costs such as the patient's travel costs, housekeeping costs, extra diet costs and extra costs 
for the patient's family are relevant costs that ideally should be incorporated. The 
importance of nonmedical costs varies between treatments and patient groups. For 
example, in cost comparisons between home care and hospital care for terminally ill 
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cancer patients it is important to include nonmedical costs. As home care requires 
participation of the patient's family in the treatment process, there are good reasons to 
assume that nonmedical costs to a larger extent are associated with home care. Indirect 
costs represent resources lost due to the treatment and illness. Traditionally, indirect costs 
are valued as the changes in the productivity of the patient in the labour market, i.e. the 
human capital approach. This means that the indirect costs are estimated as the value of 
the goods and services not produced due to cancer. However, there are good reasons to 
include changes in the productivity of leisure activities as well; otherwise time costs for 
patients who do not participate in the labour market, e.g. retired people, children and 
housewives, are estimated to be nil. By using the willingness to pay approach these time 
costs can be estimated, either by explicitly asking individuals how much money they are 
willing to spend for achieving a better productivity on leisure activities, or if possible, by 
deriving the value by observing their behaviour (revealed preferences). 
The indirect costs primarily stem from changes in the patient's health status. The patient's 
quality of life changes due to changes in labour productivity and leisure activities might, 
at least to some degree, reflect the effectiveness of the intervention measure. Hence, there 
is a risk that productivity changes will be included on the cost side as well as on the 
outcome side. In order to avoid double-counting indirect costs have to be handled with 
care. 
When presenting cost data it is useful to make a distinction between fixed and variable 
costs. Fixed costs do not change with the volume of the activity (e.g. the number of 
procedures and patients), while variable costs do. In identifying the costs per unit of 
activity (e.g. per patient), it is further necessary to distinguish average costs from 
marginal costs. The marginal cost refers to the extra cost of 'producing' (e.g. treating) 
one additional unit (e.g. patient). In situations where the fixed costs are all relatively high 
the marginal cost for an extra patient will be much heavier than the average cost per 
patient (e.g. in radiotherapy). 
2.4.3 Perspective alld scope of cOSlillg 
The costs so far have been classified from the type of resources. However, the classifica-
tion can be performed from the perspective of who pays. The perspective is important, 
because the costs for different actors might vary. In a traditional CBA which takes 
'society as a whole' as the viewpoint, all costs, direct as well as indirect, should be 
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included regardless of who pays and regardless of who benefits. From this viewpoint a 
treatment is "profitable" if the total benefits exceed the total costs. 
In order to correctly calculate the relevant costs of a health care intervention, the view-
point of the analysis should first be identified. However, other perspectives may be 
relevant. From the perspective of national health care system the objective is to allocate 
resources to achieve the maximum health benefit within the limits of resources available 
for the health care sector. Costs of resources other than those controlled by the health 
care system, are not included. From the hospital point of view only costs for resources 
paid by the hospital are relevant; the insurer only takes account of costs charged to him 
and from the patient's viewpoint only the costs for the patient are of interest. Which 
viewpoint is relevant, depends upon the aims of the study. Obviously, if the perspective is 
not clearly identified, cost data may be used in a misleading way. 
The fact that a cost is not paid by, for example, the hospital does not mean that the cost 
is zero. Too narrow a perspective might lead to suboptimal health care resource allocation 
decisions. 
However, the societal perspective is not without controversy either. In most countries the 
provision of health care is also guided by ideas of justice and equity which implies for 
example that priority setting must not be based on the patients socioeconomic status. 
However, the amount of indirect costs obviously depend on the status of the patient. This 
is hence an argument for excluding the indirect costs and taking into account only the 
costs paid by the national health care system, i.e. the perspective is limited only to one 
sector. These considerations underline the need for a systematic presentation of the data 
so that others can analyse the data in different ways. 
2.4.4 Tillie scale 
When calculating the costs of a health care intervention, it is important to take a suffi-
ciently long time span into account. Many cancer patients sooner or later relapse and will 
need further treatment. Ideally, the time span should be long enough to include the costs 
of all these therapies; preferably, the patients should be followed until death. Too short a 
time span can lead to doubtful or incorrect conclusions, since part of the relevant costs, 
on which conclusions should be based, would be omitted. Obviously, it is not always 
possible, nor feasible, to take such a long time span, but one should be aware of the 
possible erroneous conclusions, based on a short duration. 
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2.4.5 Collecting data 
Cost-effectiveness studies most frequently assemble information on the resource implicati-
ons of interventions by I. retrospectively using data from individual RCTs, literature 
surveys, or epidemiological data and clinical advice to derive probabilities attached to 
treatment pathways and events along them; 2. collecting descriptive resource data from 
previous costing studies or published unit cost averages, which enable these pathways and 
events to be costed; and 3. valuing the identified resource implications of each treatment 
path and associated probabilities. 
It is possible to collect economic data prospectively in a RCT, and to perform economic 
analysis alongside the clinical and epidemiological aspects of the trial. The potential 
benefits of doing so have been set out by Drummond and Stoddart (1984) and by 
Mugford and Drummond (1989). They argue prospective collection of cost information 
may be desirable if the resource consequences of the treatment gaining widespread 
acceptance are likely to be substantial; if diffusion is thought likely; or if resource 
constraints are likely to force decision makers into choices between alternatives. Using 
these three criteria, Mugford and Drummond found that almost one-half of 100 perinatal 
trials sampled should have, but did not incorporate, economic analysis. 
The main difference between retrospectively collected and prospectively collected data is 
that prospectively collected data offers better opportunities to examine variations in cost 
between patients, and therefore to report the distribution of cost data, thus allowing 
opportunities to examine the statistical significance of cost differences between patient 
groups. 
To ensure consistency and comparability of cost data between study settings, a number of 
steps should be taken: 
a. where possible, resource data should be presented in the form of volumes, such as 
in-patient days, number and length of consultations, or drugs consumed and prices 
separately. Summary measures such as drug-days (number of drugs x number of days on 
drugs) are more useful than no information. Where space does not allow presentation of 
such data, authors should still make clear that it is available. Such volume data facilitates 
comparison between practice settings. 
b. where these resources are valued, the basis of this should be made clear. In particular, 
it should be stated whether valuation is based on prices charged or on actual resource 
costs; if the perspective of the analysis is that of the health care financing institutions, 
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charges are relevant, but if the viewpoint of the hospital is taken, it is wrong to 'approxi-
mate' the cost of an intervention with charge data. In this situation, the actual costs of the 
resources used should be calculated; whether any consumption taxes such as value added 
tax are included or excluded; which year and currency the values are expressed in; and 
the basis for any adjustment in the reported year (for example, whether a consumer price 
index or some other form of index was used to inflate or deflate values). 
c. if resources are valued in a currency other than the currency of the territory in which 
the study was performed, or if the study covers more than one territory, the method used 
to translate valuations into other currencies (in particular, the date and basis such as 
exchange rate or GDP purchasing power parity) should be explicit. 
d. where cost-effectiveness ratios are being reported, the numerators and denominators as 
well as the ratios should be attached to the results. 
2.5 Review of cUITelll practice 
2.5.1 Economic evaluation - a general review 
Current concerns over exploding health care costs and scarce resources have led to a 
steady increase in studies wholly or partly containing economic evaluations. Elixhauser et 
al. (1993) counted a total of 88 CBAs and CEAs carried out in 1979. By 1990 the annual 
average was 247 with the overall 1979-1990 total being 1802 studies. This increase on the 
one hand has led to attempts at cataloguing economic studies in databases and on the 
other it attempts to develop methods of systematically reviewing a group of studies on the 
same subjects and of generalising their results. Backhouse et al. (1992) have published the 
content of their database, containing 1887 economic studies published between 1964 and 
mid-1992. A similar database has also been recently published by Elixhauser et al. (1993) 
for the period 1979-1990. Both pUblications provide a very useful starting point for any 
search of the economic literature as they incorporate SUbject and author indices. 
Such a plethora of available studies would on the surface indicate an adequate and reliable 
coverage of the main topics of medical practice. To assess such qualities, however, a 
systematic review of the topic is needed, but at present there are very few such reviews 
of economic evaluations. Those that exist all point to considerable gaps in the overall 
reliability of methodology used in available economic evaluations. 
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Gerard reviewed 51 eVAs carried out in 14 different countries and found source validity 
in only 41 % of the studies (Gerard, 1992). In the discussion of her study Gerard 
expressed doubts as to the methodological validity of aggregating results of eVAs in 
so-called QALY league-tables, a process which has the aim of indicating "best buy" 
procedures for clinicians and managers. Gerard's doubts are shared by Mason et al. 
(1993) and Drununond et al. (19931). 
This far from satisfactory picture is further confirmed by another study which carefully 
reviewed methods used in 77 economic analyses with different subjects (Vdvarhelyi et al., 
1992). The authors recommended that readers should be careful in interpreting results and 
should scrutinise methods used carefully. Such a suggestion however is unlikely to be 
ideal for busy clinicians with no training in health economics. 
Poor teclmical execution was also found by Adams et al. (1992) in the cmcial area of 
economic analysis nested within ReTs. Such a finding raises the real problem of the 
waste of scarce resources in ill-conceived and poorly executed economic evaluations and 
of a clear requirement to standardise international economic methodology (DmnmlOnd et 
al., 1993). Additionally, only 0.2% of ReTs contained economic analyses. lefferson and 
Demicheli reviewed 90 published and unpublished studies on the economics of introducing 
vaccination against Hepatitis B (Jefferson and Demicheli, 1994). They found that 92% 
recommended vaccination on economic grounds, but a sizeable minority (38%) showed 
major methodological inconsistencies. The authors also found very wide variations in 
basic variables used in the reviewed studies (for instance, the within-country incidence of 
Hepatitis B used to assess the economic burden of the disease in the same popUlation and 
the application of basic mles of economic evaluation). An example of the confusion on 
the subject is given in Table 2.1 where the spread of costs due to Hepatitis B is shown, 
converted in US Dollars and adjusted to 1993 values using the Retail Price Index. Such a 
large variation is unlikely to have been caused wholly by different patterns of resources 
used. 
The table also illustrates a possible way of attempting to pool results from different 
economic studies in order to reach a verdict on whether an intervention is economical or 
not. At present, efforts are being made to develop such a methodology further (Mugford 
et al., 1994). 
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Table 2.1. Cost per case due to Hepatitis B infection, sunmlary descriptive statistics. 
All costs are in US Dollars adjusted from year of publication to 1993 values 
using the US Retail Price Index (Jefferson and Demicheli, 1994). 
Type of cost 
Direct Indirect Indirect intangible 
Number of studies 36 20 II 
25th percentile 650 1843 14164 
Median 1793 3584 54272 
75th percentile 3768 12473 127592 
There is probably only one overview on the economics of cancer literature where an 
attempt has been made at generalising results of different studies (Brown and Fintor, 
1993). In this overview Brown and Fintor examined the cost-effectiveness of screening 
for breast cancer and used a computerised model to 'reconcile' differences in cost-effecti-
veness ratios from two studies. Encouragingly, they concluded that cost-effectiveness 
estimates for breast cancer screening reported by different studies are not as arbitrary as 
they seem. 
In sununary, although the science of systematic reviews of economic evaluations is in its 
infancy, the current methodological validity of international literature is open to question 
and readers should beware of uncritically accepting results from published works without 
prior scrutiny by a health economist. 
2.5.2 Review of studies specific to callcer 
As discussed above, there has been an increase in the number of studies on the cost-effec-
tiveness of cancer interventions; be they screening, treatment or prevention. This section 
provides a critical review of the methodological standards of a selected number of recent 
studies pertaining to a specific common disease area, namely cancer of the bronchus and 
a specific intervention type, namely screening. This part focuses on studies which include 
both elements of costs and of effectiveness. The purpose of this review is thus to 
highlight methodological inadequacies in these studies, using the checklist of guidelines 
discussed in Section 2.2.3 as a reference. They are selected examples of problems and the 
strengths of the studies have not been highlighted because of this. 
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a. Ecollomic evalualiolls of Irealmelll for IUllg callcer 
After a fairly detailed literature search only a few studies concerned with the treatment of 
lung cancers were identified. The majority of these studies pertained to chemotherapy 
treatment although one concerned the cost-effectiveness of radiotherapy treatment and two 
concerned the staging of lung cancer. The study methods and results are outlined in Table 
2.2. Whilst these studies have made a major contribution to the literature, there is a need 
for improved data. Since this chapter is critically examining the use of economic 
evaluation in cancer the rest of this section concentrates on the weaknesses of these 
studies. The major methodological failings of these studies are as follows . 
• The evidence of the effectiveness does not always appear appropriate. The preferred 
source of evidence of the effectiveness of interventions is results obtained from a large 
randomised clinical trial. Most of the selected studies obtained evidence of the effective-
ness of interventions from RCTs (e.g. laakkimainen el al., 1990; Goodwin el al., 1988). 
However, in other studies it is unclear from where evidence of the effectiveness of the 
alternatives evaluated was obtained (e.g. Rees, 1985). Even when data is from RCTs it is 
not clear whether this is representative of the literature . 
• Not all relevant costs of treatment are included in some studies thus questioning the 
reliability of study results. In an economic evaluation all the costs relating to treatment 
should be considered. What the relevant costs are depends on the perspective of the study. 
However, in the study by Dillman el al. (1990), both the costs of treating side-effects and 
of follow-up care are excluded. This may be of importance, as the treatment which was 
found to be cost-effective did involve greater hospitalisation due to side-effects. 
.. Certain studies did not include all relevant consequences, especially the effect of 
treatment on the quality of life of individuals. Quality of life is often inappropriately 
omitted from economic evaluations of cancer therapies e.g. in the study by Rees (1985) of 
the cost-effectiveness of various cancer therapies including palliative care for carcinoma 
of the bronchus, the benefit from treatment is measured solely by the prOlonging of life 
and the effect of treatment on the quality of a patient's life is disregarded. Similar 
concerns exist over other studies (e.g. Dillman el al., 1990 and laakkimainen el al., 
1990), as the omission of quality of life considerations questions the validity of study 
results. However, the study by Goodwin el al. (1988) does illustrate how the credible 
valuation of the quality of life of patients can be incorporated within a study. Quality of 
life is all the more important since the great majority of treatment aims at palliation rather 
than cure. 
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Tabel 2.2 Economic evaluations relating to lung cancer 
Ref. Country Study area Alternatives Main results 
and evaluated 
analysis 
Dillman USA Induction chemo~ Radiation plus The inclusion of induction 
el 01. therapy plus radio- chemotherapy chemotherapy leads to a 
(1990) CEA therapy for patients vs radiation 33 % increase in the costs of 
with non~small cell alone. therapy but a 100% increase 
lung cancer. in mean survival after 2 and 
3 years. 
Eddy Canada Staging of lung can- CT scan vs no The approach of using a CT 
( 1990) cer - evaluating the CT scan. scan to determine the need 
CMA mediastinum before for mediastinoscopy with 
surgery. nodal biopsy rather than 
giving these tests routinely 
reduced the costs of treating 
these patients. 
Good- Canada Treatment of exten~ Chemotherapy The most expensive regimen 
win sive small-cell lung regimes. (cyclophosphamide, 
el 01. CUA cancer. vincristine and doxorubicon) 
(1988) was more CEo as it was 
more effective and savings 
were made in other resour~ 
ces. 
Houston USA Staging of lung can- CT scan vs no CT scans appeared to be no 
el 01. cer ~ evaluating the CT scan. more accurate than current 
(1985) CMA mediastinum and routine tests and the use of 
assessing metastases. CT scans was more expen~ 
sive. 
Jaakki- Canada Treatment of Chemotherapy Both drug regimes were CE 
mainen advanced non-small regimes vs best when compared to best care. 
el 01. CEA cell lung cancer. care. The less expensive regime 
(1990) (cyclophosphamide, doxo-
rubicin and cisplatin) was 
more CE and cost saving. 
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Ref. Country Study area Alternatives Main results 
and evaluated 
analysis 
Pashko USA Chemotherapy treat- Chemotherapy The regime involving the 
ef a/. ment in small cell regimes. oral administration of a 
(1992) CMA lung cancer. larger dose of otoposde on 
study days 2 and 3 rather 
than a summer intravenously 
administered dose was less 
costly. Both regimes were of 
equal efficacy. 
Rees UK Palliative treatment Radiotherapy vs Palliative care had a higher 
(1985) for carcinoma of the no intervention. cost per "notional patient 
CEA bronchus. benefit year" than curative 
therapies for other cancer 
therapies. 
II The methods used by most of the published studies to measure and value resource use 
are not ideal. Most of the studies reviewed adopt a methodology similar to Pashko and 
Johnson (1992), whereby the average use of resources attributable to a procedure are 
measured and an average cost per unit for each fOlm of resource employed is calculated. 
An average resource cost per procedure can then be estimated. In the study by Rees 
(1985), the methods for the measurement of resource use are not made clear. An 
alternative, more accurate, method is to monitor a sample of patients throughout their 
course of treatment (either prospectively by the use of case record forms, or retrospecti-
vely by examining hospital charts), measuring resource use as it is employed and from 
this analysis derive a marginal cost for the procedure. The studies by Houston ef a/. 
(1985) and Eddy (1989) adopted this approach . 
.. In almost all of the studies selected there is a failure by authors to include any analysis 
of the sensitivity of their results. However, the studies by Goodwin el al. (1988) and 
Jaakkiminen el al. (1990) include several such analyses. 
b. Economic evaluations of cancer screening programmes 
There are relatively felV comprehensive economic evaluations of cancer screening 
programmes or policies. Most pertain to the area of breast cancer screening, partly due to 
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the important body of literature on randomised and case controlled clinical trials in this 
field. Economic analyses of cervical cancer or colorectal cancer screening initiatives are 
more scarce. The majority of economic analyses of breast cancer screening are based on 
theoretical models, which combine efficiency results from fOlmer clinical trials with 
actual costs of screening programmes or clinical practice. Analyses of cervical and 
colorectal cancer screening programmes either base estimates on theoretical models or are 
limited to very small numbers of cases. Among the studies presented in Table 2.3, the 
following remarks need to be addressed regarding to methodology: 
" The evidence for effectiveness is not always based on RCTs and, if so, the results of 
RCTs are not readily applicable to the situation. Joseph ef al. (1988), for example, base 
their measurement of the HemoQuant test's effectiveness in screening for bowel cancer on 
a sensitivity value obtained in a study of only 30 patients. Obuko el al. (1991) use a 
combination of sources for estimates of efficiency, yet fail to address the possible 
discrepancies in the calculation of these estimates. Van der Maas el al. (1989) and De 
Koning ef al. (1991) suitably address the problem of the applicability of clinical trial 
results by combining results from two respected clinical trials for the measurement of 
outcome in their analysis. The reliability and applicability of results from clinical trials 
performed several years prior to the economic evaluation or a screening programme must 
be assessed with respect to possible changes in teclmology and in popUlation demograp-
hics which could limit their relevance to the current situation. 
" A comprehensive description of alternatives is not always provided and rendering 
interpretation of results and applicability of conclusions are difficult. In their evaluation of 
cervical screening policies, Parkin and Moss (1986) analyse seven alternative policies in 
terms of cost-effectiveness, yet the distinction between the alternative policies is at times 
unclear throughout the text. In the study by Johnson el al. (1987) no alternative situation 
is discussed. In Mandelblatt el al. (1988) the number of screened patients included in the 
study is very small and the logical comparison group, non-screened patients of similar 
age, is excluded from all analyses. 
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Tabel 2.3 Economic evaluations relating to cancer screening programmes 
Ref. Country Study area Alternatives Main results 
and evaluated 
analysis 
Joseph USA Colorectal cancer HemoQuant vs Despite higher sensitivity 
el at. screening. Hemoccult of the HemoQuant test, its 
(1988) CEA screening. high cost is only justified if 
it can provide a specificity 
similar to that of the Hem-
occult test. 
Johnson USA Mass colorectal Self-adrniniste- The studied programme 
el at. cancer screening. red stool blood costs per cancer detected 
(1987) CEA test (no alter- are fairly high (S 9670). 
natives). The authors advocate mass 
screening programmes to 
be targeted towards at-risk 
populations. 
Mandel- USA Cervical cancer One-time Pap- The proposed programme 
blatt screening in low- anicolaou test would both be efficient and 
el at. CEA income, elderly for cervical cost-saving, thus suppor-
(1988) women. cancer vs no test ting cervical cancer screen-
(hypothetically) ing of elderly women. 
in the same 
population. 
Parkin UK Cervical cancer 7 screening The best CE-ratio obtained 
and screening. policies recom- corresponds to screening at 
Moss CEA mended in the 5-year intervals of women 
(1986) UK since 1966 over 35. Extension of 
(using different screening to women under 
screening sche- 35 leads to loss of effi-
dules and tar- ciency. 
geting different 
age groups). 
Mooney UK Breast cancer scree- Manunography, Mammography (single 
(1982) ning, women aged 40 thermography reporting) combined with a 
CEA to 59. and clinical single clinical examination 
exam vs mam- showed the most attractive 
mography and cost-effectiveness ratio of 
thermography the alternatives studied. 
(6 alternatives 
in total). 
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Ref. Country Study area Alternatives Main results 
and evaluated 
analysis 
Forrest UK Mass breast cancer ManmlOgraphy Mass screening by 
(1987) screening by mam- as 3-year inter- manmlOgraphy at 3-year 
CUA mography, women vals in women intervals would result in 
aged 50 to 64. aged 50 to 64 vs 695 QALYs per 100.000 
no screening. women invited for scree-
ning. 
Van der NL Breast cancer scree- 4 alternatives Mammographic screening 
Maas ning by mammo- based on differ- of women aged 50-70 at 2-
e/ al. CEA graphy, women aged ent screening year intervals allows for 
(\989) 50-70 years. schedules: 4- savings of $ 4850 per life 
year,2-year, year saved, a ratio which 
I ,3-year, and 1- compares favourably to that 
year frequen- of screening at either shor-
cies, are com- ter or longer intervals and 
pared to a no- to that of other health 
screening situa- interventions. 
tion. 
De NL Mass breast cancer The invitation Mass screening of women 
Koning screening by mal11- schedules used aged 50-70 would appear to 
el al. CEAi mography in women in the Van der affect quality of life very 
(1991) CUA aged 50-70. Maas study are little, as the cost per 
compared for QALY differs little from 
their respective the cost per life year 
effect on quality gained unadjusted for 
of life and quality. The authors recolll-
QALYs. mend the adoption of a 
national screening policy 
based on a 2-year schedule. 
Eddy USA Mass breast cancer Annual mam- Reduction in the costs of 
e/ al. screening by mam- mography for treatment in screened 
(\988) CEA mography in women women aged 40 women under 50 would be 
under 50. to 49 already outweighed by extra costs 
having had a of screening and necessary 
physical exam biopsies. 
vs physical 
exam alone. 
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Ref. Country Study area Alternatives Main results 
and evaluated 
analysis 
Obuko Japan Breast cancer scree- Physical exam According to the computer 
el al. ning in women 30-80 alone (current simulation model, scree-
(1991) CEA years old. Japanese policy) ning by mammography 
vs combinations alone provided the best 
of manuno- (lowest) CE-ratio of the 
graphy and studied alternatives. 
physical exam 
vs no screening. 
Gravelle England Breast cancer scree- Physical exam The authors conclude that 
el al. and ning in women over + mammo- the introduction of scree-
(1982) Wales 40. graphy vs con- ning would increase costs 
ventional man- for the NHS, yet the cost 
CAl agement (no per life year saved is very 
CEA screening). low. 
.. Economic studies of screening policies often fail to include all relevant costs of scree-
ning (especially capital costs) and all relevant consequences (especially morbidity). Little 
consideration is given to the effect on patients' quality of life. Indeed, the only study 
which incorporates quality of life measurements is the study by De Koning el al. (1989) 
on breast cancer screening, all other studies being of cost-effectiveness. The study by 
Joseph el al. (1988) considered mortality as the only possible negative consequence of 
Hemoccult and HemoQuant screening, and limited costs to the charge for the screening 
procedure, excluding all capital costs. Johnson el al. (1981) took the total cost of the 
programme and divided it by the number of cancers detected in the study group to obtain 
a cost-effectiveness ratio. Inadequacies in the estimation of costs and outcomes question 
the credibility of economic evaluations . 
.. Costs and consequences are not always adjusted for differential timing. Most of the 
studies in Table 2.3 include appropriate discounting of cos Is and consequences of 
screening, although no discounting is done in the case of Johnson el al. (1987) and only 
outcomes arc discounted in the study by Parkin and Moss (1986) . 
.. The costs and outcomes of differenl screening alternatives are rarely studied in the 
context of an incremental analysis, and only total sums and average costs are presented 
and discussed. The articles by Van del' Maas el al. (1998) and De Koning el al. (1989) 
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are two examples of studies which include detailed incremental analysis in their estimates 
of cost-effectiveness . 
.. The discussion in these papers presents the authors' recommendation for screening, yet 
fails to discuss its implementation or to place the study results within the context of health 
care priorities. Since the goal of economic evaluation is to aid policy makers in choosing 
among competing policies, the conclusion of most studies either advocates in favour of or 
against the implementation of a given screening policy. However, very few studies 
mention which difficulties might arise in the implementation of policies, or which 
competing policies should also be analysed in terms of cost-effectiveness. An example can 
be found in Mandelblau's recommendation to implement cervical cancer screening 
programmes for elderly women (Mandelblatt el al., 1988). The author never addresses 
the issue of cervical screening in younger women (under 70 years) and neither does she 
compare the cost-effectiveness ratio in women over 70 years to that obtained in studies of 
younger women. 
Other, also methodological problems with breast cancer screening studies are discussed 
further by Skrabanek (1991). 
2.6 Use of resulls of economic evalualions 
2.6.1 Use by policy makers 
The policy maker's aim is that of choosing and implementing a "best-buy" strategy to 
deal with a particular aspect of cancer, be it prevention, treatment or care for cancer 
patients and their families. This is particularly important in the field of neoplastic diseases 
which tie up a considerable amount of resources. Such a requirement is especially 
important when the policy maker is in a purchasing role and must make best use of 
available resources in commissioning a new service or must look at making best alterna-
tive use of available resources. 
If the decision making process is to be of good quality it must be based on reliable 
assumptions. If the reliability of international economic literature is open to question, 
where should the decision maker go for advice? Probably the quickest way of getting such 
advice is to ask an economist, in other words somebody who not only has the technical 
knowledge required to provide sound advice, but also whose everyday work is economic 
evaluation. If not involved in the specific field of enquiry a local economist should be 
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able to direct the enquirer to economists active in the field. Alternatively, some national 
or international organisations are beginning to develop a strategy to review and dissemi-
nate results of economic evaluations. These include the Cochrane Collaboration through 
Centres in Oxford, Copenhagen, Ontario and other international centres, and the 
University of York in the United Kingdom and the offices of Health Technology Assess-
ment, being established in many countries (e.g. Sweden, Canada and Australia). 
2.6.2 Use by clinicians 
The results of economic evaluation of therapies should not be regarded as being simply in 
the domain of planners and 'purchasers'. In our cost-constrained world decisions on 
health care spending are going to be everyones business. As expensive new therapies 
develop health care planners are not always going to make hard decisions on whether to 
pay for them. Onen they will allow clinicians to use such treatments, provided that they 
are paid for out of the cllrrent budget. Clinicians will, in this situation, need to under-
stand any available economic evaluation and be able to compare it with economic 
evaluations of other therapies they provide. Only then they will be in a position to decide 
which treatments to use. In cost-constrained health systems management does not have 
sufficient expertise or manpower to make decisions based on economic evaluations in the 
myriads of interventions in many areas of medicine. Inevitably this role will often be 
devolved to the individual clinicians or departments. 
2.6.3 Use of tile results of econolllic evaluations 
Comprehensive cost-effectiveness studies can be expensive to perform, and may be hard 
to repeat if attachcd prospectively to a large randomised controlled trial. Given the 
comparatively small number of studies performed each year, and the likelihood that their 
results will have a limited lifetime before being overtaken by changes in technical or 
allocative efficiency or by technical progress, it is important to find ways of making 
maximum use of their results. The transferability of the results of a cost-effectiveness 
study may be considered in a number of dimensions: 
a. Tile perspective of tile study: A study may have been performed from one of a number 
of perspectives, such as that of a third party payer, the health sector, the public or private 
sub-component of the health sector, or society as a whole. This may restrict the transfer-
ability of the results to another setting with different divisions of responsibility or with 
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different information requirements. Transferability would therefore be facilitated by 
reporting, where possible, the results from a standard perspective, which may be the 
baseline perspective adopted by the study or a supplementary part of the analysis. The 
health sector as a whole would probably raise fewest problems of transferability although 
also this perspective may pose problems at least for studies in e.g. the field of terminal 
care or home care, since whether such types of care fall under the 'health care' or 'social 
services' may vary widely between countries. Further work is required in this area before 
prescriptive guidelines could be agreed. 
b. The care level of the study: A cost-effectiveness study performed in a teaching hospital 
or trial setting may be based on substantially higher unit costs than would be the case in a 
non-teaching hospital. Therefore some indication of the extent to which the costs reported 
can be regarded as typical of the health sector as a whole would be useful. 
c. Regional differences: Similarly there may be regional differences in costs within a 
country that result in the reported results being typically low or high for the country as a 
whole. Some indication of this would also be useful. 
d. The time the study was petjormed: A cost-effectiveness study may make use of 
information on costs, treatment paths and outcomes, all from different sources and 
potentially different times. These data, and in particular the technology and organisation 
of care in the treatment paths, must be made explicit in order that obsolescence of the 
study can be judged. 
e. The COllfltly of the study: To facilitate wider use of the study, it may be tempting to 
consider ways of transferring results from one country to another. To facilitate this, it is 
essential that the guidelines set out above in section 2.4, as well as items a-d on transfer-
ability are closely adhered to. Efforts to achieve this are in their infancy and more effort 
is needed on the methodologies and empirical procedures relevant to international 
transferability. 
2.7 Recommendations 
We have the following recommendations: 
a. When any clinical trial is being plamled the potential economic outcome of the 
intervention should be considered. The requirement for economic evaluation should also 
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be examined. Even when this is considered inappropriate thought should be given to 
collecting basic data which might be used for a later economic evaluation. 
b. If an economic evaluation is being planned the advice of a health economist should be 
sought at the outset. 
c. Funding for RCTs is limited. Ask yourself is the design efficient, is it likely to answer 
the question or make a useful contribution, would the money be better spent elsewhere? 
d. Do not try to replicate locally an economic evaluation study you have found in the 
literature without involving a trained economist. Listings of health economists will be 
available from national Offices of Health Teclmology Assessment and in Europe from the 
EORTC office in Bmssels. 
e. Where possible, resource data should be presented in the fonn of volumes, such as 
in-patient days, number and length of consultations 01' drugs consumed. After the 
identification of the cost of each of the resources, the costs can be calculated. Authors 
submitting cost-effectiveness studies should ensure that, where available, results report 
ranges and confidence intervals around the cost data used, and that sensitivity analyses on 
the main dimensions of the study are performed and reported. Results in the form of a 
single point estimate of cost-effectiveness for a given intervention should be discouraged. 
Numerators and denominators of cost-effectiveness ratios should be reported. 
f There is a need for dialogue between clinicians, policy makers and health economists. 
The present gap is liable to lead to inappropriate health evaluations and ill informed 
discussion. The end result may be poorer health care for patients. 
g. There is a need to ensure methods used in studies. In all published studies, the 
methods used in measurement and valuation of all costs and consequences must be made 
clear - to allow both policy makers to detemline whether the study's results are applicable 
to their policy arena and to help other researchers avoid duplication of research and to 
facilitate the extrapolation of studies to other settings. However, this has to be balanced 
with editors' desires to constrain the space available to report such studies. Often when 
researchers are criticised for not accurately displaying the methods adopted this is the 
result of editors being parsimonious wilh the space available to present the work and not 
with any desire on behalf of the authors to conceal their methods. 
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Editors and authors must consider how to make a detailed description of methods 
employed more available. Methods could be made available by being published as an 
appendix to the main article. However, given space constraints this is an unlikely option. 
As the trend to make journals available online gathers pace, one alternative available is to 
include within the online version of the journal details of the methods employed. Another 
alternative is for editors to insist that authors make available a full description of the 
methods to all those requesting them. Even if the methods are not contained in the main 
body of text within their journal, they must still be made subject to peer review. There is 
a need for a European Workshop to discuss standardisation of method and reporting with 
a special emphasis on transferability. 
h. Editors should ensure that a health economist is included among referees for papers 
containing an economic evaluation component. 
i. Coordination of teaching and education: In order to achieve optimal understanding and 
cooperation between health economists, clinicians and policy makers, each party must be 
able to appreciate the objectives, methodology and priorities of the others' vision of the 
health care sector. This mutual understanding and respect can be achieved by integrating 
elements of health economics into medical school curricula and similarly by giving health 
economics students basic medical concepts. On a European ConmlUnity level, a forum for 
dialogue between all parties can be achieved in the form of symposia, guidelines 
recommending the inclusion of economic aspects in evaluations of oncological interven-
tions, or encouragement of multidisciplinary approaches in cancer care research. 
j. Economic evaluation of cancer care is complicated by the poor quality of the evidence 
currently available on treatment efficacy. The lack of data on quality of life and symptom 
control further complicates assessment of efficacy in what is often palliative therapy. 
k. Analyses of the cost-effectiveness in cancer care must be based on economic evaluation 
studies. As there are so far few studies of good quality the information and knowledge 
from existing studies is of great importance. Where possible health economics should 
provide information on on-going studies to a central database. The EC has an important 
role to encourage this and, especially by overcoming the problems of recognising and 
translating non-english language papers. 
I. Health policy makers should be considering the need for an economic analysis of any 
new expensive therapy. They may choose only to recommend such therapies for licensing 
and wide spread use if this economic evaluation is favourable. 
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Economic evaluation alongside cancer trials 
3.1 Summary 
A recent extension of clinical evaluation is "economic evaluation II , which seeks to 
characterise each relevant alternative health care strategy in terms of a summary measure 
incorporating the costs and benefits of such strategies. In an economic evaluation, 
separate measurements of resource volumina and resource prices on the cost side, and 
separate measurements of survival and quality of life effects and valuation of these 
outcome effects on the benefit side are required. From these effect parameters, which 
should be calculated for all competing strategies considered in the analysis, the relative 
cost-effectiveness of one strategy as against the other can be derived. The degree of gene-
ralisability of the study results determines the validity of economic evaluation in decision 
making. This depends on the generalisability of the clinical findings, and in this respect 
the so-called "piggyback" economic evaluation, which is added to a clinical trial, has its 
limitations. In the field of cancer, specific attention should be given to costs and effects 
occurring after non-mortality end points, to patient and family costs and to variations in 
treatments between settings of care. It is argued that conventional clinical trials and eco-
nomic evaluations will integrate further in the future. 
3.2 Introduction 
Cancer not only accounts for a major burden of mortality and morbidity (about one third 
of all mortality in the Netherlands, for example), its economic impact is also considerable 
(Koopmanschap et al., 1991; Broder, 1991; Yarbro, 1991). During the last few decades, 
fundamental and clinical research have provided a better understanding of cancer, and as 
a result improved prognosis (survival, quality of life) of patients can be observed. These 
results have been achieved through the development of refined diagnostics, new surgical 
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techniques and new dmgs, but also through rigorously carrying out clinical experiments 
and thoroughly analysing their results. One of the methodological innovations has been 
the introduction of quality of life outcome measures in clinical evaluation research, in 
addition to the use of standard fixed year survival rates. Moreover, the apparent trade-off 
between survival prolongation and quality of life improvement has urged the development 
of combined m0l1ality-morbidity measures (Goldhirsch et al., 1989). Economic evaluation 
is an even more recent development which broadens the scope of evaluation (Dmmmond 
et al., 1987(1); Drummond et al., 1987(III». It has been induced by increased awareness 
of limited health care resources, and the consequent need for economically and medically 
sound choices. Particularly in the case of cancer, the economic issue is relevant (Yarbro, 
1991; Heine and Rothenberger, 1991; Berg, 1991) as the costs per case are usually high, 
and expected benefits are still small for large groups of patients (Hancock, 1992). This 
article describes some theoretical aspects of economic evaluation and some practical 
issues of economic evaluation are combined with a clinical trial (Dmmmond and Davies, 
1991). Its application in oncology is illustrated. 
3.3 Economic evaluation: theO/y 
3.3.1 Theoretical foundation 
If costs have to be taken into account in clinical decision making, the problem arises of 
how to incorporate this argument. Apparently, additional data and new definitions of the 
optimal choice are needed. To understand the peculiarities of economic evaluation as 
more than merely an additional technique in epidemiology requires some notion of its 
theoretical background. From an economic point of view, health care resource allocation 
is rather inefficient. Policies directed to more efficiency appear to be necessary, and have 
to be guided by systematically collected and integrated information on the costs and 
benefits of health care. The traditional economic instlUment for evaluating alternative 
public sector initiatives in this way is cost-benefit analysis (CllA) , which is founded in 
Paretian welfare economics. This theory defines a situation as "efficient" if no potential 
Pareto improvement is possible, the latter implying that at least one person can be made 
better off and no one worse off if the losers are compensated from the beneficiaries' gains 
(Mishan, 1984). In this definition, the individual's own utility or willingness to pay is 
decisive, which poses some restrictions on the use of CBA when other values are deemed 
important, as is the case in health care (Culyer, 1991). Thus, a broader framework is 
needed in health care with the same goal in mind: the determination of a unique preferen-
tial ordering of (health care) progranunes (DlUnunond, 1992). This broader framework 
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again starts from quantification of all costs and benefits but the measurement of benefits is 
adapted. Instead of monetary units, such as the willingness to pay, non-monetary units 
may be used. In standard cost-effectiveness analysis (CEA) , the benefits are expressed in 
one appropriate natural unit as, for instance, life years saved. CEA is often used to 
describe this whole cluster of economic evaluation approaches. More recently, cost-utility 
analysis (CUA) has emerged, which applies so-called utility values which aggregate dif-
ferent dimensions of benefits. Note that the latter approach is particularly relevant in the 
case of oncology, where we often meet different arrays of effects under different 
therapeutic options. Benefits measurement in economic evaluation in trying to cover all 
relevant outcome aspects is not new, but it specifically aims at summary values which can 
bear the claim that they represent overall societal preference values. 
3.3.2 Choice of perspective 
The preferred choice of perspective in CEA (as in CBA) is that of "society", as opposed 
to, for example, 1!patient U or "insurance company1!. This perspective implies that all costs 
and benefits for all parties in society should be accounted for. Some of the less obvious 
consequences of this perspective are listed below. First, patient costs (both out of pocket 
expenses and time-investments) should be included. This theoretical point is relevant in 
patients with cancer as they, for example, frequently apply dietary measures and spend 
much time in diagnosis and treatment. For similar reasons, the care by close relatives or 
friends is not zero-priced, but appropriately valued. In oncology, we frequently observed 
the erroneous assumption that non-professional care of terminally ill patients by volun-
teers and close relatives is a preferable option because it is zero-priced. Second, the lost 
production due to illness or treatment is also a cost to society, and the associated indirect 
costs should be included in the analysis (for a description of techniques see Koopman-
schap and Van Ineveld, 1992). Indirect costs in cancer are usually substantial. Third, ac-
cepting society's perspective implies that the real use of resources should be measured 
and valued rather than the charges paid by patients or third parties, as the latter may bear 
little resemblance to actual costs. This is, for example, relevant in the assignment of costs 
to days of hospitalisation, laboratory tests and medical services. An example in oncology 
of a more remote consequence is that economic evaluation uses the expected market price 
of a new chemotherapeutic drug, even if it may be temporarily zero-priced for research 
purposes. 
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3.3.3 Choice of approach 
There are several pathways which arrive at the numerical values of the indicators for cost-
effectiveness. In this paper, we will concentrate on the so-called "piggyback" design, par-
ticularly in oncological research. "Piggyback" indicates that the economic evaluation is 
added on to an established clinical trial as a prospective or retrospective supplement 
(Drummond and Davies, 1991). If the clinical trial provides insufficient data or a pro-
spective experimental design is not feasible, some secondary options are usually feasible, 
particularly the synthesis of the major findings from literature within a mathematical 
model (Martens et al., 1989). 
Below we discuss the "piggyback" approach and potential frictions arising from the 
reconciliation of the study requirements for clinical and economic evaluations. These 
frictions disclose the different perspectives of clinical versus economic evaluations: the 
clinical investigator generally seeks to demonstrate effectiveness in a well-defined patient 
group on the basis of a sensitive (clinical) outcome indicator, while the economist prima-
rily wants to support a policy decision on an intervention or progranmle by assessing its 
general cost-effectiveness in routine medical practice, comparing the best alternatives 
available. 
3.4 Economic evaluation as an add-on to a controlled clinical trial 
Controlled clinical trials (CCT) are increasingly considered as natural vehicles for 
economic evaluations (DmnuTIond and Davies, 1991). The added costs of an economic 
evaluation are obviously relatively low, and the importance of economic evidence at an 
early phase of the health policy process is acknowledged by all health care parties invol-
ved (Rutten and Bonsel, 1992). With the resulting closer integration of economists within 
the clinical trial setting, the following issues have emerged. 
3.4.1 Mode of comparison 
As in a clinical trial, a randomised controlled comparison is preferred in an economic 
evaluation. However, in some cases the formation of a control group may be difficult for 
ethical or organisational reasons. For example, the course of disease under conventional 
treatment may be invariably lethal, making patients reluctant to participate on a random i-
sed basis if a new potentially life saving therapy is offered (e.g. an immune therapy 
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versus placebo trial in melanoma). In the absence of a control group, prognostic model-
ling of control group survival may be an option (Bonsel el al., 1990), but economic 
evaluation invariably requires a parallel prognostic model for information on the costs in 
the control situation. In selected cases, another option for obtaining control group 
estimations may be the extrapolation of waiting list data on survival, quality of life and 
costs (Van Hout el al., 1993). 
3.4.2 Choice of allemalives 
The choice of alternatives within a CCT determines the suitability of the trial for add-on 
economic evaluation. If the CCT does not include the usual or the best alternative 
treatment as a control, an economic evaluation is impossible. Placebo control, often 
essential in determining efficacy, is only suitable in economic evaluation if the no-
treatment option reflects the best alternative action. However, in other cases, economic 
evaluation would sometimes require the placebo or no-treatment option in a CCT where it 
is not included. An example of the latter case might be an add-on economic evaluation 
comparing G-CSF (filgrastim) versus placebo in the treatment of febrile neutropenic 
episodes. The economically relevant question is not only whether G-CSF decreases length 
of hospital stay given a set of criteria for discharge, i.e. if G-CSF increases efficiency 
within this context, but also what is the (cancer-specific) cost-effectiveness of the overall 
treatment protocol to which G-CSF is added. The same question will often apply to trials 
on salvage therapy. 
Economic evaluation prefers the inclusion of preventive alternatives when considering 
diseases with a strong risk factor component (e.g. smoking in cancer of the lung, oeso-
phagus and bladder). What seems efficient from a narrow perspective, may have an 
unfavourable cost-effectiveness from a broader view. 
3.4.3 Choice of end poillls and follow-up lillie 
This issue pertains both to the principal question of which outcome measure is at stake, 
and to the practical question of which end point results in a feasible sample size, given a 
reasonable time frame and the usual values for precision and power. Theoretically, the 
primary outcome measures in economic evaluations are cumulative life years gained and 
differential costs. The usual primary end points in cancer trials are fixed time (e.g. I year 
or 5 years) survival rates and disease-free survival rates. From a clinical viewpoint, the 
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choice of the analytical follow-up time (for example, 1 year or 5 years) may be difficult if 
the intervention has lifelong influence on survival (e.g. breast cancer) or if the impact of 
alternatives on survival differs over time. Statistical methodology exists to deal with 
incomplete empirical follow-up (censoring of observations), enabling comparisons of 
survival rates. In economic evaluation, lifelong follow-up is also preferred. Except for 
rare cases with either complete recovery or death within the empirical follow-up time, 
lifelong consequences cannot be observed. What happens after censoring should be 
explicitly estimated, which requires advanced statistical analysis. Usually mathematical 
modelling is applied, based on comprehensive data of patients at the time of censoring 
(Bonsel el al., 1990; Van Hout el al., 1993). Systematic studies on patients with recurrent 
or terminal disease are rare, and cancer is no exception. Consequently, valid lifelong esti-
mates may be difficult to obtain. 
Related to the end point definition and the empirical follow-up is the determination of the 
sample size. From a conceptual point of view, economic evaluation requires a separate 
sample size determination, based on distributions of costs and benefits in any of the 
alternatives distinguished. In practice, lack of reference values for costs and quality of life 
data may restrict sample size considerations to the clinical part of the trial. However, in 
economic evaluation, statistical significance of differences and the absolute magnitude of 
differences are equally important (De Koning el al., 1991). 
3.4.4 Delermination of ollleome 
In economic evaluation, the determination of length of survival is straightforward, except 
for the modelling of incomplete observations. The measurement of health status/quality of 
life changes is more complex. Measurement instruments can be divided into two main 
categories: the generic instruments and illness-specific questionnaires. Generic instruments 
are developed to monitor changes in all health dimensions and allow comparison of 
outcomes across different disease categories. The Nottingham Health Profile, the RAND-
MOS 20 and the related Short-Form 36 questionnaire seem to be suitable instruments. 
Illness-specific instruments measure health problems specific for an illness. These 
instruments are more sensitive for specific problems concerning a particular disease. 
Cancer-specific instruments often used are the Rotterdam Symptom Checklist, the 
EORTC Core Quality of Life Questionnaire and the Cancer Rehabilitation Evaluation 
System-Short FornI. So far, clinical and economic evaluations coincide. 
46 
3 Economic evaluation alongside cancer trials 
As explained earlier, economic evaluation also tries to arrive at a summary value of the 
patient benefits. The following procedure applies. First, so-called utility values (a figure 
between 0 and 1 to indicate the preference value of a certain health state) have to be 
attached to outcomes. There are three dominant methods of acquiring utility values: direct 
rating, standard gamble (more convenient in surgical interventions) and time trade-off 
(more convenient in medical interventions). Utility values may be elicited from the 
general public (preferable within the societal perspective) and the patients themselves. 
Torrance provides an extensive description of these utility teclmiques (Torrance, 1986). If 
utility values for each characteristic health state have been acquired, the constlUction of 
quality adjusted life years (QALYs) becomes feasible, allowing the improvement in 
outcome to be expressed in terms of QALYs gained and, consequently, the constlUction 
of a cost-utility ratio. 
3.4.5 Delerminalion of cosls 
The first step is tabulation of resources in appropriate natural units (DlUmmond el al., 
19871), with an emphasis on the counting of variable cost items. A priori estimation of 
the relative importance of these cost items should guide the data collection (Turk el al., 
1989). Sometimes, costs per diagnosis-related group (DRG) may be readily available 
(Munoz el al., 1989). Case registry forms, as normally used in CCTs, provide insuffi-
cient information as tabulation of major cost items is usually incomplete. Contrary to 
these forms, hospital administration data are usually complete, but they contain only a 
few cost items which can be related to patients. As a result, enumeration of hospital cost 
volumina is performed using a mixture of appended case registry forms, patient question-
naires, hospital data, and occasionally, on-site observations. Additionally, hospital admi-
nistrative data provide information on fixed costs (overheads) and patient questiomlaires 
are useful for obtaining information on direct patient's costs, indirect costs and costs 
related to outpatient care. 
Next, prices are attached to these natural units. Frequently, prices differ substantially 
from the charges for a particular servicc (in both directions, see section on Economic 
Evaluation). In the last step, volumina and prices are multiplied. In addition to the 
empirical costs detennination, economic evaluation includes estimates of future costs 
(disease-related and disease-unrelated) if follow-up of patients is incomplete. Particularly 
if the tail of the survival distribution is long - the usual case in cancer - these long-term 
estimates are of vital importance: average costs (as used in cost-effectiveness ratios) may 
largely exceed median costs (Carlsson el al., 1989). 
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3.4.6 Ethics 
In our view, economic evaluation does not carry with it specific ethical issues regarding 
data collection. From an ethical point of view, people may judge separately whether or 
not to participate in an add-on economic evaluation. So far, we have never been confron-
ted with a refusal for the economic part of the CCT, perhaps because most patients and 
their families face material and immaterial costs, which they are not compensated for, but 
which they feel are identified by economic evaluation. More frequently, we met with 
some reluctance of hospital administrators and doctors to cooperate in case a substantial 
departure of economic cost estimates from current charges and fees was likely to be 
detelmined. 
3.4.7 Generalisation 
From an economic perspective, the generalis ability of CCT results is usually rather 
limited due to a variety of reasons. Clinical research attempts to demonstrate validly the 
effectiveness of a technology and, consequently, the design (patient selection, treatment 
allocation, treatment guidelines) is rigorous. Moreover, research patients are more com-
pliant, clinical investigators are more competent, and the hospital setting offers more 
facilities than its counterparts in general practice. The better a CCT satisfies design 
criteria, the more easily the study results will be accepted for their reproducibility and 
scientific soundness. However, these criteria and the selective environment often drive a 
CCT far from the average clinical practice, and thus the role of CCT in health care deci-
sion making outside the CCT enviromnent may be limited. 
For cross-country generalisation, the general level of a national health care system 
(quality, accessibility) requires attention, particularly in economic evaluation. What may 
be regarded as routine hospital care for any patient in one country, may be care which is 
restricted to special cases in another. Cultural differences may account for other patterns 
of care. For example, in the Netherlands, an important role of the general practitioner 
and close relatives in terminal care may be observed, whereas in other EC countries 
emphasis may be more on hospital care. Two additional factors limit generalisability from 
the economic perspective. For the same health care services, prices between and even 
within (Clark, 1992) countries show differences to such an extent that cost-effectiveness 
ratios are usually incomparable (Shapiro, 1992). Besides, the cross-cultural application of 
values attached to health care benefits requires more investigation. 
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3.5 Specific issues in economic evalualion in cancer 
Economic evaluation sometimes causes uneasiness in patients and doctors, and occasional-
ly the introduction of economic considerations is even stated to be unethical. This is 
particularly tme for disease groups with specific societal connotations like cancer and 
AIDS, and for the telminal stages of any disease (Hancock, 1992). We think that in view 
of the general scarcity of medical resources, all disease groups should be judged alike: a 
preterm painful death from systemic lupus or sclerosing cholangitis is not preferable to 
dying from cancer due to its pathophysiological base alone. The reluctance to apply 
economic evaluation in everyday practice may pal1ially explain the current restriction of 
economic evaluation to screening programmes (breast cancer, colo-rectal cancer): less 
than 10% of the recent Medline literature on costs and cancer refers to non-screening 
topics. 
A recurrent problem in the economic evaluation of cancer treatment is the complete 
definition of alternatives. As the perspective is lifetime, it is important that the treatment 
protocols include details on long-term treatment. Generally, the highest costs in cancer 
are incurred after its detection (incidence costs, recurrence costs), and during the temlinal 
phase (mortality costs) (De Koning el al., 1991; Beck-Friis el al., 1991; Bried and 
Scheffler, 1992). Thus, in the economic evaluation of primary therapies, significant 
differences may arise (particularly in quality of life and costs) due to uncontrolled 
variations in tenninal treatment. If data on terminal stages are unavailable, combinations 
of trial data with "adjuvant" modelling using various "average" data are required (Baker 
el al., 1991). Another problem encountered in cancer trials is the "minimal" change of a 
protocol during study. The cost impact of these changes is usually underestimated, if esti-
mated at all, and trial data before and after the change may not be safely combined. The 
same argument applies to uncontrolled inter-centre variations in supportive treatment, 
particularly with antibiotics. 
Three problems of outcome measurement deserve attention. First, the general lack of 
prognostic models for the more advanced stages of disease. Second, the understandable 
lack of knowledge on long-tenn effects of new life saving approaches (e.g. bone marrow 
transplantation (Rillner el al., 1992». Both can only be dealt with through sensitivity ana-
lysis. Finally, the observed reluctance to apply comprehensive quality of life measure-
ments because of the presumed burden on patients. If properly infonned about the 
purpose and contents, few patients in our experience withdraw from completing extensive 
quality of life questionnaires: most of them express gratitude for the opportunity to 
communicate their feelings, abilities and general rating of life. 
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A specific issue in cost measurement is the appropriate measurement of costs incurred to 
the patient (waiting, travelling) and his or her family (Beck-Friis ef al., 1991; Houts ef 
al., 1984). These are usually measured by way of a patient questiOlmaire, and in 
valuation, standardised methods are applied. Another problem to deal with is the fair 
assignment of costs to the diagnostic and therapeutic nucleus on the one side, and to costs 
which are induced by the research protocol on the other side. The latter may be con-
siderable (Kennedy, 1991). If the CCT is multi centred, the usual case, heterogeneity 
between hospitals on costs may be disturbing. Volume heterogeneity is generally caused 
by different policies not dealt with in the protocol (e.g. antibiotic prevention and curation, 
rehabilitative services). Price heterogeneity may be caused by incomparability of the cost 
structure of cancer treatment, even within one country. Even if the potential effect of 
policy heterogeneity on effectiveness is neglected, cost analysis may be cumbersome. 
3.6 Disclissioll 
We believe that economic evaluation can playa valuable role in decisions on the adoption 
and utilisation of new technologies (Laupacis ef al., 1992). Economic evaluation in the 
field of medical research may take two forms, either as an add-on study or as a primary 
economic study. In both cases, specific economic features concern the mode of compari-
son, the defined alternatives, the primary end points (effects and costs), the perspective 
(society), the time period (lifetime) and finally, the generalisability of results. The add-on 
study is the more familiar approach, and particularly in areas of clinical research with 
high methodological standards, as in oncology, the pros and cons of add-on economic 
evaluation disclose much of the underlying philosophies. In some features (comparative 
mode, to some extent the choice of alternatives, the perspective), the requirements of 
CCT and economic evaluation are similar. In others (costs, time period), economic evalu-
ations require extension rather than change of a given CCT protocol, though the work 
load involved may exceed the clinical research part of the CCT. Good clinical practice 
standards are more established in hospitals than appropriate economic and administrative 
management, implying a major empirical task of cost measurement. 
Apparently, some unresolved discrepancies remain: the width of the scope of alternatives, 
the role of quality of life and utility measurement, and the attitude towards generalisabili-
ty. We believe that they will disappear with the further integration of evaluative methods, 
and also that these changes will be observed in clinical areas, like oncology, with a strong 
methodological tradition: the gradual change of medical services from a mythic event to a 
societal commodity is irreversible. 
50 
4 
Measurement and valuation of quality of life 
4.0 Preface 
The international literature on quality of life research is vast and rapidly expanding. 
Evaluating instruments for applications within cancer trials is a continues process. The 
papel' presented here is based on a literature review from 1980 to 1992. More recently, 
information on the psychometric features of the Short Form-36 (SF-36), the European 
Organisation for Research and Treatment of Cancer Core Quality of life Questionnaire 
(EORTC QLQ-C30), and the Functional Assessment of Cancer Therapy Scale (FACT-
scale) has become available. In Chapter 13 paragraph 2 the use of these instruments in 
economic appraisal of cancer treatments will be discussed. 
4.1 SlImma!)' 
In the economic evaluation of teclmologies in cancer treatment at least three end points 
are relevant: costs, survival and quality of life. This article is focused on quality of life. 
Economic evaluation requires the use of generic and valuation quality of life instruments 
at a disease non-specific level, but the inclusion of cancer-specific instruments may be ad-
visable, particularly for reasons of explanation if changes in dimensions are small or 
conflicting. Given the pros and cons of the available questionnaires, we advocate the use 
of the Nottingham Health Profile, the EuroQol and the Rotterdam Symptom Checklist. In 
our experience the quality of life issue in economic evaluation linked with cancer trials is 
associated with practical problems like questionnaire composition, follow-up time, 
interviewing schedule, patients' compliance and doctors' acceptance. These problems are 
discussed and some practical guidelines for the design of quality of life measurement in 
cancer trials are given. 
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4.2 Illfroductioll 
Cancer is a major cause of illness and death, responsible for almost a quarter of total 
m0l1ality in Western countries. During the last few decades cancer treatment has shown a 
rapid evolution. It is now a multidisciplinary treatment strategy incorporating surgery, 
radiotherapy, chemotherapy and/or immunotherapy. Treatment usually has important side-
effects, especially radiotherapy and chemotherapy. For example, radiotherapy causes 
tiredness, skin injury and emotional discomfort. Chemotherapy, often considered even 
more burdensome, is given over longer periods and its toxicity causes hair loss, nausea 
and vomiting, fatigue and emotional problems. Consequently, those involved in the care 
and treatment of cancer patients have wondered whether improvements in survival 
probabilities outweigh the burden of these severe side-effects in all cases (De Haes and 
Knippenberg, 1985). Not only life years gained, but also the quality of years alive is at 
issue. 
The high incidence and prevalence of cancer make it a major economic issue. The direct 
medical costs are considerable, especially during primary treatment and metastatic periods 
and amount to 5 % of health care expenditure in the Netherlands (Koopmanschap et al., 
1991). Future expenditure may be even higher due to the increased use of expensive 
drugs and radiotherapy equipment, the growing emphasis on various kinds of palliative 
interventions and survival success. The prevalence of morbidity, mortality and the conse-
quent loss in labour and household prodUction also cause substantial indirect costs. These 
phenomena and trends imply a growing role of economic evaluation in the cancer field 
and justify consideration of the specific problems of applying economic evaluation in this 
area. In the economic evaluation of technologies in cancer treatment at least three end 
points are relevant: costs, survival and quality of life. Quality of life will be the focus of 
our discussion. The discussion is based on a literature survey and our own experience 
with economic evaluation linked with cancer trials in the Netherlands, concerning patients 
with haematologicalmalignancies and solid tumours. 
4.3 Objectives of quality of life research 
When two treatment modalities differ with respect to quality of life the main clinical end 
point, mortality, should be considered in relation to outcome indicators for quality of life, 
such as clinical outcome data, disease-specific quality of life measures and general scales, 
although the choice between these is not clear cut. Dl1Immond and Davies (1991) point 
out that the different types of measures complement each other by adding important 
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information about the consequences of various health care interventions. The usual 
objective of carrying out quality of life research is to gain insight into the reactions of 
patients to cancer and on cancer treatment and the interrelations of these different 
reactions with the overall quality of life. Furthermore, data concerning the impact of a 
certain therapy on quality of life may increase the knowledge about the effectiveness of 
such therapy (De Haes and Knippenberg, 1985). 
Quality of life studies generally give a description of health status. Depending on the type 
of study, they deal with more or less objective features of health. Most studies use 
dimensions of the concept such as the physical, psychological and social dimensions 
(Hi:irnquist, 1982). More extended concepts even incorporate material and religious 
dimensions. To evaluate a specific therapy in clinical studies, the end points most 
commonly used are survival rates, disease- and/or symptom-free survival, response rates 
and response duration. When quality of life is taken into account, there is more emphasis 
on the physical and psychological aspects of life, sometimes complemented with aspects 
of social functioning. 
Economic evaluation is intended to support health policy at different levels of decision 
making. In cancer treatment, decisions are generally made in a public sector context, 
implying that one tries to maximise health outcome given a social budget. This requires 
the summary measure used in economic evaluation to be applicable to health care 
interventions in general, and also to be uniform in the sense that all interventions are to 
be judged in an equal manner. If the treatment is to be seen more as a private good, and 
subject to an individual decision, economic methods exist to derive a numeric value for 
the utility of outcome; thus a cost-benefit analysis becomes feasible, allowing an absolute 
judgement on the efficiency of a treatment strategy. 
From the economic perspective, the objective of studying quality of life is to determine 
the contribution of changes in quality of life to a summary measure for the outcome of an 
intervention. Such summary measures may be in natural units (as "life years" commonly 
used in cost-effectiveness analysis), in terms of utility (as in cost-utility analysis) or in 
monetary terms (as in cost-bencfit analysis). When there is more than one effect parame-
ter (e.g. survival and health status improvement) or when effccts are measured in more 
dimensions of quality of life, a value judgement (utility weight) should be given to each 
of these parameters or quality of life dimensions in order to arrive at such summary 
measures. As in cancer treatment, both survival and quality of life (in several dimensions) 
are important aspects of outcome, and only cost-utility and cost-benefit analysis are 
appropriate instruments to measure the efficiency of cancer treatment. 
53 
I Methodological and practical issues 
4.4 Description alld valuation of quality of life ill ecollomic evaluation 
Descriptive instruments can be divided into two main categories: the generic instruments 
and disease-specific questionnaires (Patrick and Deyo, 1989). Generic instruments are 
developed to measure all health dimensions. They can be used over a wide range of 
disease categories and are, therefore, suited to function as generally applicable descriptive 
instruments for measuring quality of life improvement in economic evaluation. In this 
respect they provide a reference for quantitative assessment of quality of life changes in 
economic evaluation and have been used in many economic appraisals. 
Generic instruments most frequently used are: the Nottingham Health Profile (NHP) 
(Hunt et 01., 1986), the Sickness Impact Profile (SIP) (Bergner et 01., 1981) and the 
abbreviated RAND-Medical Outcome Study questionnaire (Stewart et 01., 1988). The 
newly developed Short Form-36 may be regarded as an extension of the abbreviated 
RAND-Medical Outcome Study questionnaire / RAND-MOS 20, or indeed as a reduction 
of the original longer RAND-MOS questionnaire (McHorney et al., 1992). 
Disease-specific instruments measure health problems specific for an illness or disease 
category. These instruments are measuring specific quality of life aspects which are 
typical for a particular disease, and are, therefore, more sensitive for changes in health of 
patients haVing that disease. Concerning cancer, these instruments can be divided into: 
a. Cancer-specific questionnaires (for all cancers) and 
b. Specific cancer questionnaires (for one type of cancer). 
The following cancer-specific instruments are often used: the Functional Living Index for 
Cancer (Schipper et al., 1984), Spitzer QL index (McDowell and Newell, 1987), 
European Organisation for Research and Treatment of Cancer Core Quality of Life 
Questionnaire (EORTC Core QLQ) (Aaronson et 01., 1988), Cancer Rehabilitation 
Evaluation System-Short Form (CARES-SF) (Ganz et al., 1992) and the Rotterdam 
Symptom Checklist (De Haes et al., 1990). Examples of specific cancer instruments are: 
the Breast Cancer Chemotherapy Questionnaire (Levine et al., 1988), the Performance 
Parameters for Head and Neck Cancer (Lansky et al., 1988) and the Linear Analog Self-
Assessment (LASA) of Voice Quality for laryngeal cancer (Llewellyn-Thomas et al., 
1984). 
For the description of quality of life in economic evaluation, generic instruments suffice 
for overall comparison and testing, but the inclusion of specific instruments may be 
54 
4 Quality of life measurement 
advisable, particularly for reasons of explanation if changes in dimensions are small or 
conflicting. By using generic instruments it is not always possible to gain insight into how 
changes in health have taken place. For some generic questionnaires, an algorithm is 
available to calculate a sununary measure, but this may not reflect the weights of the 
various dimensions in the hea lth questionnaire as may be derived from value judgements 
of the relevant patient group or other relevant representative groups. 
When strategies score differently on different dimensions and when one needs a summary 
measure of outcome comparable across a range of interventions, it is necessary to get 
valuation of health states in one single dimension representing an overall judgement of 
quality of life of a health state. This would then allow the calculation of "quality adjusted 
life years", where a life year gained is "adjusted" using this value judgement for quality 
of life. To acquire valuations, respondents are requested to value health states. These 
states are derived from a set of health state descriptors. The values usually range from 0 
to 1 (0 = "worst imaginable health state", 1 = "best imaginable health state"). By means 
of modelling teclmiques a multi-attribute utility function may be derived to predict values 
of any composition of health states. There are three methods of acquiring valuations: 
direct rating (e.g. determining a point on a line with clearly defined end points), 
standard gamble (choosing between options under uncertainty) and 
time trade-off (choosing between options with different durations of a particular 
health status) (Drummond et al., 1989; Torrance, 1987). 
Furthermore, there are two basic approaches used to measure the utility of health status. 
In one approach, actual patients who are in a particular health state are used as SUbjects to 
determine their utility for such a state. Using subjective utility assessments is most in line 
with conventional welfare theory. In the other approach, the health states are assessed by 
subjects who mayor may not have personal experience with the health state being 
measured, but are thought to represent public opinion. Which approach is preferable 
depends on the viewpoint of the study. When a study is conducted from the societal 
viewpoint and is pertinent to public policy decision making, the appropriate utilities are 
those of the general public (Drununond et al., 1989). If a fixed set of utility values 
generated from a representative sample from the general public can be related to all 
possible outcomes from a generic health questionnaire, and if such a generic instrument 
would then be used to measure health outcomes in an economic evaluation, this would 
add to the comparability of results from economic evaluations and be in line with the 
public sector context of decision making to be supported with results from an economic 
evaluation. The problem with soliciting value judgements from persons without relevant 
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disease experience is that the person should tmly understand what the described health 
state is like. For some of the generic health measurement instmments such a set of utility 
values is known allowing the calculation of QALYs gained when such a generic instm-
ment is used to assess health outcomes. The descriptive part of the EuroQol instrument is 
especially developed to be used in economic evaluations and a validated set of utility 
values is available for this instmment (EUROQOL Study Group, 1990; Essink-Bot et al., 
1990). Other available valuation instmments are the Quality of Well-being Scale (QWB) 
(McDowell and Newelll, 1987), the McMaster Utility Measurement Questionnaire 
(MUMQ) (Bennett and Torrance, 1990), the Torrance's Health State Classification 
System (Torrance et al., 1982) and the Rosser & Kind Index (Rosser and Kind, 1978). 
4.5 Choice of lIleasurelllelll instJ'lllllellls 
In clinical trials the choice of measurement instmments depends on crileria such as 
psychometric features (internal consistency, reliability, validity, etc.), specific patient 
features, feasibility and on the possibility of gaining insight into the quality of life aspects 
of the disease itself, and into the side-effects of treatmen!. Quality of life measurements in 
economic evaluation should foremost allow comparison across different technologies and 
diseases. This requires the inclusion of a generic health measurement instmment wilh the 
opportunity to derive utility values (or indeed an instmment soliciting value judgements 
directly from the patients) and, if deemed necessary for reasons explained above, the 
inclusion of a cancer-specific instmmen!. The precise combination of instmments depends 
on the required psychometric and specific patient features and feasibility aspects. An 
important aspect of the lauer is the duration of the whole interview. Table 4.1 describes 
the psychometric features and the duration of the interview. 
Concerning the generic instmments, there are hardly any differences between the psycho-
metric features of the instmments mentioned. The test-retest reliability is slightly in 
favour of the NHP and the SIP. Concerning the internal consistency per dimension the 
NHP is preferable to the SIP. All instmments mentioned have content and constmct 
validity. Considering the psychometric features, we prefer the NHP to the SIP and the 
RAND-MOS 20. 
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Table 4.1 Description and valuation of quality of life 
Measurement instrument Reliability Internal Validity Interview 
consistency duration 
Generic: 
Nottingham Health Profile 
- Physical mobility 0.77 - 0.88 0.81 Content IO min. 
- Pain 0.77 Construct 
- Sleep 0.69 
- Social isolation 0.42 
- Emotional reaction 0.75 
- Energy 0.68 
Sickness Impact Profile 
- Physical 0.90 - 0.91 Overall: Content 20 - 30 min. 
- Psychological 0.79 - 0.84 0.81 - 0.94 Construct 
- Overall 0.75 - 0.92 Per dimension: 
0.23 - 0.80 
Rand Medical Outcome 
Study (RAND-MaS 20) 
- Physical functioning 0.78 0.85 Content 3 - 4 min. 
- Role functioning 0.69 0.80 Construct 
- Bodily pain 0.58 -
- Social functioning 0.75 -
- Mental health 0.83 0.89 
- General health perception 0.85 0.91 
Cancer-specific: 
Rotterdam Symptom 0.82 - 0.88 0.81 - 0.93 Content 8 min. 
Checklist Construct 
Cancer Rehabilitation 0.86 0.61 - 0.85 Concurrent Unknown 
Evaluation System-Short 
Form (CARES-SF) 
Va/uatio,,: 
Quality of Well-being 0.90 Unknown Content 18 min. (descr) 
Scale (QWB) Construct Unknown (val) 
EuroQol 0.69 - 0.94 Not relevant Content 1 min. (deser) 
20 min. (val) 
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Measurement instrument Reliability Internal Validity Interview 
consistency duration 
Valuation: 
McMaster Utility 0.66 - 0.94 Not relevant Content 45 min. 
Measurement Questionnaire (descr and val) 
(MUMQ) 
Torrance's Health State 0.86 - 0.94 Unknown Unknown Unknown 
Classification System 
Rosser & Kind Index 0.79 - 1.00 Unknown Content 10 min. (descr) 
> 1.5 hrs (val) 
References: De Haes, el al., 1990; Essink-Bot and Rutten-Van Molken, 1991; 
Schag el al., 1991; descr, descriptive point; val, valuation point. 
The RSCL and the CARES-SF seem to be suitable cancer-specific instruments to be used 
in economic evaluation. Both instruments have good test-retest reliabilities. When 
comparing the internal consistency and validity of the tests, there is some preference for 
the RSCL. In addition, this instrument has the potential to add items (illness or treatment-
related variables). By adding items concerning possible side-effects associated with a 
particular treatment, it is possible to gain more insight into these side-effects. For 
example, in a study comparing the cost -effectiveness of a treatment with a colony stimula-
ting factor and a conventional treatment, we added some items concerning possible side-
effects associated with the colony stimulating factor (see * in Appendix A3). As there is 
little infonnation on the psychometric features of the EORTC Core QoL questionnaire, 
this questionnaire has not been taken into account. However, this questionnaire is still 
used in several EORTC trials. Thus, in the near future more information about the 
psychometric features of this questionnaire may be expected. 
As stated, in economic evaluation valuation of health states in tenns of one value 
judgement is necessary. The valuation instruments mentioned are divided into two palis,a 
descriptive and a valuation part. By using the descriptive part it is possible to construct 
health states which can be evaluated by the general public. The valuation part mostly 
consists of a thennometer which enables the patient to evaluate his or her own health 
state. When a study is conducted from a social viewpoint the valuations of the health 
states by the general public have to be taken into account, but by acquiring valuations of 
own health states by patients the opportunity arises to compare these with the values from 
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the general public. However, when a validated set of utility values is available, the use of 
the descriptive part may be sufficient. Concerning valuation instruments, the Torrance's 
Health State Classification System, and the Rosser & Kind Index have good reliability 
features, but the internal consistency of these questionnaires is unknown. The Torrance's 
Health State Classification System is used less often and is, therefore, not appropriate. 
The MUMQ lasts about 45 minutes and the Rosser & Kind Index lasts at least 1. 5 hour, 
so these instruments are also not appropriate for economic evaluation of technologies in 
cancer treatment. The valuation instrument developed by the EuroQoL group (rating scale 
using a thermometer) has good psychometric features. The descriptive part of the 
EuroQol lasts about 1 minute, the valuation part about 20 minutes. 
The QWB scale also has good psychometric features, but the descriptive part lasts about 
18 minutes. While combining this instrument with a generic and a cancer-specific instlu-
ment, the duration of the whole interview would become too long. For that reason we 
prefer the use of the EuroQol to the QWB. 
When using the NHP, the RSCL and the descriptive part of the EuroQol the whole 
interview would last about 20 minutes. We know from experience, based on 200 patient 
questionnaires administered at several states in the cancer treatment, that this is acceptable 
to patients. 
4.6 Design and practical issues 
For the design of quality of life measurement in economic evaluation of technologies in 
cancer treatment at least the following issues have to be taken into account: the choice of 
respondent, the method of data collection, the time and frequency of administering 
questionnaires and the analysis of data. 
Quality of life questions are usually addressed to the patient. When the patient is not in a 
position to answer the questions, for example, due to serious health problems, the respon-
dent could be a relative, nurse or doctor (Sprangers and Aaronson, 1992). There are 
several methods of data collection available, namely verbal (interview), written (question-
naires) and the personal computer. The written questionnaires are most often used and 
require less infrastructural arrangements. 
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Ideally, the data collected should describe quality of life of patients before, during and 
after treatment. The choice of time scale depends on the nattlral history of the disease and 
on the timing and pattern of treatment. During intensive treatment periods it may be 
imp0l1ant to have frequent measurements of quality of life, sometimes intervals of 1 or 2 
days may be desirable (Fayers and Jones, 1983). If there is a survival benefit it is 
important to take into account quality of life during life years gained. In this respect, it is 
necessary to make a distinction between curative and palliative treatment modalities. In 
both modalities quality of life measurement is very important, but the outcome indicators 
differ. In palliative treatment modalities, quality of life is the single most important 
outcome indicator. For curative treatment modalities, the most important indicator is the 
assessment of quality of life of life years gained, which is estimated by a separate 
observation of survival and quality of life. 
There are several constraints on the choices regarding frequency and timing of quality of 
life assessments. If these are infrequent, then transient effects most likely during and after 
each treatment, may be missed. On the other hand, enquiries which are too frequent may 
well be too imposing on the patient, especially as this may be a time of particular stress 
because of the disease and its treatment. Patients' compliance is likely to depend on the 
way in which the assessment forms are explained to patients if self-assessment is 
required, the degree of encouragement given and the frequency with which the completed 
forms are collected and inspected; hence in a multicentre trial, patients' compliance may 
vary considerably from centre to centre (Fayers and Jones, 1983). Good coordination may 
enhance response rates and this may require one person being responsible for all aspects 
of processing of the interviews. 
As economic evaluation generally requires lifelong follow-up, a modelling approach may 
be necessary to predict lifelong consequences. By specifying a simulation model or a 
MARKOV model defining various states characterised by health status andlor specific 
treatment (associated with a cost profile), the follow-up period of the actual clinical trial 
may be reduced. (Figure 4.1). It will be assumed that each state can be characterised by a 
unique quality of life. The following disease states are possible: disease-free, partial 
remission, relapse (symptom-free), relapse (symptoms) and terminal state. The measure-
ment and valuation of quality of life of patients in the terminal phase of cancer may be 
difficult, because these patients may be "off protocol" and difficult to approach. Accep-
table compliance rates require motivation of the patient, sophistication of the procedure 
and a permissive attitude towards the ideal interview schedule. 
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Figure 4,1 Example of a modelling approach 
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To analyse the data several statistical methods and computer programmes are available, 
The choice depends on the design and the type of data, The study protocol should include 
a brief description of how the data are to be analysed, including the tests which are to be 
used, 
4,7 Discllssion 
Quality of life measurement and valuation is an essential part of economic appraisal of 
programmes in cancer treatment. To improve the comparability of the results of such 
studies and to increase the opportunities to generalise from the resulting findings it is 
necessary to achieve standardisation in design of quality of life research and the choice of 
instruments, Given that in most prospective studies a "piggyback" economic analysis is 
performed, meaning that the economic evaluation is added on to a clinical trial (some-
times after major decisions on design and data collection have been taken), the economic 
analyst finds himself in a stronger position when there is already consensus among 
researchers about the requirements for quality of life measurement from the economic 
perspective, This paper aims at contributing to consensus building in this area, 
A practical problem in the selection of instruments is their availability for use in studies, 
There seems to be a tendency toward commercialisation and consequent restriction of 
usage which may hamper a free scientific discourse on psychometric properties and pros 
and cons of the available instruments, In our opinion there is not yet enough empirical 
data to decisively assess the comparative advantages of existing measurement and 
valuation instruments and no thresholds should be formed for producing such evidence, 
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A final problem is the measurement and valuation of quality of life in the terminal phase 
of cancer. In prospective trials it is often difficult to organise data collection on quality of 
life of patients in the final stages of the disease as they may be "off protocol" or 
otherwise difficult to approach. It seems practical to launch a specific research pro-
gramme to measure quality of life in these stages and to analyse differences across disease 
categories in order to produce a set of generally applicable values to be used in other 
studies. 
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Cost of stem cell transplantations 

5 
ABMT in non-Hodgkin's lymphoma and acute leukaemia 
5.1 Summary 
In a Dutch "investigative medicine" project, where autologous bone marrow transplanta-
tion (ABMT) was compared with conventional chemotherapy in non-Hodgkin's lymphoma 
(NHL) patients (HOVON-3 study), a cost analysis was carried out in five Dutch hospitals. 
By means of detailed cost registration forms, hospital information systems and interviews 
with haematologists, research nurses and research analysts, the costs of ABMT were 
estimated at US$ 35220' per patient. The HOVON-3 study only concerned NHL patients. 
The costs of ABMT in other patient categories were almost similar to the cost in this 
category with the exception of acute leukaemia patients. In general the latter patients 
stayed longer in hospital and needed more intensive isolation care, more blood transfu-
sions and more antibiotics. The costs of this group were estimated at US$ 48000 per 
patient. 
5.2 Introduction 
In the Netherlands, little is known about the cost of ABMT. This kind of information is 
important for the reimbursement policy. In 1987, a cost-effectiveness analysis concerning 
bone marrow transplantation had been carried out (Engel et al., 1987). This study placed 
emphasis on allogeneic transplantations. Furthermore, a clinical trial has been carried out 
in patients with non-Hodgkin's lymphoma (NHL). This study compared ABMT with 
conventional chemotherapy (HOVON-3 study; HOVON = Dutch Working Party on 
Haemato-Oncology). A cost-effectiveness analysis was linked to this trial. 
Contrary to the Dutch paper, the costs mentioned in Ihis chapler are presented in US dollars, where 
1 USS = 1.8 DUlCh guilders. 
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The registration of costs took place in 5 Dutch hospitals, namely the Dr. Daniel den Hoed 
Cancer Centre in Rotterdam and the university hospitals in Rotterdam, Utrecht, Gronin-
gen and Maastricht. Information to calculate the unit prices was collected in the centres in 
Rotterdam and in Utrecht. 
In April 1992 the Health Executive Board asked the HOVaN-group some questions about 
the daily practice of ABMT in the Netherlands. One of these questions concerned the 
costs of this treatment modality. On request of the HOVaN-board, we have carried out a 
side-study to calculate the average costs of ABMT in the Netherlands. For this side-study, 
data from the HOVON-3 cost-effectiveness analysis have been used. This analysis concer-
ned 18 completed transplantations. This was about 15% of all ABMTs in this patient 
group in the period 1989 - 1991 (Dutch Health Executive Board, 1993). 
The HOVON-3 study only considers patients with NHL. Therefore, we have also 
analysed 20 patients with acute leukaemia. Based on these data sets, the average costs of 
ABMT in the Netherlands have been estimated. 
5.3 Methods 
A registration system has been developed to collect information on the resource 
utilisation. A pre-transplantation and a transplantation period were distinguished. Unit 
costs of all activities during these two periods were determined, reflecting the real use of 
resources. As far as the Dutch tariff system reflects real resource use, a unit charge was 
used (Rutten et al., 1993). As mentioned above, 18 ABMTs in patients with NHL and 20 
ABMTs in patients with acute leukaemia have been analysed. The year of study was 
1991. The most important activities and the corresponding unit prices were as follows: 
Staff: The following staff was included: doctors, nurses, anaesthetic-analysts and research-
analysts. The calculation of labour costs were based on Dutch salary scales. The average 
cost per hour varied from US$ 17.51 (nurses) to US$ 69.44 (doctors), including a 35% 
increase for social security premiums. 
Hospitalisation: The costs of hospital days were divided into direct and indirect costs. 
The direct costs concerned manpower and materials. Indirect costs were related to 
overheads. The costs of normal haematological care, care in a protected environment and 
intensive care were analysed in detail. A hospital day costs about US$ 347 for normal 
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haematological care, US$ 536 for care in a protected environment and US$ 1167 for 
intensive care. 
Laboratory services: The output of laboratory services is measured using a point system, 
and with each point (unit of output) a unit price is associated. Each laboratory service 
corresponds to a number of points. The price of a laboratory service can be calculated by 
multiplying the number of points by a unit price per point. In general, the tariff is about 
US$ 0.94 per point. However, by summing up the direct and indirect costs of a particular 
laboratory and by dividing these costs by the total number of produced points in that 
laboratory, a global indication of the unit price per point can be obtained. The prices per 
point varied from US$ 0.62 (biochemistry and haematology services), to US$ 2.81 
(virology tests). 
Medical procedures: For all other medical procedures, the Dutch tariff system has been 
used as an approximation of unit costs. The tariffs were regarded as reflecting the real 
use of resources (Rutten et al., 1993). The assumption was that about 60% of the ABMT 
patients were covered by the Sick Fund Insurance and 40% of the patients were privately 
insured. 
5.4 Results 
5.4.1 Results non-Hodgkin's lymphoma group 
The ABMT period has been divided into a pre-transplantation and a transplantation 
period. The following results concerned 18 patients with NHL. 
Pre-transplantation period: The costs of the pre-transplantation period were divided into 
the costs of bone marrow harvest and other costs, such as hospitalisation, visits, labora-
tory services, medical procedures and medication (Table 5.1). New techniques, such as 
bone marrow purging, have not been applied in the HOVON-3 study, therefore these 
costs were not included. The costs of bone marrow harvest consisted of staffing, surgery 
room, medical equipment, and quality control of the bone marrow. The total personnel 
costs amounted to about US$ 678. The costs of the surgery room included other staff 
(mainly administration), materials and indirect costs. These costs amounted to about US$ 
500. The costs of medical equipment and the type of equipment used differed between 
hospitals, but were similar when aggregated. The average costs were about US$ 583. The 
other material costs included for example aseptic bottles, filters, medium, heparin, iodine 
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glasses, gloves, injections and bone marrow filter sets and amounted to about US$ 222. 
The quality control of the bone marrow consisted of bacteriological- and stem cell 
cultures. 
The costs of stem cell cultures were added to the bone marrow harvest. The bacterio-
logical cultures cost about US$ 167, i.e. on average 8 cultures per patient. 
Table 5.1 The average costs of the pre-transplantation period (in USS) 
Pre-transplantation period Costs 
(n=18) (US$) 
Bone marrow harvest 2150 
Hospitalisation and visits 1097 
Laboratory services 944 
Medical procedures 433 
Medication 42 
Total 4666 
Concerning the hospitalisation, the patients stayed on average 3 days in hospital on the 
normal haematological care ward. Furthermore, they were visited by a dentist and an ear, 
nose and throat (E.N.T.) specialist. The costs of laboratory services mainly consisted of 
auto-/alloantibodies against platelets and granulocytes and immunotyping. The medical 
procedures consisted of X-rays, electrocardiograms (ECGs) and bone marrow studies. 
The medication amounted to about US$ 42. However, this amount did not contain the 
high-dose chemotherapy, which the HOVON-3 patients received. 
Transplantation period: The 18 patients stayed on average 37.5 days in hospital (range: 
29-60). They stayed on average 12.4 days on the normal haematological care ward, 21.9 
in a protected environment and 3.2 days on the intensive care ward. The average costs of 
hospitalisation amounted to about US$ 19780 (Table 5.2). The medical procedures mainly 
consisted of the insertion of a central venous catheter and X-rays, ECGs and 
computerised tomography scans (CT-scans). FurthelIDore, a day before the ABMT the 
patients received total body irradiation (TBI). 
The medication consisted of cytostatics, antibiotics, drugs for selective decontamination of 
the digestive tract (SDD) and anti-emetics. The demanded nutrition differed between 
patients: some patients received bacterial free nutrition, other patients received parenteral 
nutrition. 
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Table 5.2 The average costs of the transplantation period (in US$) 
Transplantation period Cost 
(1/= 18) (US$) 
Hospitalisation (hotel) 19780 
Laboratory services 3350 
Medical procedures 1167 
Medication and nutrition 3422 
Blood transfusions 1667 
Total 29386 
The number and type of blood transfusions varied between patients and between hospitals 
(for example there was a difference between the number of donors per transfusion and the 
filtration andlor irradiation of the transfusions). The average costs were about US$ 1667 
per ABMT. This amount consists of 8 (filtered andlor irradiated) units of packed cells 
and 9 platelet transfusions, i.e. 6 donors, filtered and irradiated. The average costs of the 
transplantation period amounted to about US$ 29386. 
Average cost of ABMT: Only 80% of the bone marrow harvests actually resulted in 
transplantation. Therefore, for one transplantation about 1.25 bone marrow harvests had 
been carried out. This resulted in an average cost per ABMT of about US$ 35220. 
5.4.2 Results acme leukaemia group 
The costs of 20 ABMTs of patients with acute leukaemia have been analysed separately. 
The patients came from the university hospitals in Rotterdam and Utrecht and from the 
Dr. Daniel den Hoed Cancer Centre in Rotterdam. The number of days in hospital varied 
from 31 to 82 days; the average hospital stay was 49.3 days. The patients stayed on 
average 19.8 days on the normal haematological care and 29.5 days in a protected 
environment. The hospital costs were about US$ 22694. The costs of laboratory services, 
medical procedures, medication (excluding the antibiotics) and nutrition depended on the 
number of days in hospital. Therefore, these costs were multiplied with a factor 1.31 
(49.3 days I 37.5 days). The costs of laboratory services amounted to about US$ 4389 
and the medical procedures cos ted about US$ 1528. The costs of medication (excluding 
antibiotics) and nutrition were about US$ 1864. The costs of antibiotics were analysed 
separately and amounted to about US$ 3967. 
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These patients received more blood transfusions than the patients with NHL. Further-
more, the administration of these blood transfusions continued after hospital discharge. As 
these outpatient administration of transfusions belonged to the ABMT, these costs were 
included. During the transplantation period, the blood transfusions costed on average 
about US$ 4342 and after hospital discharge they costed about US$ 3358. The total 
transfusions costs were about US$ 7700. The average costs of ABMT in this patient 
group amounted to about US$ 48000. 
5.5 Discllssion 
The HOVON-3 study only concerned patients with NHL. As the results of this study 
could not be generalised over all patient groups, we have carried out a side-study. The 
costs of the pre-transplantation and transplantation period turned out to be comparable to 
other patient groups, with the exception of patients with acute leukaemia. The supportive 
care for acute leukaemia patients was more intensive; patients stayed longer in the 
hospital, needed a longer stay in a protected environment and needed more antibiotics and 
blood transfusions. The laboratory services, medical procedures and the other medication 
depended on the number of days in hospital. Therefore, we analysed the costs of ABMT 
in patients with acute leukaemia separately. 
In 1991, the average costs of ABMT amounted to US$ 48000 for patients with acute 
leukaemia and US$ 35220 for other patient groups. However, these results did not include 
the costs of follow-up after an ABMT, such as outpatient visits, laboratory services and 
re-admissions due to complications. This information is also of importance for the 
decision whether or not to allocate separate funds for ABMTs. 
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6.1 SUII/II/Gly 
In a retrospective study, we calculated the treatment costs of 63 patients, who received 
either autologous bone marrow transplantation (ABMT) with recombinant human granulo-
cyte colony-stimulating factor (G-CSF) (filgrastim) (I! = 13) or without G-CSF (1!=22) or 
alternatively, peripheral blood progenitor cell (PBPC) transplantation mobilised by G-CSF 
(1/=28). The recovery of granulocytes, platelets and reticulocytes after PBPC was 
markedly accelerated as compared with ABMT with or without G-CSF. The accelerated 
haematopoietic recovery was associated with a reduction in platelets and red blood cell 
transfusion requirements, with a reduction in episodes of fever and with earlier discharge 
from the hospital. This resulted in the average cost per treatment of the PBPC group 
being almost 30% lower than the treatment costs in the ABMT groups. 
6.2 Introductiol! 
Bone marrow transplantation, as an adjunct to very intensive chemo- and radiotherapy. 
has significantly improved remission rates and survival in the treatment of acute leukae-
mias and malignant lymphomas. However, the procedure-associated risk of 5-15% fatal 
complications and the adverse effect on patients' morbidity can be serious due to a 
pancytopenic period of 3-4 weeks (Brandt et al., 1988). Moreover, the costs of autolo-
gous as well as allogeneic bone marrow transplantation are high, and the additional 
burden that these treatments place on hospital budgets raises concern (Dufoir et al., 1992; 
Welch and Larson, 1989). It is, therefore, relevant to not only assess the additional 
benefits to patients of new treatment options, but also to monitor their cost implications. 
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Haematopoietic growth factors make it possible to accelerate the haematopoietic recovery 
after an autologous bone marrow transplantation (ABMT) and thereby reduce the therapy-
related toxicity. As a result, a reduction in the initial hospitalisation and in the number of 
days on intravenous antibiotics was demonstrated (Nemunaitis et al., 1991). However, 
although the use of haematopoietic growth factors caused a shortening of the neutropenic 
period, the patients still had a median duration of severe neutropenia for 2 weeks, and 
had more than 3 weeks of thrombocytopenia (Nemunaitis et al., 1991). Therefore, 
additional strategies to further sh0l1en this period are required. 
In recent years, autologous transplantation of peripheral blood progenitor cells (PBPC) 
has attracted considerable interest because of the potential advantages in comparison with 
bone marrow, with respect to haematopoietic recovery (Bntgger et al., 1992; Siena et al., 
1989; Kessinger et al., 1989; Advani et al., 1992). PBPC might be used in conjunction 
with haematopoietic growth factors to support haematopoietic recovery after high-dose 
chemotherapy. 
This study considers the costs of PBPC transplantation mobilised by G-CSF (filgrastim) in 
comparison with ABMT without G-CSF and ABMT with G-CSF. The results are based 
on a retrospective study of detailed records of 63 patients. The perspective of the study 
was the hospital's point of view, that is, all hospital costs associated with PBPC and 
ABMT were considered. 
6.3 Patients and methods 
A total of 22 patients received ABMT without G-CSF (six solid tumours and 16 malig-
nant lymphomas), 13 patients received ABMT with G-CSF (12 solid tumours and one 
malignant lymphoma) and 28 patients received PBPC with G-CSF (19 solid tumours and 
nine malignant lymphomas) (Richel, 1992: Richel et al., 1993). The latter group included 
six patients, who received a second PBPC reinfusion within 4 weeks. For the patients 
who received two reinfusions, the average costs of the two PBPC reinfusions were taken 
into account, as the aim of the cost analysis was to compare the costs of PBPC with the 
costs of ABMT. These patients received only one PBPC mobilisation and harvest; the 
costs of the pre-transplantation were not averaged. 
Patients' characteristics are summarised in Table 6.1. The solid tumours mainly consisted 
of patients with breast cancer and germ cell tumours. The high-dose chemotherapy 
regimen of this group consisted of CTC (cyclophosphamide, thiotepa and carboplatin). 
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The regimen for patients with malignant lymphomas consisted of carmustine, cyclophos-
phamide, etoposide, and cytarabine (BEAC) or cyclophosphamide, carmustine and 
etoposide (CBV) or carmustine, etoposide, cytarabine and melphalan (BEAM). The 
proportion of solid tumours and malignant lymphomas was not equal across the three 
treatment groups. As all treatments consisted of similar high-dose chemotherapy, 
regardless of ABMT or PBPC, the costs of these regimen were considered as identical 
and disregarded in our analysis. 
Table 6.1 Palients' characteristics 
Control group ABMT + PBPC + 
ABMT G-CSF G-CSF 
group group 
Number of patients 22 13 28 (34') 
Median age, years (range) 30 (21-54) 32 (18-44) 41 (18-60) 
Sex: 
- Male 11 7 12 
- Female 11 6 16 
Diagnosis: 
- Breast cancer 1 4 11 
- Non-Hodgkin's lymphoma 10 4 3 
- Morbus Hodgkin's 6 1 6 
- Germ cell tumours 5 4 6(11') 
- Neuroblastoma 0 0 I (2') 
- Medulloblastoma 0 0 1 
. Six patients received 2 PBPC reinfusions: five patients with germ cell tumours and 
one patient with neuroblastoma. 
The PBPC mobilisation was performed on an outpatient setting. The lymphoma and germ 
cell tumour patients received one course of chemotherapy, namely cyclophosphamide (1 
g/m2) on day 1 and etoposide (100 mg/m2) on days 1-3 intravenously. The breast cancer 
patients received one course of FEC (500 mg/m2 5-fluorouracil, 120 mg/m2 epidoxombi-
cin and 500 mg/m2 cyclophosphamide). The chemotherapy was immediately followed by 
the administration of G-CSF at a dosage of 300 flg subcutaneously, daily for 10 days. 
The leucaphereses were performed with a leucapherese machine (the CS300 of Cobe) on 
3 consecutive days. Both the leucaphereses and the bone marrow were cryopreserved. 
Additionally, a Hickman catheter was inserted. Three days after the administration of the 
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high-dose chemotherapy, the stem cells were reinfused. The patients received 300 I'g G-
CSF daily until the granulocytes' recovery was stable. 
The costs were considered separately for the pre-transplantation and the transplantation 
period. The pre-transplantation period included bone marrow (BM) or peripheral stem cell 
(PSC) harvest, cryopreservation and cultures, diagnostics, laboratories, hospitalisation, 
day-care department, medication, blood transfusions and the insertion of a Hickman 
catheter. The costs in the transplantation period related to days in hospital, laboratory 
services, diagnostics (mainly X-rays and ECGs), medication (antibiotics, anti-emetics, 
etc.) and blood transfusions. These costs have been registered through cost registry 
forms. Cost price studies have been carried out for all costs. The years of study were 
1990-1992. 
Statistical methods included Kruskal-Wallis tests for comparisons of costs and for 
comparisons of time-to-event outcomes for the days in hospital (Glantz, 1989). 
6.4 Unit prices 
For each of the activities mentioned above, unit prices were determined reflecting the real 
use of resources. The year of study was 1992 (1 US$ ~ 1.8 Dutch guilders). The unit 
prices are sununarised in Appendix A4. The cost of hospital days and treatment in a day-
care department were divided into direct and indirect costs. The direct costs concerned 
manpower (doctors, nurses, etc.) and materials (medical devices, supportive patient care, 
etc.). The indirect costs were related to overheads. The cost of hospitalisation amounted 
to approximately US$ 354 per day for normal haematological care; the direct costs were 
US$ 238 and the indirect costs were US$ 116. Staying in a protected environment cost 
approximately US$ 552; divided into direct costs of US$ 398 and indirect costs of US$ 
154. None of the patients was treated on an intensive care ward. A day of treatment in a 
day-care department cost approximately US$ 134 (approximately 50% direct costs and 
50% indirect costs). 
The output of laboratories in the Netherlands is measured in terms of a point system, and 
by each point (unit of output), a cost per unit or price may be associated, which differs 
across types of laboratories. The prices per point varied from US$ 0.62 (biochemistry and 
haematology laboratories) to US$ 2.81 (virology tests). The price of a routine test 
(including Hb, Ht, leucocytes and thrombocytes) amounted to 5.75 points and cost US$ 
3.58. For all other diagnostics, the Dutch tariff system has been used as an approximation 
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of unit costs (an X-ray chest about US$ 31 and an ECG US$ 22). The cost of the 
insertion of a Hickman catheter was US$ 504 (including the costs of the catheter). The 
drug prices used were wholesale prices. The costs of a 300 p.g vial of G-CSF (intrave-
nous) amounted to US$ 138. 
An additional study was performed to assess the average costs of both pre-transplantation 
periods. The cost of BM harvest, cryopreservation and cultures was estimated at US$ 
2043. In the PBPC group, the cost amounted to US$ 2740. The BM harvest was carried 
out on an inpatient basis, while the PCS harvest took place on an outpatient basis. The 
total costs of the pre-transplantation period amounted to US$ 5006 for both ABMT 
groups, and to approximately US$ 5915 in the PBPC group. 
6.5 Results 
6.5.1 Clinical results 
Table 6.2 shows that haematological recovery was significantly accelerated with PBPC 
transplantation as compared with ABMT. The time to recovery of granulocytes to > 
0.5x10'/l was 15.0 days for the control group, 12.5 for the patients who received ABMT 
with G-CSF and 8.0 for the PBPC group. For reticulocytes recovery to > 10%, it was 
23.0 days in the control group, 25.5 in the group receiving ABMT with G-CSF and 13.5 
in the PBPC group. The median number of days for platelets recovery to > 20xlO'/i in 
the PBPC group was approximately half that of the control group and the ABMT with G-
CSF group (10.9 versus 20.2 and 23.8 days, respectively). The median number of days 
for temperature recovery to < 38° C was also lower in the PBPC group: 2.5 versus 4.6 
and 5.5 days in the ABMT with and without G-CSF, respectively. 
Table 6.2 Clinical results 
Control group ABMT + PBPC + 
ABMT G-CSF G-CSF 
(1I~22) group group 
(median, range) (II ~ 13) (1I~34) 
(median, range) (median, range) 
Days granulocytes> 0.5xlO'/i 15.0 (11-17) 12.5 (9-18) 8.0 (6-11) 
Days reticulocytes > 10% 23.0 (17-28) 25.5 (15-38) 13.5 (10-22) 
Days thrombocytes > 20x1O'/i 20.2 (15-40) 23.8 (12-38) 10.9 (7-25) 
Days temperature > 38° C 5.5 (5-12) 4.6 (0-12) 2.5 (0-12) 
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6.5.2 Results cost analysis 
Patients treated only with ABMT or with ABMT and G-CSF had a mean hospital stay of 
37.9 days (range 19-70) and 36.2 days (range 24-68), respectively, while patients in the 
PBPC group had a mean stay in hospital of 22.4 days (range 17-38) (Figure 6.1). 
, 
" 
Figure 6.1 Days in hospital 
0.8 __________ 1. 
~0.6 
:0 
ro 
.0 
a a: 0.4 
0.2 
, 
, 
, 
" 
, 
- - - - - - - - - - .y- - - --. -
, 
, 
, 
" 
------------~-
, 
, , 
, 
o I--+I--If---- --f--I"-"---,-"+--- M------i-___ _ 
o 10 20 30 40 50 60 70 80 
Days in hospital 
FCOni",filroup - - ABMT + G-CSF ' PBPC group --l 
The most important cost items are summarised in Table 6.3. The patients in the control 
group stayed for 21 days in a protected environment, the ABMT with G-CSF group 14 
days and the PBPC group only 7 days. 
Table 6,3 Number of most important cost items 
Control group ABMT + PBPC + 
ABMT G-CSF G-CSF 
(11=22) group group 
(mean, range) (II = 13) (11=28) 
(mean, range) (mean, range)· 
Number of days in hospital 37.9 (19-70) 36.2 (24-68) 22.4 (17-38) 
Number of platelet transfusions 47.1 (18-179) 70.8 (10-161) 26.7 (9-100) 
Number of red cell transfusions 10.1 (3-21) 13.5 (4-35) 6.2 (1-29) 
Days of G-CSF treatment - 19.4 (10-30) 13.6 (8-45) 
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The accelerated haematopoietic recovery in the PBPC group was associated with a 
reduction in platelets and red blood cell transfusion requirements. G-CSF was given for 
19.4 days (range: 10-30) in the ABMT with G-CSF group, and for 13.6 days (range: 8-
45) in the PBPC group. 
The costs of the three treatment groups are sununarised in Table 6.4. The differences 
across the groups in the cost of the pre-transplantation period were in favour of the 
ABMT groups; US$ 5006 for both ABMT groups versus US$ 5915 for the PBPC group. 
However, the differences in the transplantation period were more pronounced and 
definitely in favour of the PBPC group. The hospitalisation costs amounted to approxima-
tely US$ 17578 for the ABMT group, US$ 15603 for the ABMT group with G-CSF, and 
US$ 9318 for the PBPC group. 
Considering only costs, ABMT with G-CSF does not seem to be a better treatment option 
than ABMT alone. Although the costs of hospitalisation were lower due to a shorter stay 
in hospital and in the protected environment, the costs of laboratory services, diagnostics, 
medication/nutrition and transfusions were higher. 
As compared with the other treatment groups, expenditure of the PBPC group was lower 
for all activities. The costs of hospitalisation decreased by more than 40%. The costs of 
medication/nutrition and transfusions were also significantly lower when compared to both 
ABMT groups, as were the costs of laboratory services and diagnostics. 
The costs of G-CSF were zero in the control group, US$ 2703 in the ABMT with G-CSF 
group, and US$ 1843 in the PBPC group. The costs of antibiotics and other medication 
decreased from US$ 3562 and US$ 3593, respectively, in the ABMT groups with and 
without G-CSF, to US$ 1590 in the PBPC group. Combining the costs of G-CSF with 
medication and nutrition, the costs of medication were somewhat lower in the PBPC 
group (US$ 3433) as compared to the control group, but this difference was not statisti-
cally significant. The medication/nutrition costs in the ABMT with G-CSF were remar-
kably higher (US$ 6296) as compared with the other two groups. 
The costs of transfusions decreased by more than 45%; from US$ 1584 and US$ 2209, 
respectively, in the ABMT groups to US$ 850 in the PBPC group. 
The total costs in the transplantation period decreased by more than 35 % in the PBPC 
group as compared with the other two groups. 
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Although the costs of the pre-transplantation period were higher in the PBPC group than 
in the ABMT groups, the total treatment costs decreased significantly; from US$ 30592 in 
the control group and US$ 32443 in the ABMT with G-CSF group to US$ 21809 in the 
PBPC group. 
Table 6.4 The average costs of ABMT with and without G-CSF 
in comparison with PBPC transplantation (in US$) 
Conlrol gl'Oup ABMT + G-CSF 
ABMT group 
Period (1/=22) (1/=13) 
Pre-transplantation 
BM or PSC harvesl, cryo-
preservation and cultures 2043 2043 
Diagnostics, laboratories 885 885 
Hospitalisation/outpatient visits 1367 1367 
Medication/transfusions 191 191 
Hickman calheler 520 520 
Total pre-transplantation 5006 5006 
Transplantation 
Hospitalisation 17578 15603 
Laboratory 2626 3006 
Diagnostics 236 323 
Medication/Nutrition 3562 3593 
G-CSF (filgrastim) 0' 2703 
Transfusions 1584 2209 
Total transplantation 25586 27437 
Total treatment costs 30592 32443 
PBPC + G-CSF 
group 
(1/=28) 
2740 
875 
402 
1378 
520 
5915 
9318' 
2123' 
170' 
1590' 
1843 
850' 
15894' 
21809 
Kruskal-Wallis test: • P < 0.05; , P < 0.01; 1 US$ = 1.8 Dulch guilders. 
A sensitivity analysis was performed to assess the effect of changes in the costs of 
hospital stay, transfusions and G-CSF. The dominance of PBPC was robust, even if the 
savings in hospital days were not taken into account. 
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6.6 Discussion 
The aim of our study was to assess the costs of PBPC in comparison with ABMT. 
Previous studies have already demonstrated the feasibility of PBPC (Brugger el al., 1992; 
Siena el al., 1989; Kessinger el al., 1989; Advani el al., 1992; Richel, 1992; Richel el 
al., 1993). Our results confirm that PBPC is an effective alternative to ABMT. ABMT is 
a costly procedure, as specialised care units and extensive supportive care are required. A 
reduction in costs of ABMT through the administration of haematopoietic growth factors 
could not be demonstrated in our study. Our results show a reduction of hospital days, 
but the costs of medication, due to the additional costs of the G-CSF, and transfusions 
were still higher in the ABMT with G-CSF group as compared with ABMT alone. 
However, for almost all activities, PBPC was cheaper than ABMT with or without G-
CSF. 
Often new treatment options show additional benefits to patients, but also add to the 
health care bill. To say that this will not be true for PBPC transplantation would be a 
premature statement as one may expect this new option, which constitutes a lighter 
burden both to the patient and to the financial manager in the hospital, to diffuse more 
rapidly in cancer treatment than ABMT. Our results suggest, however, that for patients 
with malignant lymphomas or solid tumours, who receive high-dose chemotherapy, PBPC 
transplantation is more cost-effective than ABMT. Further research will be needed to 
confirm this result. Moreover, as ABMT is associated with high mortality and morbidity 
rates, it may be worth also taking the effectiveness, including patients' quality of life, of 
PBPC into account. A "piggyback" economic analysis (an economic evaluation performed 
alongside a clinical trial) may be combined with future prospective trials to confirm the 
dominance of PBPC over ABMT in the patient groups considered here. 
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Stem cell transplantation in patients with multiple myeloma 
7.1 SUlllmary 
In a retrospective study, we calculated the treatment costs of 26 patients, who received 
either high-dose melphalan combined with granulocyte colony-stimulating factor (G-CSF; 
filgrastim) (11=7) or without G-CSF (11=11) or alternatively, peripheral blood progenitor 
cell reinfusion (PBPC) mobilised by G-CSF following high-dose melphalan. In compari-
son with the control group, a shortening of the pancytopenic period and platelet recovery 
was noticed in the PBPC group. This resulted in a reduction in hospital costs, diagnostics, 
laboratory services, total parenteral nutrition and transfusions. The average costs per 
treatment in the PBPC group amounted to about US$ 17908 as compared to US$ 32223 in 
the control group, implying a cost reduction of 44% when changing to PBPC reinfusion. 
7.2 Introduction 
High-dose melphalan is associated with high response rates in mUltiple myeloma, but the 
treatment associated morbidity and mortality is high (about 20%, due to complications of 
prolonged granulocytopenia) (Lokhorst et al., 1992; Selby et al., 1987). Transplantations 
with stem cells derived either from bone marrow or from peripheral blood, and/or the 
administration of colony stimulating factors are performed to hasten granulocyte recovery 
(Barlogie et al., 1990; Kessinger et al., 1989). Peripheral blood progenitor cell (PBPC) 
transplantation is increasingly used in the treatment of malignancies to alleviate bone 
marrow toxicity resulting from high-dose chemotherapy. It is introduced as an alternative 
to autologous bone marrow transplantation (ABMT) and has several advantages over 
ABMT, such as avoiding anaesthesia. It seems that infusion of PBPC after high-dose 
chemotherapy is associated with markedly accelerated platelet and neutrophil recovery as 
compared to ABMT (Kessinger et al., 1989; Advani et al., 1992; Siena et al., 1989). 
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This study focuses on the costs associated with the treatment of multiple myeloma 
patients. The results are based on a retrospective study of detailed records of 26 patients. 
The treatment modalities were high-dose melphalan combined with or without the 
granulocyte colony-stimulating factor (G-CSF; filgrastim), or G-CSF mobilised by PBPC 
transplantation following high-dose melphalan. 
7.3 Patients and methods 
The study included 26 patients with multiple myeloma. The PBPC group consisted of 8 
patients. PBPC were mobilised by G-CSF subcutaneously, and subsequently 1 litre of 
whole blood was collected by phlebotomy, kept unprocessed at room temperature and 
reinfused 24 hours after high-dose melphalan (Ossenkoppele et al., 1994). These patients 
were compared with a group of 18 patients with multiple myeloma who met the same 
criteria and whose pretreatment characteristics were equivalent. This group consisted of 
11 patients who received no G-CSF, 4 patients who received G-CSF starting at day 28, 
and 3 patients starting at day 3 after chemotherapy. Despite the addition of G-CSF to 7 
patients, there was no difference with regard to neutrophil and platelet recovery, days 
with fever, number of transfusions or hospital stay between these 7 patients and the other 
11 patients in the control group. 
The costs that were studied concerned days in hospital, laboratory services, diagnostics 
(mainly X-rays), the insertion of a subclavian catheter, medication (antibiotics, etc.) and 
blood transfusions. Data on these costs were collected through cost registry forms. 
Statistical methods included Wilcoxon tests for comparisons of costs and for comparisons 
of time-to-event outcomes for the days in hospital (Glantz, 1989). 
7.4 Unit prices 
For each of the activities mentioned above, unit prices were determined reflecting the real 
use of resources. The costs of hospital days were divided into direct and indirect costs. 
The direct costs concerned manpower (doctors, nurses, etc.) and materials (medical 
services, supportive patient care, etc.). The indirect costs related to overheads. The costs 
of hospitalisation amounted to approximately US$ 350 per day for normal haematological 
care, and US$ 1165 for intensive care. None of the patients were treated in a protected 
environment. 
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The output of laboratories in the Netherlands is measured in terms of a point system, and 
by each point (unit of output) a cost per unit or price may be associated, which differs 
across types of laboratories. The prices per point varied from US$ 0.62 (biochemistry and 
haematology laboratories) to US$ 2.81 (virology tests), the price of a routine test, 
(including haemoglobin, haematocrit, leucocyte and thrombocyte levels) amounted to 5.75 
points and cost US$ 3.58. 
For all other diagnostics, the Dutch tariff system has been used as an approximation of 
unit costs (a chest X-ray approximately US$ 31.00 and an electrocardiogram US$ 22.00). 
The costs of the insertion of a subclavian catheter were US$ 504.00 (including the costs 
of a catheter). The drug prices used were wholesale prices. The costs of 300 mg 
melphalan (intravenous) amounted to US$ 289.00 and the costs of a 300 I,g vial of G-
CSF (intravenous) to US$ 138.00. (See Appendix A4 for a list of unit prices used in this 
study). 
7.5 Results 
7.5.1 Clinical results 
For the 8 patients treated with high-dose melphalan and reinfusion of PBPC, the median 
time to recovery of granulocytes to 0.5xlO'/I was 12.5 days, for recovery of granulocytes 
to I. Ox 10'/1 was 14 days, and for platelet recovery to 20x1O'/i was 23.5 days (Table 7.1). 
Table 7.1 Clinical results 
PBPC group Control group 
Melphalan + Melphalan ± 
Clinical data G-CSF + PBPC G-CSF 
Days granulocytes> 0.5xlO'/l 12.5 (10-35)' 38.0 (24-65) 
Days granulocytes> 1.0xlO'/i 14 (12-55)' 42 (26-72) 
Days platelets > 20x1O'/i 23.5 (14-115)' 36.0 (25-172) 
Hospital stay in days 19 (16-39)' 43 (33-71) 
Days of antibiotic use 8 (0-37)' 21 (0-48) 
Number of platelet transfusions 21 (12-102)' 54 (30-228) 
Number of red cell transfusions 6 (3-21) 12 (3-66) 
Values are expressed as median (range); • P < 0.01; , P < 0.05. 
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In comparison with the control group, the pancytopenic period and period to platelet 
recovery were significantly shortened. There was 1 patient whose results differed from 
the control group. This patient had received half body irradiation as second line therapy. 
G-CSF was well tolerated and no adverse effects were observed. Only 1 patient developed 
fever after reinfusion. 
The patients in the PBPC group had a median hospital stay of 19 days as compared with 
43 days in the control group (P<O.OOOI) (Figure 7.1). Only 1 patient was treated in the 
intensive care department. This patient belonged to the control group and stayed there for 
6 days. 
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The number of days of antibiotic use decreased from 21 to 8 days. Furthermore, the 
number of platelet transfusions was reduced significantly from 54 to 21 transfusions. The 
number of red cell transfusions also decreased, but the reduction was not significant. 
7.5.2 Results cost analysis 
Table 7.2 presents the average treatment costs per category of costs. The costs of 
hospitalisation decreased by more than 50%, from US$ 16747 to US$ 7335 (P<0.005). 
The costs of laboratory services, antibiotics and other medication, nutrition and transfu-
sions were also significantly lower in the PBPC group. 
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Table 7.2 The average treatment costs of multiple myeloma patients (in USS) 
PBPC group Control group 
Melphalan Melphalan 
+ G-CSF + PBPC ± G-CSF 
Hospitalisation (hotel) 7335" 16747 
Laboratory services 767" 1776 
Diagnostics 765" 921 
G-CSF (filgrastim) 5293 1393" 
Antibiotics and other medication 2454" 6476 
Nutrition 229" 2148 
Transfusions 1065' 2762 
Total treatment costs 17908" 32223 
" P < 0.01; , P < 0.05; 1 US$ ~ 1.8 Dutch guilders. 
The costs of G-CSF were relatively low in the control group, because not all patients 
received G-CSF. The costs of antibiotics and other medication reduced markedly, from 
US$ 6476 to US$ 2454 (P<O.OI). When the costs of G-CSF were combined with all 
other medications, the costs in the study group were somewhat lower (US$ 7747 versus 
US$ 7869), but this difference was not significant. Only 3 patients in the PBPC group 
received total parenteral nutrition, while in the control group all patients received 
parenteral nutrition. The costs of nutrition decreased from US$ 2148 to US$ 229 
(P<O.OOI). The costs of blood transfusions were reduced by more than 60%, from US$ 
2762 to US$ 1065 (P<0.05). The total treatment costs decreased by 44% (P<0.005). 
The hospitalisation costs in the PBPC group were responsible for 41 % of the total costs, 
and for almost 52 % in the control group. 
7.6 Discllssion 
The clinical results of PBPC reinfusion mobilised by G-CSF collected by simple phlebo-
tomy without further processing showed a remarkable shortening of the haematopoietic 
recovery period in patients with multiple myeloma treated with high-dose melphalan. The 
neutropenic recovery was shortened with a median of 25.5 days, and the platelet recovery 
was also accelerated. This resulted in a remarkable decrease in hospital days and reduced 
use of antibiotics, platelet and red cell transfusions. One may argue that the addition of 
G-CSF to all patients in the control group would result in a cost reduction. However, the 
addition of G-CSF did not result in a reduction in the number of transfusions or in the 
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length of hospital stay in the patient group studied. Therefore, we do not expect a 
decrease in the total costs in the control group when G-CSF is provided to all patients. 
In general, when new treatment modalities become available, the additional financial 
burden that these treatments place on the health care system raises concern. However, in 
this study, PBPC reinfusion mobilised by G-CSF accounted for a remarkable reduction in 
costs. The reduction was observed regarding all activities in the treatment process. An 
improvement in the quality of life during the remission period has not been documented, 
but may also be expected. 
PBPC reinfusion appears to be a promising approach with a favourable cost-effectiveness 
profile, but further research is needed to show the real benefits from the patient perspec-
tive. 
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8 
ABMT in non-Hodgkin's lymphoma 
8.i Summary 
A prospective randomised clinical trial with simultaneous data collection for an economic 
appraisal was carried out to assess the effectiveness, quality of life and cost implications 
of ABMT versus standard chemotherapy in slowly responding patients with intermediate-
and high-grade malignant non-Hodgkin's lymphoma (NHL). The patients had a partial 
response after three cycles of chemotherapy and had no evidence of BM involvement of 
NHL. The overall and disease-free survival at 3 years were 61 % and 60%, respectively, 
in the ABMT group and 85% and 77% in the CHOP group (P=NS). Moreover, there 
were more (severe) complaints and symptoms in the ABMT than in the CHOP group. 
The average costs of CHOP chemotherapy were significantly lower than the average costs 
in the ABMT group (CHOP: US$ 3118 versus ABMT: US$ 34447). Considering long-
term consequences the ABMT group was more expensive (US$ 34580) and patients 
experienced 0.14 life years and 0.22 quality adjusted life years less than the CHOP group 
(discount rate 5%). As a result, changing therapy from CHOP to ABMT, as primary 
treatment in slow responders to CHOP, can not be recommended as the required 
additional investment does not produce health gains in terms of survival or quality of life. 
8.2 introduction 
Recently, several combination chemotherapies with curative intention have been develo-
ped for patients with non-localised non-Hodgkin's lymphoma (NHL) of intermediate- and 
high-grade malignancy. These intensive chemotherapies, consisting of first, second and 
third generation regimens, have yielded high remission rates. First generation regimens, 
which generally include four chemotherapeutic agents, produced complete remission rates 
in 50% of patients and the long-term survival was about 40% (Coleman, 1985). Several 
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second and third generation treatment programmes, consisting of six to eight chemothera-
peutic drugs, have been developed since then (Coleman, 1985). 
Initially, in these phase II single institution studies remission and survival rates improved, 
but prospective comparative trials did not demonstrate superiority of the new treatment 
programmes; the efficacy of first, second and third generation treatment regimens 
demonstrated similar results (Fisher et al., 1993; Gordon et al., 1992; Armitage et al., 
1986). Hence, the combination of cyclophosphamide, doxorubicin, vincristine and 
prednisone (CHOP) has remained the standard treatment for patients with intelmediate-
and high- grade NHL until today. For patients who do not reach a remission after the 
initial therapy or who relapse after CR, the prognosis is generally pOOl' regardless of 
further therapy. The most important prognostic factors in these patients seem to be 
whether a CR was achieved initially, as well as long duration of the remission (Armitage 
ef al., 1986). These patients receive further treatment with combination chemotherapy. 
High-dose chemotherapy and ABMT is an intensive approach that may result in cure for 
some of these patients (Salles ef al., 1994; Philips ef al., 1984; Verdonck et al., 1985; 
Philip ef al., 1987; Gribben et al., 1989), but randomised trials have not been completed 
to compare ABMT with standard salvage therapy in this patient group (Armitage, 1993). 
In the Netherlands, a randomised, multi centre trial has been performed to analyse 
whether patients, who show only partial response to initial chemotherapy will benefit 
from early high-dose chemo-radiotherapy and ABMT (Verdonck et al., 1995). All 
patients were treated with CHOP and evaluated for response after three courses. Those 
who achieved a partial response were defined as slow responders. These patients were 
randomised between another 5 courses of CHOP and high-dose chemo-radiotherapy and 
ABMT. 
ABMT is a costly procedure and most patients who undergo ABMT remain pancytopenic 
for 3-4 weeks, which may result in serious morbidity or even mortality (Hillner ef al., 
1992; Gulati and Bennet, 1992; Dufoir et al., 1992; Welch and Larson, 1989; Nemunaitis 
ef al., 1991). Thus, a prospective economic evaluation was carried out in close conjunc-
tion with the randomised clinical trial to be able to assess the costs and benefits of CHOP 
therapy and ABMT in this patient group. In addition, we made a specific effort to 
monitor the quality of life of the patients. As the results of the study will be used by the 
Dutch Health Insurance Executive Board, we adopted a social perspective for this 
economic evaluation study. This perspective implies that al\ costs and benefits for all 
parties in the society will be accounted for (Bonsel ef al., 1993). 
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8.3 Patients and methods 
8.3.1 Patient population 
Untreated patients between 15 and 60 years of age with newly diagnosed NHL of 
intermediate- or high-grade malignancy stages II-IV (Working Formulation) were eligible 
(National Cancel' Institute, 1982). The study group (the slow responders) consisted of 69 
patients (of a total of 284 evaluable patients) who were treated in the haematology 
departments of eight university hospitals, one specific cancer centre and one regional 
hospital, participating in the Dutch Working Party on Haemato-Oncology (HOVaN), 
between 1987 and 1993. 
8.3.2 Study design 
All patients received three courses of CHOP (cyclophosphamide 750 mg/m2 Lv. on day 1, 
doxorubicin 50 mg/m2 Lv. on day 1, vincristine (Oncovin) 1.4 mg/m2 Lv. on day 1 and 
prednisone 100 mg per os on days 1-5). Randomisation occurred if a PR without NHL 
infiltration in the BM was achieved after the third course of CHOP (Figure 8.1). These 
patients were randomised to either ABMT preceded by high-dose cyclophosphamide (2x60 
mg/kg Lv.) and total body irradiation (TBl; 800 cGy; one fraction) or to another five 
courses of CHOP. 
/' 
Entry ~ 3 X CHOP ~ 
" 
Figure 8.1 Study design 
Complete remission 
/' 
Partial response + - Randomisation 
negative BM 
Partial response + 
positive BM 
No response 
Evaluation 
5 x CHOP 
BM harvest 
I 
I X CHOP 
I 
ABMT 
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Bone marrow harvesting and subsequent cryopreservation took place as soon as complete 
marrow repopulation had occurred after the third CHOP course. The ABMT patients 
received a fourth course of CHOP the day after the bone marrow harvest. The CHOP 
group received five courses of chemotherapy on an outpatient basis. 
8.3.3 Effectiveness analysis 
As outcome parameters, percentage of complete remissions, the overall and disease-free 
survival and the quality of life after the treatment were considered. Economic evaluation 
requires the use of a generic health status measurement instrument at a disease-nonspecific 
level (Uyl-de Groot et al., 1994III). We included the Karnofsky Performance Index and 
the Nottingham Health Profile (Hunt et al., 1986). We also used the Rotterdam Symptom 
Checklist as a more sensitive instrument for measuring health status of cancer patients 
(Haes et al., 1990). Finally, we included the EuroQol instrument allowing the calculation 
of utilities (Van Hout and McDonnell, 1991). The questionnaires were administered to the 
patients 6 months, 1 and 2 years after the date of randomisation. 
For each arm, the duration of time spent in each health state was averaged over all 
patients and quality adjusted life years (QALYs) were calculated by multiplying the 
average time spent in each health state weighted by their respective utility values and 
aggregating these weighted time-periods per arm (Drunllllond et al., 19871). 
8.3.4 Cost analysis 
The cost analysis was based on a detailed review of patient and hospital records. We 
examined in detail all resources used for 42 patients from four university hospitals and 
one cancer centre. There were 21 patients in both treatment groups. Costs considered 
were: days in hospital, outpatient visits, day-care departments, laboratory services, 
diagnostics (mainly imaging procedures), radiotherapeutical and surgical procedures, 
blood products, medication, parenteral nutrition and consultations. 
For each of the activities mentioned above unit prices were determined reflecting the real 
use of resources. The year of study was 1992 (1 US$ ~ approximately 1.8 Dutch 
guilders). The costs of hospital days and outpatient visits were divided into direct and 
indirect costs. The direct costs concerned manpower (doctors, nurses, etc.) and materials 
(medical devices, supportive patient care etc.). The indirect costs were related to 
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overheads. The costs of hospitalisation amounted to about US$ 350 per day for regular 
haematological care, US$ 536 for staying in a protected envirorunent and US$ 1223 for 
an intensive care ward. An outpatient visit was cos ted at about US$ 87 and a treatment in 
a day-care department at about US$ 134. 
The output of laboratories in the Netherlands is measured in terms of a point system and 
a cost price per unit may be associated with each point. The cost prices differ across 
types of laboratories. The cost prices per point varied from US$ 0.62 (biochemistry and 
haematology laboratories) to US$ 2.81 (virology tests). A routine test (including Hb, Ht, 
leucocytes and platelets) amounted to 5.75 points and was cos ted at US$ 3.58. 
The ABMT patients received total body irradiation. For the costs of this irradiation a 
specific cost price study was carried out (Appendix A4.2). The costs of TBI amounted to 
US$ 882. For most diagnostics the Dutch tariff system has been used as an approximation 
of unit costs. The drug prices used were wholesale prices. The mean costs of one CHOP 
course amounted to about US$ 258 (Appendix A4.1 for a list of unit prices used in this 
study). An additional study was performed to assess the average costs of BM harvest, 
cryopreservation and BM cultures. These costs were estimated at US$ 2043 (Appendix 
A4.3). 
8.3.5 Malkov model 
To estimate the lifelong consequences of the treatment modalities in terms of costs and 
QALYs we specified a Markov model (Bonsel ef al., 1993). The following assumptions 
were made: 
- There are three health states: complete remission (CR) , no complete remission (NoCR) 
and death. 
- The movement of patients between health states occurs every year. 
- The transition probabilities for the first 3 years are derived from the clinical study. 
- Patients, who are in CR for 3 years, remain in CR for the rest of their life. 
- Patients who have had a CR for 2 years, but thereafter move over to the state NoCR, 
have a 50% chance to achieve a second CR. When a patient did not achieve a second 
CR, there is a 50% chance of dying in the next year. All other patients will die in 
the year after this. 
- When a patient dies, it occurs on average halfway through the period remaining in a 
particular state. 
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These assumptions were based on interviews with haematologists. As both costs and 
QALYs are not expected to change after 8 years, we considered a follow-up period of 8 
years. Both costs and QALYs were discounted at 5% (Drummond et al., 19871). 
8.3.6 Statistical analysis 
Survival and disease-free survival were calculated according to the Kaplan-Meier method 
(Kaplan and Meier, 1959). The costs of both groups were compared for the treatment, as 
well as the follow-up period using the Wilcoxon test (Glantz, 1989). The quality of life 
items are presented as mean scores. For the comparisons between the items the Mann-
Whitney and the Chi-square tests were used. 
8.4 Results effectiveness analysis 
8.4.1 Treatment response 
The clinical features of the patients are shown in Table 8.1. There were no statistically 
significant differences in the patient characteristics (age, sex and performance status) and 
disease characteristics (histology, lactate dehydrogenase and stage) in both treatment 
groups. The median follow-up time was 36 months (range: 2-86 months). 
Table 8.1 Patient characteristics 
Characteristics ABMT group CHOP group 
No. of patients 34 35 
Sex: 
- Male 15 13 
-
Female 19 22 
Age: 
- Median (yrs) 44 42 
Tumour histology: 
- Intermediate-grade 25 25 
-
High-grade 9 10 
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Characteristics ABMT group CHOP group 
Stage: 
-
II 17 15 
- III 6 9 
-
IV II II 
Extrallodal sites (1I0): 
- 0 17 17 
-
1 12 13 
- 2-4 5 5 
Lactate dehydrogellase (LDB): 
- < 250 U/I 7 7 
-
250-750 U/I 21 20 
- > 750 U/I 6 8 
Peljormallce statlls (WHO): 
- 0 13 15 
-
1 18 18 
- 2 3 2 
Following randomisation, eight patients assigned to the ABMT arm did not proceed to 
ABMT because of refusal (1/=3) and early relapse or progressive disease (11=5). Of 
patients allocated to CHOP treatment, seven patients did not complete the eight courses of 
CHOP because of progression of disease. The analysis was according to the "intention to 
treat" approach. After randomisation, a complete remission on treatment was achieved in 
68% of the ABMT patients and in 71 % of the CHOP patients. 
8.4.2 Overall survival alld disease-free survival 
In Table 8.2 the actuarial overall survival and disease-free survival are presented. The 
actuarial overall survivals at 1 year were 79% in the ABMT group and 88% in the CHOP 
group. At 2 and 3 years these percentages were 71 % and 61 %, respectively, in the 
ABMT group and 85% in the CHOP group. The disease-free survival at 1 year was 81 % 
in the ABMT group and 87% in the CHOP group. At 2 and 3 years these percentages 
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were 68% and 60%, respectively, in the ABMT group and 77% in the CHOP group. 
These differences were not statistically significant. 
Table 8.2 Actuarial overall survival and disease·free survival 
at 1, 2 and 3 years after randomisation 
ABMT group 
(p ± SE) 
Actuarial overall survival 
· at 1 year 78.5 (± 7.2) 
· at 2 years 71.2 (± 8.2) 
· at 3 years 61.0 (± 9.7) 
Actuarial disease{ree survival 
· at 1 year 80.5 (± 8.8) 
· at 2 years 67.5 (± 11.2) 
· at 3 years 60.0 (± 12.2) 
p = probability; SE = standard error. 
8.4.3 Quality of life study 
CHOP group 
(p ± SE) 
87.8 (± 5.7) 
84.6 (± 6.4) 
84.6 (± 6.4) 
87.0 (± 7.0) 
76.7 (± 9.2) 
76.7 (± 9.2) 
The results are based on 51 patient questionnaires. The non·response percentage was 
10%. 
Generic questiollnaires: 
The scores of the Karnofsky Perfonnance Index were slightly in favour of the CHOP 
group at all measurement points in time (Table 8.3). In the ABMT group, as well as in 
the CHOP group, the patients were feeling better over time. Considering the first part of 
the Nottingham Health Profile questionnaire (NHP·I) ABMT patients at 6 months and 1 
year, and the CHOP patients at 6 months reported mobility problems. The emotional 
reactions of the patients varied over time and between the treatment groups. At all time 
points holh patient groups had "lack of energy". The patients in both groups had problems 
with sleeping in the beginning. The NHP·II deals with activities of daily life. The ABMT, 
as well as the CHOP treatment had consequences for work/job, home duties, sex life and 
interests/hobbies. 
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Table 8.3 Mean quality of life scores in both treatment arms 
at 6 months, 1 and 2 years after randomisation 
Treatment arm ABMT CHOP 
6 months 1 yr 2 yrs 6 months 1 yr 
Questionnaire (11=7) (II =6) (11=7) (II = 6) (11= 12) 
KamoJsky Illdex' 79 85 89 83 88 
Nottillgham Health Profile l' 
- Mobility 12 12 4 12 3 
- Emotional reactions 6 4 3 3 6 
- Energy 36 25 27 25 28 
- Social isolation 0 7 9 0 7 
- Pain 7 3 0 0 12 
- Sleep 18 15 6 22 18 
Nottillgham Health Profile 11 
Present state of health causes 
problems for (% yes): 
- Job or work 29 40 29 50 33 
- Looking after home 43 17 29 33 25 
- Social Life 29 0 14 17 8 
- Home life 14 0 14 17 0 
- Sex life 29 17 14 67 8 
- Interest and hobbies 43 33 29 50 33 
- Holidays 14 0 14 17 25 
EuroQol' 
Patient score 54 81 87 78 76 
Population score3 66 72 89 86 80 
2 yrs 
(II = 13) 
92 
3 
5 
15 
6 
0 
7 
23 
15 
15 
8 
15 
23 
15 
88 
87 
'Range 0-100: from worst (0) to best health states (100); 'Range 100-0: from worst (l00) to 
best health states (0); 'Utility scores based on the valuations of patients and of a representative 
panel of the population for each health state were used to calculate average summary scores 
for each arm. 
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Treatment arm ABMT CHOP 
6 months 1 yr 2 yrs 6 months 1 yr 
Questionnaire (11=7) (II =6) (II =7) (II =6) (II = 12) 
R'dam Symptom Checklist' 
I. Dry mouth 3.4 2.5 2.0 1.3 1.2 
2. Tiredness 2.7 2.2 2.1 2.2 2.2 
3. Low back pain 2.1 1.8 1.7 1.5 1.7 
4. Anxiety 2.0 1.8 1.7 1.5 1.5 
5. Sore muscles 2.0 2.5 1.7 1.2 1.8 
6. Lack of appetite 2.0 1.3 1.3 1.2 1.2 
7. Lack of energy 2.0 1.7 1.6 1.5 1.6 
8. Worrying 2.0 1.7 1.6 1.5 1.5 
9. Decreased sexual interest 1.9 2.3 1.8 1.8 1.7 
10. Rash l.l 1.2 1.2 2.0 1.8 
'Answer possibilities: 1 = not at all, 2= a little, 3= quite a bit and 4=very much. 
The average values are presented. 
EuroQol: 
2 yrs 
(11= 13) 
1.4 
1.7 
1.4 
1.5 
1.4 
l.l 
1.5 
1.5 
1.4 
1.3 
At 6 months, the patient score and the population score were highest in the CHOP group. 
In both groups, the patients were feeling better over time. Two years after the randomi-
sation the score in both groups rose to 90 (average for the general population is ;:e 90 
(Bonsel et ai" 1992». 
ROllerdam Symptom Checklist: 
There were more (severe) complaints and symptoms in the ABMT than in the CHOP 
arm, especially at 6 months after randomisation (Table 8.3). The most important 
problems in the ABMT group were dry mouth (because of TBI), tiredness, low back 
pain, anxiety, sore muscles, lack of appetite, lack of energy, worrying and decreased 
sexual interest. Half a year after randomisation the most important complaints and 
symptoms in the CHOP group were tiredness, anxiety, rash and decreased sexual interest. 
Problems decreased over time in both groups. 
8.4.4 LOllg-term effectiveness 
For this analysis, we only distinguished between patients who were in CR and patients 
who were not in CR. Table 8.4 presents the utility scores as derived from the EuroQol 
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questionnaire for the two treatment arms per disease stage. For the Markov model the 
average utility of all patients who were not in CR will be used for both treatment groups. 
For the patients who were in CR the scores are derived from Table 8.3. The state "death" 
got the utility zero. 
Considering a follow-up period of 8 years, the cumulative, discounted survival amounted 
to 4.49 life years in the ABMT group and to 5.04 in the CHOP group on the basis of 
predictions using the Markov approach. The quality adjusted survival was 0.49 in favour 
of the CHOP group. 
Table 8.4 Utilities per stage and (quality adjusted) life years 
ABMT group CHOP group 
Utilities per stage 
CR 
- 6 months 0.63 (1I~6) 0.78 (1I~5) 
- I year 0.84 (II ~ 5) 0.81 (II~ 11) 
- 2 years 0.91 (II ~6) 0.92 (II~ 12) 
NoCR 
- 6 months 0.50 (1I~1) 0.65 (1I~1) 
- 1 year 0.50 (1I~1) 0.57 (1I~1) 
- 2 years 0.69 (1I~1) 0.53 (1I~1) 
Markov model: 8 years [allow-up 
- life years 5.01 5.81 
- life years discounted 4.49 5.04 
- QALYs 4.34 5.06 
- QAL Ys discounted 3.84 4.33 
8.5 Results cost analysis 
8.5.1 Costs of treatment alld follow-up 
Table 8.5 presents the average costs of treatment and follow-up per category of costs. 
Concerning the treatment period the hospitalisation costs in the ABMT group were 
responsible for 60% of the total costs, and almost 10% in the CHOP group, reflecting 
that the ABMT was given on an inpatient and the CHOP treatment on an outpatient basis. 
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The costs of laboratory services, diagnostics, medication (including the cytostatic drugs), 
nutrition and transfusions were also significantly lower in the CHOP group. The total 
treatment costs in the ABMT group amounted to US$ 34445 (range: US$ 5772 - US$ 
69065) and in the CHOP group US$ 3118 (range: US$ 1943 - US$ 6453) (P<O.OI). 
Table 8,5 Treatment and follow-up costs per patient in the ABMT and CHOP group 
Costs Costs 
ABMT group CHOP group 
(USS) (USS) 
(11=21) (11=21) 
Costs ill the treatmelll period 
BM harvest 2042" 0 
Hospitalisation 20759" 304 
Outpatient visits 207 766" 
Laboratory services 3128" 165 
Medical procedures 2300" 530 
Medication and nutrition 4368" 1353 
Transfusions 1641" 0 
Total treatment costs 34445" 3118 
Costs ill the follow-lip period 
BM harvest 117 333 
Hospitalisation 6055 4501 
Outpatient visits 2099 1132 
Laboratory services 1743 1147 
Medical procedures 3628 3800 
Medication and nutrition 1688 1368 
Transfusions 507 155 
Total follow-lip costs 15837 12436 
"P < 0.01; 1 USS = 1.8 Dutch guilders. 
The cost analysis includes two patients in the ABMT group who did not have an ABMT. 
Therefore, the average cost of an ABMT was higher, namely about US$ 37500. The 
mean hospital stay for ABMT was 38.74 days. The patients who had an ABMT stayed on 
average 14.74 days in a normal haematological care unit, 19.58 days in a protected 
environment unit and 4.42 days in an intensive care unit. 
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The follow-up period in the ABMT group concerned 20 patients, one of whom died 
during ABMT treatment. Twelve patients were hospitalised at least once. Furthermore, 
one patient received a second ABMT. This patient stayed 40 days in hospital and his total 
costs of treatment were US$ 34444. The total costs per patient in the follow-up period 
amounted to US$ 15837 (Table 8.5). 
Twenty-one CHOP patients were followed up. In the first year only one patient died. Two 
patients who did not achieve a CR, received an ABMT. These patients stayed 26 and 37 
days in hospital and their treatment costs were US$ 47744 and US$ 60147 respectively. 
The total costs per patient in the follow-up period amounted to US$ 12436. 
The total discounted costs of the ABMT group, comprising the initial treatment costs and 
the costs of the follow-up, amounted to US$ 49983 and in the CHOP group US$ 15285 
(Table 8.6). 
Table 8.6 Total costs per patient in the ABMT group versus CHOP group 
ABMT group CHOP group 
(USS) (USS) 
Total costs (1/=21) (1/=21) 
BM harvest 2159" 333 
Hospitalisation 26814" 4805 
Visits 2306 1898 
Laboratory services 4871" 1312 
Medical procedures 5928" 4330 
Medication 6056" 2721 
Transfusions 2148" 155 
Total costs 50282" 15554 
Total costs (discoul/ted at 5%) 49983" 15285 
Markov lIIodel: 8 years follolV-up 
Total costs 57102 20951 
Total costs discounted 56512 20397 
"P < 0.01; 1 US$ = 1.8 Dutch guilders. 
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8.5.2 Long-term costs 
The costs in the follow-up period differed between patients who achieved a CR and 
patients who did not achieve a CR (NoCR). However, there were no significant differen-
ces between ABMT and CHOP patients. The follow-up costs of patients who were 
disease-free during the 2-year follow-up, amounted to US$ 6686 in the first year and US$ 
2204 in the second year after randomisation. In the CHOP group these costs amounted to 
US$ 3793 in the first year and US$ 711 in the second year. 
Patients who did not achieve a CR, received second-line treatment. The average costs of 
the second-line treatment in the ABMT group amounted to US$ 27128 in the first year 
and US$ 8018 in the second year of follow-up. In the CHOP group the second-line 
treatment casted on average US$ 24584. The second year of follow-up amounted to US$ 
8167. 
Considering a follow-up period of 8 years, the cumulative costs according to the Markov 
approach amounted to US$ 56512 in the ABMT group and to US$ 20397 in the CHOP 
group (discount rate 5%). 
8.6 Discussion 
ABMT is now routinely used for the treatment of several haematologic malignancies. In 
this study we have assessed the effectiveness, quality of life and cost implications of 
ABMT versus standard CHOP chemotherapy in slowly responding patients with interme-
diate- and high-grade malignant NHL. The results of the clinical trial showed no 
significant differences in the rate of complete remissions, overall survival and disease-free 
survival. Long-term quality of life has been measured by multiple instmments, but there 
were no significant differences between the ABMT and the CHOP group. However, the 
cumulative costs in the ABMT group were significantly higher than those in the CHOP 
group. 
Considering the costs of ABMT and the failure of this very intensive treatment to 
improve overall and disease-free survival and quality of life, we conclude that early 
application of ABMT in slowly responding patients is not indicated. However, a small 
benefit in favour of ABMT cannot be completely excluded, but is very unlikely (Ver-
donck et al., 1995). 
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Although the study results were not in favour of the ABMT group, the results may still be 
useful. In the literature little is known about the expenses and long-term quality of life of 
NHL patients following ABMT. The study shows that both long-term ABMT and CHOP 
survivors had a relatively good quality of life. Furthermore, the cost analysis provides 
insight into the costs of ABMT, chemotherapy and follow-up including relapse treatment 
in this patient group. As the costs are presented in detail and specific cost studies have 
been carried out, the results may be useful to policy makers. 
Generalisation of our results may be slightly limited due to the location of the trial, that is 
mainly haematological intensive care hospitals. Such a "selective enviromnent" makes it 
impossible to generalise study results to the average clinical practice. However, ABMT 
will not be carried out in average clinical practice and the treatment protocols are 
standardised. Thus, the costs of ABMT will hardly differ between these hospitals. 
However, the costs of CHOP chemotherapy and follow-up may differ from the general 
practice. 
Generalisation of the results to other countries is not straightforward as health care 
organisation and prices differ. Several cost studies in patients with other diseases have 
shown higher cost of ABMT. Hillner el al. (1992) reported a decision analysis of ABMT 
in metastatic breast cancer. The ABMT cost was only based on six patients and included a 
3-month cycle. The total charges were estimated at US$ 87980 and the estimated cost was 
US$ 66200 (our result: US$ 34445). The average hospital stay was 40 days and compa-
rable with our findings. The charges for pharmacy services were US$ 26470 and were 
remarkably higher than our findings (US$ 4368). Gulati and Bennet (1992) reported the 
results from a randomised, double-blind, phase III clinical trial comparing ABMT with 
and without GM-CSF in patients with Hodgkin's disease. The patients stayed on average 
40.5 days in hospital and the hospital costs amounted to US$ 34400. The median total 
ABMT charges were US$ 62500 and were comparable with the study of Hillner. In the 
study of Gulati, the high ABMT costs were mainly caused by the routine use of either a 
BM transplant unit or an intensive care unit, regardless of whether it was necessary. The 
costs per hospital day were similar to those in our study (for example, a day in an 
intensive care unit was valued at US$ 1317 (in 1989 dollars). The costs of supportive 
patient care, such as medication, transfusions and parenteral nutrition, were again much 
higher than in our study. The reason is twofold. First, in our study the patients received 
less supportive care. Second, the supportive care given, especially the medication, was 
much cheaper. In studies concerning patients with acute leukaemia, patients stay longer in 
the hospital and need more supportive care than NHL patients (Dufoir el a/. , 1992; 
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Welch and Larson, 1989). Thus, the costs of ABMT in this patient group are considera-
bly higher. 
The use of haematopoietic growth factors stimulates haematopoietic recovery and may 
reduce the costs of ABMT through a reduction in hospital days, antibiotics and transfu-
sion requirements (Gulati and Bennet, 1992; Nemunaitis et al., 1991; Uyl-de Groot et al. 
1994II). In the study of Gulati and Bennet the cost of ABMT with GM-CSF amounted to 
about US$ 39800, which is significantly lower than the treatment cost in the placebo 
group and is almost identical to our result. 
PBPC transplantation is a less costly alternative to ABMT (Uyl-de Groot et al., 1994II), 
but both the addition of growth factors and the use of PBPC transplantation are not 
expected to decrease treatment costs beyond the level of those in the CHOP group. 
Although ABMT as first-line therapy was not more cost-effective than CHOP therapy in 
non-Hodgkin's lymphoma patients who reached a partial response after three conventional 
cycles of chemotherapy and with BM free from NHL, this may not hold for other patient 
groups, such as patients who relapse from a previous CR after CHOP (Verdonck et al., 
1992). The additional costs of introducing ABMT for these patient groups will be 
considerable, but the effectiveness, including quality of life, of ABMT in these patient 
groups has barely been assessed (Desch et al., 1992). Further studies are needed to 
ascertain the benefits of ABMT in these patient groups. 
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GM-CSF in elderly patients with acute myeloid leukaemia 
9.1 Summary 
We conducted a prospective, randomised, multicentre clinical trial comparing the effects 
of GM-CSF as an adjunct to intensive chemotherapy in elderly patients with acute 
myeloid leukaemia (AML). The study was a combined study of the EORTC Leukaemia 
Group and the Dutch HOVON Haemato-Oncology Group and was supported by the Dutch 
Health Insurance Executive Board. The cost-effectiveness analysis part of the study has 
been conducted exclusively in the Netherlands. 
Patients of 60 years or more with untreated newly diagnosed AML were entered into the 
phase III study. The study was open to entry from November 1990 to October 1994. The 
patients were randomised to either daunomycin-cytosine arabinoside (control alm) or 
daunomycin-cytosine arabinoside with GM-CSF (GM-CSF arm). GM-CSF was given to 
the second group of patients during chemotherapy as well as during the phase of bone 
marrow suppression post chemotherapy. The patients were treated with one, or in case of 
a partial response, with two remission induction cycles, and when a complete remission 
was attained, they received one additional course of consolidation therapy. 
The primary end point was the effect of GM-CSF on the percentage of complete remissi-
ons (CRs). Survival duration, disease-free survival, the percentage of excessive toxicity, 
number of nights spent in hospital and frequency of admission, number of transfusions, 
frequency and nature of haemorrhages and infections, number of days of haematopoietic 
recovery, number of episodes of fever, infections, quality of life and costs were evaluated 
separately. 
CR was achieved in 46.2% (after induction cycle I) and 57.9% (after cycle II) of the 
patients in the control group and in 50.0% (after the first chemotherapy cycle) and 54.9% 
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(after cycle II) of the patients in the GM-CSF group (P=NS). The duration of survival 
and disease-free survival at 2 years after randomisation were estimated at 26% and 19% 
for the control group and 23% and 11 % for the GM-CSF group (P=NS). 
Thus there were no apparent differences as regards the response to chemotherapy, 
survival or disease-free survival as the result of GM-CSF treatment. However, there were 
significant differences in the time of recovery of neutrophils. For neutrophils > 0.5xlO'/1 
the median time to recovery was estimated at 3.74 wks in the control group and 3.62 wks 
in the GM-CSF group (P=0.003). The median time of recovery of neutrophils > 
1. Ox 10'/1 was estimated at 4.36 wks in the control group and 3.75 wks in the GM-CSF 
group (P=0.0003). 
Furthermore, the administration of GM-CSF resulted in moderate to severe toxicities 
attributed to GM-CSF. The quality of life analysis showed more problems with regard to 
depressed mood, diarrhoea and rash/eczema. Considering the long-term quality of life 
there were no significant differences between the two groups. Considering a follow-up 
period of 2 years, the cumulative, discounted survival amounted to 0.979 life years for 
the control group and to 1.007 for the GM-CSF group. The quality adjusted survival was 
0.800 for the control group and 0.816 for the GM-CSF group. 
The average costs of the primary treatment were higher in GM-CSF treated patients than 
in the control group, i.e. US$ 40782 and US$ 34465, respectively (P<O.OI). The costs 
during the follow-up period did not differ between the two groups. They averaged about 
US$ 11000 during the first year of follow-up and about US$ 6000 during the second year. 
The results of this randomised clinical trial indicate that daunomycin-cytosine arabinoside 
plus GM-CSF is not a cost-effective treatment strategy as compared with daunomycin-
cytosine arabinoside alone. 
9.2 Introduction 
Acute myeloid leukaemia (AML) is mainly seen in elderly patients. The generally reduced 
tolerance of older patients to the toxicity of chemotherapy and the increased preleukaemic 
conditions require special treatment strategies for AML in the elderly. Only few studies 
have especially dealt with therapy development of AML in elderly patients. 
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Complete remission (CR) rates achieved with intensive chemotherapy in older subjects 
have shown considerable variation among different studies. For instance, in a total of 431 
patients of 60 years and older among 5 studies, the CR rates following anthracycli-
ne/cytarabine treatment appear quite heterogenous: 49% CR (n=59) (Keating el al., 
1981),40% (n=226) (Yates el al., 1982),76% CR (n=33) (Foon el al., 1981),42% CR 
(n=43) (Rai el al., 1981), 28% CR (n=40) (Kahn el al., 1984), and 58% CR (n=31) 
(Lowenberg el al., 1989). A combination of mitoxantrone and cytarabine as first-line 
therapy did not result in improved complete response rates (Liu Yin el al., 1991). The 
results from studies also indicate that the probability of attaining CR declines progressi-
vely with increasing age (Keating el al., 1981; Yates el al., 1982). In a randomised phase 
III study in the elderly of the EORTC Leukaemia Cooperative Group the CR rate was 
58% in patients of 65 years and older (Lowenberg el al., 1989). About 20% of complete 
responders became "long-term" disease-free survivors even with no maintenance therapy 
for 2 years or more. One other comparative study of full-dose and attenuated chemother-
apy in 40 AML patients of 70 years and more has demonstrated that the toxicity was 
better tolerated when less than standard doses of anthracycline were applied to elderly 
patients (Yates el al., 1982). However, when chemotherapy dosage was reduced too 
much, treatment became inadequate and CR rates decreased significantly (Rai el al., 
1981). These observations are consistent with the conclusion that the balance between the 
benefits and risks of intensive chemotherapy are delicate, particularly in older patients 
(Keating el al., 1981; Foon el al., 1981; Kalm el al., 1984). 
Once a complete remission is obtained, duration of remission and survival are usually not 
different from those observed in younger patients. Obviously, the gain of achieving CR in 
aged patients should be deliberately weighed against the probability of drastically 
shortened survival in others. The advent of haematopoietic growth factors which on the 
one hand may improve the response and on the other shorten the neutrophil regeneration 
after chemotherapy, might be especially important in improving the outcome of the older 
category of AML patients. 
We conducted a prospective, randomised, multicentre clinical trial comparing the effects 
of granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to intensive 
chemotherapy in elderly patients with AML. The study was a combined study of the 
EORTC Leukaemia Group and the Dutch HOVON Haemato-Oncology Group and was 
supported by the Dutch Health Insurance Executive Board. The cost-effectiveness analysis 
part of the study has taken place in the Netherlands only. The aim of the latter analysis 
was to compare the costs and effectiveness of GM-CSF as an adjunct to intensive 
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remission induction chemotherapy. Special attention has been given to both the short- and 
long-term quality of life of the patients. 
9.3 Patients and methods 
9.3.1 Study design and treatment 
Patients of 60 years or more with untreated newly diagnosed AML were entered into the 
phase III study. The study was open to entry from November 1990 to October 1994. 
Eligible patients had to satisfy the following criteria: 1. cytological diagnosis of AML 
characterised by at least 30% blast cells in bone marrow smears belonging to one of the 
cytological subtypes of MO through M7 according to the French-American-British (FAB) 
classification. Patients were eligible when WHO performance was 2 or less and when no 
severe heart, renal, hepatic or pulmonalY disease or active uncontrolled infection were 
present. 
Patients were not eligible when they were refractory to platelet transfusion. Patients with 
blast crisis of chronic myelogenous leukaemia, myelodysplasia previously treated with 
chemotherapy or cytokines, other malignant diseases except basal cell carcinoma of the 
skin and stage I cervix carcinoma were ineligible. 
Figure 9.1 presents the study design. The patients were randomised to either two types of 
remission induction treatment, i.e., daunomycin-cytosine arabinoside without GM-CSF 
(control group: arm I) or daunomycin-cytosine arabinoside with GM-CSF (GM-CSF 
group: arm II). GM-CSF administration was initiated one day prior to the start of chemo-
therapy and was subsequently administered during chemotherapy (in an effort to enhance 
the cytotoxic efficacy of the chemotherapy by priming the GM-CSF sensitive leukaemia 
cells) as well as during the aplastic period post chemotherapy (in an effort to accelerate 
haematopoietic recovery from intensive chemotherapy and thereby mitigate haematopoietic 
toxicity). The patients were treated with one, or in case of a partial response, with two 
remission induction cycles, and when a complete remission was attained, they received 
one additional course of consolidation therapy (arm I: without GM-CSF and arm II: with 
GM-CSF). 
CSF 39-300 sterile powder (GM-CSF, Leucomax", Sandoz, Basle) for injection was 
supplied in vials as sterile lyophilised powder formulated with mannitol, human serum 
albumin, polyethylene glycol, and citrate/phosphate buffer. 
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Figure 9.1 Study design 
Randomisation 
Remission (Remission Consolidation Follow-up 
arm I induction I induction II) 
r-- r--
- DNR 30 mg/m2 iv days 1-3 same, but DNR 
- Ara-C 200 mg/m2 cont.iv days 1-7 only on day 1 
Entry 
Remission (Remission Consolidation Follow-up 
arm II induction I induction II) 
I-- f--
- DNR 30 mg/m2 iv days 1-3 same, but DNR 
- Ara-C 200 mg/m2 cont.iv days 1-7 only on day 1 
- GM-CSF 5 ltg/kg conLiv day 0 
to +28 or until granulocytes 
> 0.5xlO'/I (for 3 days) 
Attempts were made before, during, and following chemotherapy to control any medical 
problems such as bleeding, infection, and metabolic abnonmalities. Patients received 
platelet transfusions for haemorrhages. During the chemotherapy the patients were placed 
on a prophylactic regimen of transfusion to keep platelet counts above 10xlO'/I. Patients 
with fever received broad-spectrum antibiotics intravenously. Antibiotics were adjusted 
according to the in vitro sensitivity whenever a pathogen had been isolated. Red blood 
cell support was given to maintain the haematocrit above approximately 30%. 
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9.3.2 Evaluation of ol/tCOllle 
The primary end point was the effect of GM -CSF on the percentage of complete remissi-
ons (CRs). CR was defined as follows: a nonnocellullar bone marrow containing less than 
5 % blast cells including monocytoid cells, less than 10% blast cells and promyelocytes, 
and less than 50% eryUu'oid cells, no evidence of extramedullary leukaemia, and recovery 
of peripheral blood values to platelet counts of at least 100xlO'/I and neutrophils of at 
least 1.5x1O'/I. 
Partial remissions (PRs) were defined by bone marrow smears containing between 5.1 % 
and 25.0% blasts and less than 5% circulating blast cells. Failures to induction chemo-
therapy (NoCR) were classified according to Preisler el al. (1979), Le., drug resistance, 
regeneration failure, prolonged hypoplasia, hypoplastic death (Le., after the chemotherapy 
cycle), and early death (Le. during induction treatment). 
Survival duration was expressed in months (from diagnosis to death) and disease-free 
survival was expressed as the time interval (in months) between attainment of CR and 
relapse or death whatever came first. Frequencies of excessive toxicities, number of 
nights spent in hospital, frequencies of admission, frequencies of transfusions, frequencies 
and nature of haemorrhages and infections, number of days towards haematopoietic 
recovery, number of episodes of fever and infections were evaluated separately. 
9.3.3 Quality of life analysis 
The quality of life of the patients was measured through several patient questionnaires. 
First, the Karnofsky index was included. This index emphasises the physical performance 
and dependency. Second, the patients were asked to complete the Nottingham Health 
Profile. The Nottingham Health Profile was selected as a generic instrument to measure a 
broad spectrum of health dimensions and can be used over a wide range of disease 
categories. The following dimensions of well-being were measured: physical mobility, 
emotional reactions, energy, social isolation, pain and sleep. Third, the Rotterdam 
Symptom Checklist, a cancer specific questionnaire sensitive to changes in health of 
patients having cancer, was applied. 
As it is preferable in an economic evaluation to value health states in terms of one 
summary measure, the EuroQol, a valuation instrument, has been added to the question-
naire. This instrument allows the calculation of "quality adjusted life years" (QALYs), 
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where a life year gained is "adjusted" using this value judgement for quality of life. A 
multi-attribute utility function is available to calculate the values of all health states 
distinguished in the EuroQol questionnaire. The latter function can be used to arrive at 
utility values for each health state reported by the patients. 
Patients were asked to fill out the questionnaires at the start of the first treatment, during 
hospitalisation (Le. 2 days after (theoretically) completing GM-CSF treatment) after 
hospitalisation (when the patient was at home), and because a survival benefit was 
expected also during follow-up at 6 months, 1 year and 2 years after the date of randomi-
sation. 
9.3.4 Cost analysis 
The cost analysis was based on a detailed review of patient and hospital records. We 
examined in detail all resources used for the patients from the Dutch hospitals. Costs 
considered were: days in hospital, outpatient visits, day-care departments, laboratory 
services, diagnostics (mainly imaging procedures), radiotherapeutical and surgical 
procedures, blood products, medication, parenteral nutrition and consultations. 
For each of these activities unit prices were determined reflecting the real use of resour-
ces. The base year for the study was 1992. The costs of hospital days and outpatient visits 
were divided into direct and indirect costs. The direct costs concerned manpower 
(doctors, nurses, etc.) and materials (medical devices, supportive patient care etc.). The 
indirect costs were related to overheads. The costs of hospitalisation amounted to about 
US$ 350 per day for regular haematological care, US$ 536 for staying in a protected 
environment and US$ 1223 for an intensive care ward. An outpatient visit was calculated 
at about US$ 87 and a treatment in a day-care department at about US$ 134. 
The output of laboratories in the Netherlands is scored according to a point system. Each 
point can be expressed in a cost price per unit. The cost prices differ across types of 
laboratories. A routine test (including Hb, Ht, leucocytes and platelets) costed US$ 3.58 
and a blood culture costed about US$ 20.50. For most diagnostics the Dutch tariff system 
has been used as an approximation of unit costs. The cost of the insertion of a central 
venous catheter was US$ 504 (including the costs of the catheter). The drug prices used 
were wholesale prices. The costs of a 300 !'g vial of GM-CSF (intravenous) cos ted about 
US$ 138 and a 400 I'g vial about US$ 184. (Appendix A4.3 for a list of unit prices used 
in this study). 
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The cost analysis distinguishes treatment costs and costs of the follow-up period (maxi-
mum of 2 years). A discount rate of 5% was used. 
9.3.5 Statistical analysis 
The primary end point was the effect of GM-CSF treatment on the percentage of CR. In 
order to detect an increase of 15% (a = 0.05) in the CR rate from 50% to 65%, with a 
power of 85 % the required number of patients was 155 per treatment arm. Therefore, a 
total of 310 patients were required to be randomised. Approximately 310 patients will 
also allow to detect a treatment difference from 15 % to 25 % in terms of patients alive at 
2 years (a = 0.05 and fi = 0.20). 
For the comparison of the clinical characteristics and the quality of life and cost items the 
chi-square, the two-tailed Fisher's exact test, the Wilcoxon-Mann-Whitney test and 
Student's t-test as appropriate were used. 
9.4 Clinical results 
9.4.1 Response to treatment 
There have been 326 patients registered, 316 were eonsidered as eligible and 10 as 
ineligible. Reasons of ineligibility were incomplete data (1/=2), poor physical condition 
(1/=3) and other malignant disease (n=5). Of the remaining 316 patients, 289 patients 
have been documented and evaluated at the time of the analysis for this repOli. Table 9.1 
presents the patient characteristics. 
CR on the first induction cycle was achieved in 67 patients (46.2%) in the control group 
and in 72 patients (50.0%) in the GM-CSF group (P=0.884) (Table 9.2). Of 39 patients 
with a partial response 35 received a second cycle of induction treatment (19 reached CR) 
and 4 patients were "too early" to evaluate. A patient classified as resistant after inducti-
on, received a second induction course and reached CR. In total, 26 additional patients 
reached CR, leading to 163 CRs. Reasons for not attaining CR were related to resistance 
to chemotherapy, prolonged hypoplasia, death in hypoplasia and early death. In summary, 
there were no significant differences between the two groups. 
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Table 9.1 Patient characteristics 
Control group GM-CSF group 
Sex: Male 51.7% 55.6% 
Female 48.3% 44.4% 
Age (year): 60 - 70 year 70.4% 68.5% 
70 - 80 year 28.0% 29.0% 
> 80 year 1.6% 2.4% 
WEe: < 30 70.4% 67.5% 
< 100 20.8% 22.8% 
100+ 8.8% 9.8% 
FAB cytology: MO 5.9% 5.1 % 
MI 14.4% 20.3% 
M2 43.2% 35.6% 
M3 1.7% 1.7% 
M4 12.7% 14.4% 
M5 17.8% 16.1 % 
M6 4.2% 5.1 % 
M7 - -
Total: 145 144 
• WBC ~ white blood cell count (x109/1) 
Table 9.2 Response to induction and consolidation chemotherapy 
Control group GM-CSF group 
(I/~ 145) (I/~ 144) 
Complete response (%) 
After remission induction cycle I 46.2 50.0 
After remission induction cycle II 57.9 54.9 
No complete response (%) 
Resistance to chemotherapy 28.3 27.1 
Prolonged hypoplasia 0.7 4.2 
Death in hypoplasia 9.7 13.9 
Early death 3.4 -
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9.4.2 Overall survival alld disease-jree survival 
The duration of survival at 6 months, 1 and 2 years after randomisation were 61 %, 41 % 
and 26%, respectively, in the control group and 67%, 46% and 23%, respectively, in the 
GM-CSF group (P=0.62) (Figure 9.2). Of the 163 complete responders to intensive 
chemotherapy 12 patients died in CR (7 patients in the control group and 5 patients in the 
GM-CSF group). 
Figure 9.2 Overall survival of patients treated with chemotherapy with or without GM-CSF 
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Figure 9.3 shows the disease-free survival. The disease-free survival at 6 months, 1 and 2 
years after randomisation were 72%, 41 % and 19% in the control group and 80%, 37% 
and 11 %, respectively, in the GM-CSF group (P=0.65). 
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Figure 9.3 Disease-free survival of patients treated with chemotherapy with or without GM-CSF 
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9.4.3 Hospitalisation, GM-CSF and haematopoietic recovery 
Figure 9.4 shows the duration of hospitalisation during induction cycle 1. The median 
number of days in hospital are 32.0 days in the control group and 32.5 days in the GM-
CSF group (control group: mean 33.88 and range 3-75; GM-CSF group: mean 34.54 and 
range: 11-98) (P=0.87). The patients in the GM-CSF group received on average 17.78 
days GM-CSF treatment (median: 20; range: 0-46). GM-CSF administration started on 
day a in 68.6% of the patients. In 21.5% of the patients the GM-CSF administration 
began between 1-4 days after the start of the chemotherapy, in 7.4% between 4-6 days 
and in 2.5% after more than 6 days. This was in most instances according to the protocol 
as GM-CSF was required to be postponed in case of white blood cell counts (WBC) of 
30xlO'/l or more and was indicated to be initiated as soon as WBC had declined to 
20xl0'!!. In 43.5% of the patients the GM-CSF was interrupted or stopped although the 
WBC was less than 30, mainly due to possible toxicity of GM-CSF. 
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Figure 9.4 Duration of hospitalisation during induction cycle I. 
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Figures 9.5 and 9.6 present the time to recovery of polymorphonuclear neutrophils 
(PMN) of 0.5 and 1.0xlO'/l, from day I of treatment in patients who reached CR after 
induction cycle I. For PMN = 0.5xlO'/l the median time to recovery Was estimated at 
3.74 wks in the control group and 3.62 wks in the GM-CSF group. The relative risk of 
GM-CSF versus control is 1.852 and the 95% CI is (1.23, 2.78) (P=O.003). The median 
time of recovery of PMN > I. Ox 10'/1 was estimated at 4.36 wks in the control group 
and 3.75 wks in the GM-CSF group and the relative risk of GM-CSF versus control is 
2.145 (CI: 1.42 - 3.24) (P=O.0003). About 15-20% of the patients in the control group 
show a long lasting neutropenia and do not met PMN recovery even during 8-12 wks. 
This is in contrast to the results of the GM-CSF treated patients. 
Figure 9.5 Time to PMN > 0.5xI09/1 
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Figure 9.6 Time to PMN > 1.0xlO'/i 
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Figures 9.7 and 9.8 show the time of recovery to platelets (PLT) of 20 and 50xl0'/I from 
day 1 of chemotherapy induction cycle I for those who patients who reached CR after 
induction I. The median time of recovery to PLT > 20xl0'/I was 3.17 wks in the control 
group and 3.21 wks in the GM-CSF. The relative risk of GM-CSF versus control is 
1.188 and the 95% confidence interval (CI) is (0.80, 1.77) (P=0.39). The median time to 
recovery was estimated at 3.61 wks in the control group and 3.68 weeks in the GM-CSF 
group. The relative risk of GM-CSF versus control is 1.04 (CI: 0.73 - 1.54) (P=0.84). 
Figure 9.7 Time to PLT > 20xlO'/I 
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9.4.4 Fever 
Figure 9.8 Time to PLT > 50xW'/1 
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In Figure 9.9 the duration of fever during induction cycle I is presented. The median 
duration of fever is 6.0 days in the control group (mean: 8.13 and range: 0-41) and 10.0 
days in the GM-CSF group (mean: 11.48 and range: 0-40). The relative risk of GM-CSF 
versus control is 0.603 (CI: 0.465 - 0.780) (P<O.OOl). 
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Figure 9.9 Duration of fever during induction cycle I 
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9.4.5 Supponive care 
The patients in the control group received on average IS.12 days antibiotic treatment 
(median: 16.0; range: O-SO). In the GM-CSF group antibiotics were administered on 
average 19.9 days (median: 20.0; range: 0-40). The patients in the control group got on 
average 21.1S platelet transfusions (median: 12.0; range: 0-100). The number of platelet 
transfusions was classified as follows: 19.45 pooled donor and 1.74 single donor platelet 
transfusions. The patients in the GM-CSF group received on average 18.41 pooled donor 
and 2.65 single donor platelet transfusions, i.e. on average 21.06 platelet transfusions 
(median: 12.0; range: 0-99) (P=NS). The average number of red cell blood transfusions 
was not significantly different in the control group as compared with the GM-CSF group, 
12.46 (median: 11.0; range 2-40) versus 13.83 (median: 13.0; range: 2-48). 
9.4.6 Toxicity 
Table 9.3 shows the relative frequency of complications during induction cycle I. The 
frequencies of haemorrhages, liver abnormalities, oral toxicity, nausea, cardiac rhythm 
abnormalities, neurotoxicity, bone pain, phlebitis and infections were similar in both 
groups. However, the patients in the GM-CSF group experienced more diarrhoea, renal 
abnormalities, fever, cutaneous toxicity, hypotension, fluid retention and chills. 
Table 9.3 Relative frequency of complications during induction cycle 1 
Control GM-CSF 
group group 
Haemorrhage 
- no 50.4 49.2 
- only petechiae 23.6 27.0 
- other bleedings 26.0 23.8 
Liver 
- no abnormalities 63.1 54.1 
- mild (1.26 - 5 x normal) 26.2 35.2 
- severe (;;:: 5 x normal) 10.7 10.7 
Oral 
- no 76.0 72.1 
- erythema 17.4 16.4 
- ulcers and other toxicity 6.6 11.5 
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Control OM-CSF 
group group 
Nausea 
- no 33.3 35.0 
- yes 66.7 65.0 
Diarrhoeal 
- no 59.0 45.5 
- less than 2 days 22.1 25.2 
- more severe 18.9 29.3 
Renal' 
- normal 79.0 62.3 
- mild (1.26 - 2 x normal) 19.4 34.4 
-
moderate and severe (~ 2 x normal) 1.6 3.3 
Fever! 
- no 15.6 8.1 
- sub febrile « 38°C) 13.1 12.1 
- ;" 38°C 71.3 79.8 
Cutaneous2 
- no 59.8 41.8 
- erythema/desquamation/papules etc. 40.2 58.2 
Cardiac rhythm 
- no abnormalities 76.0 76.7 
- abnormalities 24.0 23.3 
Neurotoxicity 
- no 88.5 86.9 
- yes 11.5 13.1 
Bone pain 
- no 93.4 90.2 
- yes 6.6 9.8 
Hypotension2 
- no 88.6 69.4 
- yes 11.4 30.6 
Fluid retention2 
- no 43.1 25.8 
- yes 56.9 74.2 
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Control GM-CSF 
group group 
Chills' 
- no 86.1 64.8 
- yes 13.9 35.2 
Phlebitis 
- no 91.0 85.5 
- yes 9.0 14.5 
Infection 
- no 23.0 23.4 
- yes 77.0 76.6 
Ip < 0.05; 2 P < 0.01 
9.5 Results quality of life study 
9.5.1 Shor/-tenll quality of life 
Table 9.4 presents the quality of life of the patients at the start of the induction treatment, 
during hospitalisation and after hospitalisation for induction cycle l. At the start of the 
induction treatment there were no significant differences between the two groups. The 
scores on the Karnofsky, the EuroQol patient and the EuroQol population scores varied 
between 65 and 77. With respect to the Nottingham Health Profile, patients in both 
groups experienced problems with energy and sleep. The most prominent complaints! 
symptoms on the Rotterdam Symptom Checklist were tiredness, lack of energy, worrying, 
nervousness and lack of appetite. 
During hospitalisation the patients in the GM-CSF had more frequent problems as 
compared to the patients in the control group. The Karnofsky score, the EuroQol patient 
score and the population score in the control group were 76, 67 and 72, respectively, and 
in the GM-CSF group 63, 54 and 63, respectively. Concerning the Nottingham Health 
Profile mobility and lack of energy represent the main problems in both groups. How-
ever, taking into account the results of the Rotterdam Symptom Checklist, the patients in 
the GM-CSF treatment arm more frequently experienced "lack of energy" than did the 
patients in the control group (P<O.05). Depressed mood, diarrhoea and rash/eczema 
were less frequently seen on average in the control group. The greater frequency of 
diarrhoea and rash/eczema corresponded with the results of the toxicity analysis. All 
patients had "lack of appetite" and "loss of hair". 
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Table 9.4 Mean scores of quality of life in both treatment groups during induction I 
Start induction During After hospitalisation 
treatment hospitalisation (at home) 
Control GM-CSF Control GM-CSF Control GM-CSF 
group group group group group group 
(1/= 10) (1/= 11) (1/=20) (1/ = 10) (1/= 14) (1/ = 8) 
Karnofsky Index' 72.7 72.0 75.5 63.0 84.3 72.5 
NHP' 
- Mobility 11.5 12.2 16.9 27.4 10.5 28.0 
- Emotional reactions 8.7 18.2 8.4 16.7 5.6 6.1 
- Energy 26.9 23.5 25.7 25.9 15.9 29.1 
- Social isolation 5.5 8.6 4.1 8.3 2.9 0.0 
- Pain 5.9 6.0 4.2 14.5 3.1 4.5 
- Sleep 18.3 24.8 9.1 38.3 15.1 15.1 
EuroQol' 
- Patient score 70.6 64.8 67.1 53.5 72.7 68.0 
- Population score3 67.5 77.4 72.1 62.8 79.1 66.3 
Complaints RSCL' 
1. Tiredness 2.2 1.8 1.9 2.6 2.0 2.3 
2. Lack of energy 1.9 1.9 IS 2.5 1.4 1.4 
3. Worrying 1.9 2.0 1.5 2.0 1.3 1.6 
4. Depressed mood 1.3 1.6 1.4 . 1.6 1.2 1.3 
5. Nervousness 1.9 2.2 1.6 1.8 1.6 1.6 
6. Lack of appetite 1.9 2.0 2.0 2.7 1.5 1.3 
7. Nausea 1.2 1.7 1.6 2.1 1.4 1.1 
8. Diarrhoea 1.3 1.1 1.1' 1.9 1.0 1.0 
9. Loss of hair 1.1 1.1 2.7 2.8 2.4 2.4 
10. Shivering 1.1 1.3 1.4 1.9 1.3 1.3 
11. Rash, eczema 1.4 1.2 1.5' 3.2 1.4 1.5 
12. Painful joints 1.2 1.4 1.3 1.2 1.4 1.4 
, Range 0-100: from worst (0) to best health states (100); , Range 100-0: from worst (100) to 
best health states (0); 3 Utility scores based on the valuations of patients and of a represen-
tative panel of the population; 4 Answer possibilities: 1 = not at all, 2= a little, 3= quite a bit 
and 4 =very much. The average values are presented;· P < 0.05. 
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At home (after hospitalisation) the patients experienced fewer restrictions with respect to 
quality of life. The Karnofsky scores were 84 in the control group and 73 in the GM-CSF 
group. The EuroQol patient and population scores were 73 and 79 in the control group 
and 68 and 66 in the GM-CSF group. Considering the Nottingham Health Profile patients 
still had significant problems with energy, sleep and mobility. 
9.5.2 LOlIg-fenll quality of life 
At 6 months the quality of life scores of the control patients and GM-CSF treated patients 
did not differ (Table 9.5). The Karnofsky score, the EuroQol patient score and the 
EuroQol population score at 6 months were 90, 84 and 89 in the control group (11= 14) 
and 90, 81 and 89 in the GM-CSF group (1/= 15). 
Table 9.5 Mean scores of quality of life in both treatment arms in the follow-up period 
6 months 1 year 
Control GM-CSF Control GM-CSF 
group group group group 
(1/= 14) (1/= 15) (1/= 10) (1/ = 8) 
Karnofsky Index 90.0 90.0 83.0 82.5 
Nottingham Health Profile 
- Mobility 3.0 1.7 8.2 5.9 
- Emotional reactions 1.0 1.4 6.2 7.9 
- Energy 15.7 9.0 23.9 15.8 
- Social isolation 0.0 0.0 6.1 2.8 
- Pain 3.2 2.6 7.8 16.1 
- Sleep 3.6 2.6 3.9 20.4 
EuroQol: patient score 84.4 80.6 75.0 74.4 
EuroQol: population score 89.0 88.9 83.2 82.6 
At 1 year the Karnofsky scores and the EuroQol scores were almost equivalent. However, 
the patients in the GM-CSF group scored on average better on the dimension energy and 
scored worse with regard to the dimensions pain and sleep. As at 2 years the number of 
patients in CR and patients who are not in CR differed between the two groups, these 
scores are not presented. 
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In Table 9.6 the average quality of life scores of patients in CR and patients in NoCR are 
presented. At all time intervals the Karnofsky scores of the patients in CR were ;;" 90 and 
are similar to the scores in the general (healthy) population. The Karnofsky scores of the 
patients in CR at 6 months and 1 year are significantly better than the scores of the 
patients in NoCR. Although the scores at 2 years correspond with the scores at 6 months 
and 1 year, there were too little observations to notice a significant difference. 
Table 9.6 Average quality of life scores per remission slate in the follow-up period 
6 months I year 2 years 
CR NoCR CR NoCR CR NoCR 
(1I~22) (1I~7) (II ~ 13) (II ~ 5) (II ~4) (n~4) 
Karnofsky Index 94. I" 77.1 90.0' 64.0 95.0 70.0 
Nottingham Health Profile 
- Mobility 3.0 0.3 1.2 22.8 0.3 23.5 
~ Emotional reactions 0.6 3.0 2.3' 19.0 0.0' 27.3 
- Energy 5.5" 33.6 4.9' 6004 6.0 31.0 
~ Social isolation 0.0 0.0 1.5 12.8 0.0 16.0 
- Pain 3.8 0.0 12.9 8.0 12.0 6.5 
- Sleep 4.1 0.0 5.6' 25.8 17.8 6.5 
EuroQol 
- Patient score 87.2' 68.9 8004 56.3 81.3 59.5 
~ Population score 91.8' 80.1 92.0' 5904 97.8" 72.5 
Complainls RSCL 
I. Tiredness 1.5 2.1 1.8 2.2 2.0 2.3 
2. Lack of energy 1.2' 1.9 1.3 2.0 1.3 2.3 
3. Worrying 1.3 1.3 lA' 2.8 1.8 2.3 
4. Depressed mood 1.1 1.3 1.2 1.8 1.0 2.3 
5. Nervousness 1.3 1.1 1.7 2.2 1.3 2.3 
6. Lack of appetite 1.0 1.0 1.1' 2.2 1.0 1.8 
7. Nausea 1.1 1.0 1.1 1.2 1.3 1.3 
8. Diarrhoea 1.1 1.0 1.1 1.2 1.0 1.3 
9. Loss of hair 1.1 1.1 1.2 1.0 1.0 1.0 
10. Shivering 1.1 1.0 1.2 1.4 1.0 1.5 
It. Rash. eczema 1.1" 1.6 1.2 1.6 1.3 1.0 
12. Painful joints 1.5 1.7 1.9 2.0 2.0 1.5 
, p < 0.05. 
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At 6 months the patients in NoCR experienced more problems with energy (both on the 
Nottingham Health Profile and Rotterdam Symptom Checklist). Furthermore, the EuroQol 
population scores were better in the patients who were in CR. At 1 year not only the 
Karnofsky score was higher in the CR group, but also the dimensions emotional reac-
tions, energy and sleep of the Nottingham Health Profile, the EuroQol population scores 
and the complaints/symptoms lack of appetite and worrying of the Rotterdam Symptom 
Checklist were significantly better in the CR group. The complaint/symptom "lack of 
energy" did not differ significantly between the two groups (P=0.054). 
9.5.3 (Quality adjusted) life years 
For the calculation of the life years and QALYs we used the survival and disease-free 
survival data. Concerning the QALY calculation, we distinguished patients who were in 
complete remission and patients who were not in complete remission. The utility scores 
are derived from the EuroQol population scores at 6 months, 1 and 2 years (see Table 
9.6). The lifelong consequences of the treatment modalities have not been calculated, as 
this study only concerned elderly patients and there were no survival benefits, nor in 
favour of either the GM-CSF group or the control group. 
Table 9.7 presents the life years and QALYs in both treatment arms. Considering a 
follow-up period of 2 years, the cumulative, discounted survival amounted to 0.979 life 
years in the control group and to 1.007 in the GM-CSF group. The quality adjusted life 
years (discounted) were 0.800 in the control group and 0.816 in the GM-CSF group. 
Thus there are no differences between the two groups. 
Table 9.7 (Quality adjusted) life years in both treatment groups 
Follow-up: 2 years Control GM-CSF 
group group 
(1/=145) (1/= 144) 
Life years 0.995 1.023 
Life years discounted 0.979 1.007 
QALYs 0.813 0.828 
QAL Y s discounted 0.800 0.816 
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9.6 Results cost analysis 
9.6.1 Costs of induction and consolidation treatmellf 
We examined in detail all resources used for 109 patients; 54 patients in the control group 
and 55 patients in the GM-CSF group. Two patients in the GM-CSF group and four 
patients in the control group were analysed separately. One patient of the GM-CSF group 
went off protocol and a second patient received induction treatment I and II during the 
same hospitalisation period. In the control group, three patients received several courses 
during their first stay in hospital and one patient was submitted to get a cholecystectomy. 
Thus, the results reported below are based on 103 patients. 
Costs of induction cycle I 
During the remission induction I treatment, the patients in the control group had a mean 
hospital stay of 36.8 days (median: 36; range 3-63). The hospital care lVas divided as 
follows: 84% regular haematological care and 16% protected environment care. The 
patients in the GM-CSF group spent 37.9 days on average in the hospital (median: 35; 
range: 3-69). The hospital stay was divided in 84% regular haematological care, 14% 
care in a protected environment and 2% intensive care. Table 9.8 presents the average 
costs of the first induction treatment per category of costs. 
Table 9.8 Average costs of induction cycle I 
Control GM-CSF 
Treatment group group 
Remission induction I 
Hospitalisation 14270 14950 
Consultations 84 101 
Laboratory services 2592 2854 
Medical procedures 1437 . 1318 
Medication (excl. GM-CSF) 4412 5327 
GM-CSF 0 3314 
Nutrition 328 434 
Transfusions 2113 2301 
Total remission induction I 25236 30599 
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The costs of hospitalisation in the control group were US$ 14270 and in the GM-CSF 
group US$ 14950 (P=NS). The costs of laboratory services, diagnostics, nutrition and 
transfusions did not differ between the control group and the GM-CSF group. The costs 
of medication amounted to US$ 4412 in the control group and to US$ 5327 in the GM-
CSF group. The administration of GM-CSF costed about US$ 3314. 
The total treatment costs in the control group amounted to US$ 25236 (range: US$ 2841 -
US$ 50446) and in the GM-CSF group to US$ 30599 (range: US$ 3068 - US$ 56657) 
(P<O.OI). 
Costs of induction cycle II alld consolidation treatment 
Patients who received a second remission induction treatment spent less time in the 
hospital. Control patients spent on average 33.2 days (median: 30.5; range: 21-48) in the 
hospital and GM-CSF patients 33.3 days (median: 32; range: 23-53). The hospital stay of 
the patients in the control group was classified as follows: 72 % regular haematological 
care, 22 % care in a protected environment and 6 % intensive care. In the GM-CSF group 
these percentages were 68%, 32% and 0%, respectively. Although the mean hospital stay 
during the second induction treatment was similar in both groups, namely 33 days, the 
costs of hospitalisation were higher in the control group. This difference was caused by 
the fact that the patients in the control group spent more time in the intensive care ward 
than did the patients in the GM-CSF group. The hospital costs amounted to US$ 15068 in 
the control group and to US$ 13874 in the GM-CSF group (see Table 9.9). The total 
costs of the second induction treatment were estimated at US$ 22965 in the control group 
and at US$ 25054 in the GM-CSF group. 
For the consolidation treatment the mean hospital stay was 28.6 days (median: 29.5; 
range: 22-36) in the control group and 31.6 days (median: 29; range: 20-64) in the GM-
CSF group. The hospital stay of the patients in the control group were divided in 86% 
regular haematological care and 14% care in a protected environment. In the GM-CSF 
group these percentages were 80% and 20%, respectively. The total costs of the consoli-
dation treatment amounted to US$ 15384 in the control group and to US$ 20891 in the 
GM-CSF group (see Table 9.9). 
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Table 9.9 Average costs of induction cycle II and consolidation treatment 
Control 
Treatment group 
Remission induction 1I 
Hospitalisation 15068 
Consultations 62 
Laboratory services 1904 
Medical procedures 838 
Medication (excl. GM-CSF) 3447 
GM-CSF 0 
Nutrition 327 
Transfusions 1319 
Total remission induction /I 22965 
COl/solidatiol/ 
Hospitalisation 10916 
Consultations 19 
Laboratory services 1243 
Medical procedures 381 
Medication (excl. GM-CSF) 1942 
GM-CSF 0 
Nutrition 38 
Transfusions 845 
Total consolidation 15384 
Remission Induction II: GM-CSF group: 1/= 10; control group: 1/=12; 
Consolidation: GM-CSF group: 1/=27; control group: 1/=22. 
GM-CSF 
group 
13874 
43 
2609 
1123 
4100 
1441 
408 
1456 
25054 
12457 
75 
1657 
653 
2467 
1826 
395 
1361 
20891 
The average treatment costs largely depended on the percentages of patients who received 
a second remission treatment and the percentages of patients who received a consolidation 
treatment. For the calculation we used the percentages of the whole study popUlation 
(11=289). In the control group 12.2% of patients received a second induction treatment 
and in the GM-CSF group 7.7% of the patients received a second induction treatment (see 
Table 9.10). The percentages of patients who received a consolidation treatment were 
41.7% and 39.5%, respectively. The average treatment costs were thus estimated at US$ 
34466 in the control group and at US$ 40782 in the GM-CSF treated patients. 
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Table 9.10 Average treatment costs 
Control group GM-CSF group 
Percentage Costs Percentage Costs 
treatment treatment 
Remission induction I treatment 100.0% 25236 100.0% 30598 
Remission induction II treatment 12.2% 2813 7.7% 1932 
Consolidation treatment 41.7% 6417 39.5% 8252 
Average treatmellf costs 34466 40782 
NOle: The costs of the treatment of the patients who were analysed separately, were as follows: 
The treatment costs of the GM-CSF patient who went off protocol were US$ 108831. The 
treatment of the patient who received induction treatment I and II during the same hospitalisation 
period costed US$ 44971. In the control group, two patients received 2 induction cycles. Their 
treatment costs Were US$ 52413 and US$ 94677, respectively. One patient received 2 induction 
cycles and a consolidation cycle. The treatment costs of this patient amounted to US$ 64096. The 
fourth patient was submitted to get a cholecystectomy inmlediately after induction cycle 1. The 
treatment costs, including the costs of the cholecystectomy, were US$ 72675. No treatment 
induced differences in the cost profiles of these patients were apparent. 
9.6.2 CoSIS of follOW-lip and total costs of AML (reallllelll 
For the follow-up evaluation, i.e., after completion of the chemotherapy, we considered 
the follow-up period as half year intervals and distinguished patients who had attained a 
CR and patients who had failed to enter CR (see Table 9.11). Since discounting requires 
yearly intervals from start of treatment, the intervals were calculated from the date of 
randomisation. 
For patients in remission in the control group and in the GM-CSF group, the follow-up 
costs decreased with time. The follow-up costs of the patients not in CR depended on 
whether or not they received additional chemotherapy andlor transfusions. For the latter 
group of patients, the costs during the follow-up period varied between US$ 8594 and 
US$ 15327. 
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Table 9.11 Costs during 6 months in the follow-up period in both groups 
Control GM-CSF 
group group 
Complete remission 
- 6 months 1839 (1/=27) 1512 (1/=22) 
- 1 year 1271 (1/=15) 1392 (1/= 12) 
- 1.5 years 926 (1/= 11) 758 (1/= 10) 
- 2 years 814 (1/=6) 631 (1/ = 5) 
No complete remission 
- 6 months 10248 (1/=16) 8594 (1/ = 17) 
- 1 year 13767 (1/= 15) 13659 (1/=15) 
- 1.5 years 15327 (1/=9) 9241 (1/ = 10) 
- 2 years 9197 (1/=9) 12942 (1/=5) 
Table 9.12 presents the average costs of treatment and follow-up. The follow-up costs in 
the first year amounted to US$ 10831 in the control group and to US$ 11266 in the GM-
CSF group. In the second year the follow-up costs were less than in the first year, i.e., 
US$ 6571 in the control group and US$ 6039 in the GM-CSF group. There were no 
apparent treatment related differences between the cost profiles of control patients and 
patients on GM-CSF therapy. 
Table 9.12 Costs of treatment and follow-up in both groups 
Control GM-CSF 
group group 
Treatment costs 34465 40782 
Follow-up costs first year 10831 11266 
Follow-up costs second year 6571 6039 
Total costs 51867 58087 
Total costs discounted 51554 57799 
The total discounted costs of the control group, consisting of the initial treatment costs 
and the costs of the follow-up period, amounted to US$ 51554 and in the GM-CSF group 
to US$ 57799. 
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9. 7 Discussion 
This randomised study considered the role of GM-CSF as an adjunct to chemotherapy in 
elderly patients with AML. The assumption was that GM-CSF might improve the 
response of AML to cytotoxic therapy by combining chemotherapy with GM -CSF 
stimulation. It also was assumed that GM-CSF might possibly mitigate the duration of 
leucopenia following chemotherapy and thereby reduce the frequency of bacterial and 
fungal infections and decrease morbidity and/or mortality. The results of this study show 
that treatment with daunomycin-cytosine arabinoside combined with GM-CSF does not 
result in better response rates or better survival of patients with AML of 60 years and 
older. The percentage of patients who had a CR after induction treatment was 56.8% in 
the control group and 56.5% in the GM-CSF group. Thus apparently the co-administra-
tion of GM-CSF with chemotherapy does not increase chemo-sensitivity as the conse-
quence of AML cell "priming". Nor does the use of GM-CSF post chemotherapy reduce 
the complications during the hypoplastic phase and decrease morbidity or mortality. 
There are several possible reasons that might be considered to explain a lack of clinical 
efficacy of GM-CSF in the context of chemotherapy in patients with AML at higher age. 
Many patients, due to possible toxicity related to GM-CSF treatment, were withdrawn 
from GM-CSF treatment, so that in reality a considerable proportion of the patients 
allocated to the GM-CSF ann of the study did not receive the intended dose or schedule 
of GM-CSF. These withdrawals from protocol treatment may have minimised any 
potential difference between the two arms. 
A second possible explanation is that while GM -CSF in vitro sensitises human AML to 
the cytotoxic effects of chemotherapy, in vivo phanoacologic doses greater than tolerable 
would be needed. If dosaging of GM-CSF is sub-optimal thereby compromising any 
potential benefit, one 1V0uid conclude from the results of the study that higher dosages of 
GM-CSF cannot realistically be applied to this category of patients. This means that other 
strategies would need to be explored to enhance the efficacy of chemotherapy with the 
aim of increasing the response rate Cpercentages remission") and response duration 
("quality of remission"). Approximately 40% of patients still fails on first-line reinduction 
chemotherapy and GM-CSF does not offer a solution to this problem. 
Thirdly, there was an advantage for GM-CSF treated patients with regard to more rapid 
neutrophil recovery following chemotherapy, but this difference did not translate into 
fewer infections, shorter hospitalisation, a lesser morbidity or mortality. Apparently the 
quantitative benefit with regard to neutrophil recovery is too small to be clinically 
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meaningful. There were significant differences in the time of recovery of neutrophils. The 
time of neutrophil recovery to > 0.5xlO' and to > 1.0xl0' were significantly shorter in 
the GM-CSF group than in the control group. Time of platelet recovery to > 20xl0'/1 
and > 50xl0'/1 did not differ significantly. The administration of GM-CSF resulted in 
moderate to severe toxicities attributed to GM-CSF. Adverse events reported were diar-
rhoea, renal abnormalities, fever, cutaneous abnormalities, hypotension, fluid retention 
and chills. Patients on GM-CSF experienced more days of fever than did control patients. 
The quality of life analysis was in accordance with the toxicity analysis and revealed 
lower scores for patients assigned to GM-CSF therapy. Problems during induction 
treatment I with regard to depressed mood, diarrhoea and rash/eczema were most 
frequent. As regards the long-term quality of life there were no differences between the 
GM-CSF and control groups. There were notable differences between patients who had 
entered CR and patients who failed to reach CR. This was hue regardless whether or not 
they were on GM-CSF treatment. Patients who were not in remission were often treated 
with antibiotics and lor received transfusions. Their quality of life scores were consider-
ably lower than the scores of the patients who were in CR. Patients in remission hardly 
experienced health problems. Their quality of life scores on the Karnofsky Index, 
Nottingham Health Profile and the EuroQol were comparable with the scores of "healthy" 
elderly people. 
Considering a follow-up period of 2 years, the cumulative, discounted survival amounted 
to 0.979 life years in the control group and to 1.007 in the GM-CSF group. The quality 
adjusted survival was 0.800 in the control group and 0.816 in the GM-CSF group. 
The quality of life measurement in elderly patients with AML is associated with signifi-
cant problems that are related to the disease as well as the high age of the target popula-
tion. For reasons of comparison, we decided to use the same questionnaires as in a study 
with patients with aggressive non-Hodgkin's lymphoma who were randomised for ABMT 
or conventional chemotherapy and in a study with patients with chemotherapy- induced 
fever and neutropenia. However, contrary to these studies, for some of the AML patients 
the completion of the questionnaires appeared to be too much a burden. Reasons were the 
duration of the questionnaire and motivation (assistance of a nurse was sometimes 
necessary). These problems appear specific for this aged category of patients and resulted 
in refusals to further cooperate in the quality of life study. For future research we would 
like to pay more attention to alleviate the burden of completion of the questionnaires, 
especially for the elderly. A solution may be to use different questionnaires for the short-
and long-telm quality of life. For the short-term quality of life measurement, it is possible 
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to use a cancer-specific questionnaire (e.g. the Rotterdam Symptom Checklist or the 
EORTC QLQ-C30) in combination with the EuroQol. Before the start of the treatment 
and for the long-term quality of life, a generic instrument (e.g. the Nottingham Health 
Profile 01' the Short-Form 36) in combination with the EuroQol may be used. 
Another problem was the time of administration of the questionnaires. The questionnaires 
were given 2 days after (theoretically) stopping OM-CSF. However, OM-CSF was 
interrupted or stopped too early in a high percentage of patients. These patients did not 
fill out the questionnaire. This may have biased the results, as the quality of life of these 
patients has not been taken into account. Since, the main reason for interrupting/stopping 
OM -CSF was toxicity, the quality of life of the OM -CSF treated patients may have been 
overestimated. Nevertheless, since the results were already slightly worse for OM-CSF 
treated subjects, this most likely would not have changed the overall conclusions. 
The treatment of elderly patients with AML is a costly treatment, as specialised care units 
and extensive supportive care are required. The average costs of the primary treatment 
were greater in the OM-CSF group than in the control group, namely US$ 40782 and 
US$ 34466, respectively. The cost difference was mainly caused by the costs of the OM-
CSF administration. The costs during the follow-up period did not differ between the two 
groups. They were about US$ 11000 during the first year of follow-up and about US$ 
6000 during the second year. 
Based on the results of the study reported here, we conclude that daunomcyin-cytosine 
arabinoside combined with OM-CSF treatment is not a cost-effective treatment strategy as 
compared with daunomcyin-cytosine arabinoside alone. 
9.8 Slale of Ihe art 
The median age of all patients with AML is approximately 60 years, indicative of the fact 
that most patients with this disease belong to the aged popUlation (Liu Yin, 1993). The 
general opinion today is that intensive chemotherapy is the treatment of choice for fit 
elderly patients suffering from AML. A palliative wait-and-see strategy has been shown to 
be a poor option resulting in frequent hospitalisation and unfavourable survival (Lowen-
berg el al., 1989). Following intensive chemotherapy, approximately half of the elderly 
patients with AML will enter a complete remission (a state without clinical and 
haematological evidence of leukaemia) and approximately 117 of them will enjoy long-
term disease-free survival. However, the best medical management of elderly patients 
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with AML is still subject of investigation. The development of a treatment specific for 
and tailored to the elderly patient with AML appears of utmost importance. 
Infections and resistance of AML patients to chemotherapy have been the major causes of 
death. Therefore, these patients require intensive supportive care during hospitalisation 
including antibiotics as well as red blood cell and platelet transfusions. There has been 
hope that the haematopoietic growth factors, especially GM-CSF and G-CSF (and very 
recently thrombopoietin) might result in improved outcome of medical management either 
by enhancing the cytotoxicity of the antileukaemic chemotherapy or by reducing the 
length of post chemotherapy leucopenia or by enhancing the cytotoxicity of the antileukae-
mic chemotherapy. 
Use oj myeloid growth Jactors to accelerate recovery Jrom chemotherapy-induced 
leucopenia: 
Is there a role for the haematopoietic growth factors to be used following chemotherapy 
with the objective to hasten myeloid recovery, reduce infections, decrease hospital stay 
and reduce mortality? The results of our study would indicate that the use of GM-CSF 
does not result in improved treatment outcome, even though some favourable effect on 
white blood cell regeneration was noted. The details of our study are described in the text 
of this report. No benefits of employing GM-CSF were apparent with regard to complete 
response rate, infection incidence, hospital stay or survival. Recently two other studies in 
elderly patients with AML, one employing G-CSF and a second study with GM-CSF, 
confirm the lack of a significant survival advantage for elderly patients treated with G-
CSF or GM-CSF (Dombret et al., 1995; Stone et al., 1995). Thus, the results of three 
independent phase III studies do not lend support to the general routine and prophylactic 
application of these biosynthetic peptides as an integral part of the chemotherapy plan in 
these individuals. Obviously, this does not exclude the potential utility of these bio-
pharmaceutical drugs in individual cases, e.g. in the treatment of severe infections not 
responsive to antibiotics. 
Use oj myeloid growth Jactors ill associatioll with chemotherapy to enhance the cytotoxic 
effect oj chemotherapy: 
The myeloid haematopoietic growth factors not only stimulate normal haematopoietic stem 
cells, but also leukaemic progenitors. It has been shown in vitro that AML cell stimula-
tion with the haematopoietic growth factors GM-CSF or G-CSF would enhance cell 
killing by chemotherapeutic agents. Based on this, it has been assumed that the adminis-
tration of GM-CSF or G-CSF concomitantly with chemotherapeutic agents in vivo might 
augment the antileukaemic efficiency of chemotherapy in patients with AML. As yet, 
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there is no evidence to indicate that this effect may be exploited in the clinical setting. 
Essentially, the results of our study showed identical response rates to chemotherapy 
whether or not GM-CSF had been added to the chemotherapy. In another parallel study, 
this time in adult patients with primary AML of less than 60 years, also a lack of clinical 
benefit was seen in patients treated with GM-CSF. In the latter study (HOVON-4A, 
preliminary analysis) patients received GM-CSF combined with chemotherapy only (aIm 
I), or following chemotherapy only (arm 2), or both during and following chemotherapy 
(arm 3) or finally, they received no GM-CSF at all (arm 4). Thus, all four GM-CSF 
schedule possibilities were explored. However, again no significant difference was 
apparent among any of the GM-CSF treated cohorts as far as response and survival 
outcome is concerned. Thus, for the time being there is no established place for GM-CSF 
in the standard treatment of patients with AML. Whether this similarly applies to G-CSF 
is not yet clear. Several studies dealing with priming of AML with other growth factors 
to enllance antileukaemic therapy are still in progress and the results of these studies 
properly conducted, need to be awaited. 
Thrombopoieti II.' 
In 1995 a new growth factor, thrombopoietin, will enter clinical trials. Patients with AML 
submitted to intensive chemotherapy always enter a prolonged period of severe 
thrombocytopenia, that may last for 5-8 weeks, This severe thrombocytopenia may be 
associated with bleedings and requires intensive and expensive platelet transfusion support 
in all individuals. Some patients will become alloimmunised and as a consequence, 
require HLA selected platelet concentrates for transfusion, a product even more expens-
ive. If such compatible donors cannot be found, in the absence of platelet support, the 
patient is at serious risk of lethal blecding. While the studies G-CSF and GM-CSF have 
not shown positive effects on treatment outcome of patients with AML, it remains to be 
seen how thrombopoietin might potentially modify prognosis of adult and elderly patients 
with AML in studies to be conducted in the coming years. 
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10 
GM-CSF in chemotherapy-related febrile neutropenia 
10.1 Summary 
Purpose: To determine whether granulocyte-macrophage colony-stimulating factor (GM-
CSF) used in addition to standard inpatient antibiotic therapy shortens period of hospitali-
sation from chemotherapy-induced neutropenic fever. 
Palienls and melhods: 134 patients with a haematological (11=47) or solid tumour (11=87) 
who had severe neutropenia « 0.5xlO'/I) and fever (> 38.5° C once or > 38°C twice 
over a 12 hr observation period) were randomly assigned to receive GM-CSF (5 I(g/kg/ 
day; !I =65) or placebo (II =69) in conjunction with broad-spectmm antibiotics for a 
minimum of 4 days and a maximum of 14 days. GM-CSF/placebo and antibiotics were 
stopped if neutrophil count was more than 1.0x10'/I and temperature less than 37.5° C 
during two consecutive days or at a leucocyte count of IOxlO'/I or more, both followed 
by 24 hI' observation period (hospitalisation period). Clinical and haematological response 
as well as quality of life and cost-effectiveness were evaluated. In addition semm cytokine 
levels were measured at day 0 and 1 of therapy. 
Resll/ls: Compared with placebo, GM-CSF enhanced the neutrophil recovery. Median 
neutrophil counts at day 4 were 2.9xlO'/I (range 0-25) in the GM-CSF arm and 1.3 x 
10'/1 (range 0-9) in the placebo group (P<O.OI). No significant difference was observed 
with regard to median days less than 1.0xlO'/1 neutrophils (4 vs 4) or days of fever (3 vs 
3). The median number of days patients were hospitalised while on study was comparable 
in the GM-CSF group and placebo group, 6 (range 3-14) vs 7 (range 4-14) according to 
the intention to treat analysis (P=0.27). Multivariate Cox regression analysis after 
adjustment to all prognostic factors demonstrated a 29% reduction of the risk of 
hospitalisation for GM-CSF treatment (P=0.12). Quality of life scores in 90 patients 
demonstrated significant differences in favour of the placebo group. Hospital costs were 
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significantly higher for the GM-CSF treated patients if GM-CSF was included in the price 
(median costs GM-CSF arm: US$ 4140 Vs placebo arm: US$ 3590 (P<0.05». Finally, 
cytokine measurements of G-CSF, Interleukin-6, and Tumour Necrosis Factor-a demon-
strated no significant change due to the application of GM-CSF. 
Conclusion: These results indicate that GM-CSF does not affect the number of days for 
resolution of fever or the hospitalisation period for this patients group, although a 
significant effect of GM-CSF was observed on neutrophil recovery. 
10.2 introduction 
Chemotherapy-related neutropenia and fever is a frequently occurring complication during 
treatment of patients with cancer. In particular the severity and duration of neutropenia 
determines the risk of infection and the outcome of the patient (Bodey et al., 1966; Pizzo, 
1984). Recently, different haematopoietic growth factors (HGFs) have been produced 
which has given the opportunity to modulate the period of granulocytopenia. 
Two options are available for applying the HGFs after standard chemotherapy (Lieschke 
and Burgess, 1992). First, the HGF can be given as an adjunct to the chemotherapy till 
recovery of peripheral blood counts has been noted. In a number of studies this policy has 
resulted in a fifty percent reduction of infectious complications (Crawford et al., 1991; 
Gerhartz et al., 1993), while in other studies no significant effect has been shown with 
regard to the incidence of bacteraemia, days of fever, or the hospitalisation duration 
(Gorin et al., 1992; Pettengell et al., 1992). A second possibility would be to apply the 
HGF only in the case of infection (Biesma et al., 1990; Riikonen et al., 1994; Maher et 
al., 1994; Mayordomo et al., 1993). This approach would reduce the number of patients 
exposed to a growth factor and could potentially restrict the costs of treatment. A limited 
number of studies has tested this approach. Riikonen et al. (1994) demonstrated in a 
randomised study with 58 children that the application of GM-CSF during fever and 
neutropenia resulted in a faster recovery of the granulocytic lineage and a shortening of 
the period of hospitalisation. A recent double blind study with G-CSF in febrile neutrope-
nia demonstrated that the greatest benefit was obtained in patients with a documented 
infection with a neutrophil count less than O.lxlO'/I at start of G-CSF administration 
(Maher et al., 1994). 
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We describe a prospective mullicentre clinical trial which was designed to compare the 
effects of GM-CSF versus placebo in 153 adult patients with chemotherapy-related febrile 
neutropenia focused on whether GM-CSF affects the duration of hospitalisation in 
conjunction with quality of life and cost-effectiveness analysis. 
10.3 Patients alld methods 
10.3.1 SlIIdy population 
The study was carried out at the Departments of Haematology and/or Oncology of six 
University Hospitals and the Dr. Daniel den Hoed Cancer Centre from September 1991 till 
September 1994. Eligible patients with chemotherapy-related neutropenia «0.5xlO'!l) 
and fever (temperature of > 3SoC over a 12 hr observation period or > 3S.50C once) were 
entered. Patients with severe heart, lung, and liver impairment World Health Organisation 
(WHO) grade 3-4 were excluded as were patients with acute myeloid leukaemia, 
myelodysplasia or autologous or allogeneic bone marrow transplantation as well as 
patients already receiving antibiotics for the suspected infection. The study protocol was 
approved by the Medical Ethical Committees of the different hospitals and all patients 
gave informed consent. 
10.3.2 Design Gild treatment 
The study was a double-blind randomised phase III study. Patients were stratified for 
solid 01' haematological tumours and for the hospital. Enrolled patients were admitted to 
hospital and a full medical history was taken and physical examination was perfonned. 
Baseline investigations included full blood cell counts with differential white cell counts 
and sinus and chest radiographs. Cultures of blood (in duplicate), urine, and other 
suspicious sites were collected. In addition, semm was collected and frozen (_SOD C) at 
day 0 and 1 for cytokine analysis. GM-CSF or placebo (5 I'g/kg/day) was administered 
once daily subcutaneously for a minimum of 4 days and maximum of 14 days. GM-CSF 
or placebo was started simultaneously with intravenous empiric antibiotics according to a 
standardised local hospital policy. Both antibiotics and GM-CSF/placebo were discon-
tinued if both the temperature normalised «37.50 C) and the granulocyte count was 
1. Ox 10'/1 or more for two consecutive days. However, in the case of a leucocyte count of 
lOxlO'/1 or more, the application of GM-CSF/placebo was stopped while the antibiotic 
treatment was continued until the temperature was normalised for two consecutive days. 
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The patient was then observed for a 24 hr period and if no sign of infection was noted the 
patient was discharged from the hospital and followed twice weekly for a period of 2 
weeks or until the next chemotherapy course. 
Lyophilised E.coli GM-CSF (Leucomax"'; kindly provided by Sandoz Pharma [Basle, 
Switzerland/Schering-Plough Kenilworth, NJl) in vials of 400 I'g protein/vial was 
reconstituted in I ml water. A vial identical in appearance to the active drug, but contai-
ning Iyophilised placebo was also provided by Sandoz and used in a similar fashion. 
10.3.3 Study end points 
Primary end point was hospitalisation time with GM-CSF or placebo, which comprises 
the period of resolution of neutropenia (> 1.0xlO'/I) and fever defined as a temperature 
< 37.SoC for 2 consecutive days, followed by a 24 hr observation period. For this reason 
blood and differential counts were performed daily and temperature was recorded 3 times 
a day. Secondary end points were days on antibiotics and incidence of change in antibiotic 
treatment. Inpatients were allowed to enter the study. Some patients remained in the 
hospital aner completing the study for reasons other than continued morbidity related to 
fever and neutropenia. In these cases the hospitalisation duration was the study duration. 
10.3.4 Quality of life analysis 
The quality of life of the patients was scored by means of written questionnaires, which 
were filled in by the patients one day aner stopping the GM-CSF or placebo treatment. 
Based on methodological criteria concerning cost-effectiveness studies in cancer trials, the 
patient questionnaire consisted of a generic health status measurement instrument, a 
cancer-specific instrument and a valuation instrument (Bonsel et al., 1993; Uyl-de Groot 
et al., 1994III). The Karnofsky Performance Index and the Nottingham Health Profile 
were included as generic instruments, the Rotterdam Symptom Checklist as cancer-
specific instrument and the EuroQol as valuation instrument (Uyl-de Groot et al., 1994III; 
Hunt et al., 1986; De Haes et al., 1990; Van Hout and McDonnell, 1991). 
The Nottingham Health Profile incorporates the dimensions mobility, emotional reactions, 
energy, social isolation, pain and sleep. For the general population the average score for 
all dimensions is less than 10 (Bonsel et al., 1992). The EuroQol consisted of a descrip-
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tive part and a valuation part (a rating scale). The descriptive part allows the calculation 
of utilities. The utility scores are based on the valuation for each health state of patients 
and of a representative panel of the population (Van Hout and McDonnell, 1991). The 
average EuroQol score for the general population is more than 90 (Bonsel el al., 1992). 
The Rotterdam Symptom Checklist has the potential to add illness or treatment-related 
items. In this study, questions were added on possible side-effects associated with GM-
CSF, namely constipation, painful joints, palpitation, rash/eczema and sweating/per-
spiring. 
Furthermore, data forms were used to get daily information on patients' quality of life 
during the period of fever and neutropenia. These forms were filled in daily by nurses. 
The descriptive part of the EuroQol was used, allowing the calculation of utilities. 
10.3.5 Cosl analysis 
The cost analysis was based on a detailed review of all activities concerning the treatment 
of patients with fever and neutropenia. These activities included days in hospital, con-
sultations, laboratory services, diagnostics including imaging procedures, antibiotics and 
GM-CSF. The data were derived from all registry forms and from daily data forms. The 
latter included information on type of hospital ward and consultations. 
For each of these cost data unit prices were determined reflecting the real use of resour-
ces. The year of study was 1992 (I US$ = 1.8 Dutch guilders). The patients stayed on 
wards for regular oncological care, regular haematological care, protected environment 
and intensive care. The costs of hospital days were split into direct and indirect costs. The 
direct costs concerned manpower (doctors, nurses, etc.) and materials (medical devices, 
supportive patient care etc.). The indirect costs were related to overheads. The cost of 
hospitalisation amounted to approximately US$ 290 per day for regular oncological care, 
to US$ 350 per day for regular haematological care, US$ 536 for staying in a protected 
environment and US$ 1223 for an intensive care ward. 
The output of hospital laboratories in the Netherlands is measured in terms of a point 
system. A unit price is associated per point. The unit prices differ across types of labora-
tories. The unit prices per point varied from US$ 0.62 (biochemistry and haematology 
laboratories) to US$ 2.81 (virology tests). A routine test (including haemoglobin (Hb), 
haematocrit (Ht), leucocytes and platelets) amounted to 5.75 points and costed US$ 3.58. 
For the diagnostics the Dutch tariff system has been used as an approximation of unit 
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costs. The drug prices used were wholesale prices. A 300 p.g vial GM-CSF costed US$ 
138 and a 400 I'g vial costed US$ 184. (See Appendix A4.3 for a list of unit prices used 
in the study). 
10.3.6 Measurement of serlllll cytokine levels 
GM-CSF, Granulocyte-CSF (G-CSF), Interleukin-6 (IL-6), and Tumour Necrosis Factor-
ex (TNF-ex) serum levels were quantified using a human GM-CSF, G-CSF, IL-6, or TNF-
ex enzyme-linked immunosorbent assay (Elisa) kit (R&D, Cambridge, United Kingdom) as 
recommended by the manufacturer. 
10.3.7 Statistical analysis 
The generalised Wilcoxon test was chosen to test the difference in duration of hospitalisa-
tion between the two treatment groups. The estimated sample size was based on the Ho 
hypothesis that the median duration of hospitalisation is 11 days in both treatment groups 
vs the HI hypothesis assuming a clinically relevant difference between the two treatment 
groups with respect to the duration of hospitalisation of 2 days. Using a significance level 
of 0.05 a sample size of 70 patients per group revealed a power calculation of at least 
75%. 
For the comparison of the clinical characteristics a chi-square, two-tailed Fisher's exact 
test, Wilcoxon-Maon-Whitney test, or Students's t-test as appropriate was used. 
It was a feature of the study to allow patients to enter more than once. This was the case 
in 11 patients (7 GM-CSF vs 4 placebo). The results were analysed according to intention 
to treat. All patients who fulfilled the entry criteria and received at least one dose of study 
medication were included in this analysis. In the case of premature discontinuation, death 
or major protocol violation for the main end point analysis, the patient was "right" 
censored at day 14, the "worst outcome event". Additionally a per protocol analysis was 
performed. In this analysis the statistical approach was to censor at the time of 
discontinuation in the case of a non-infOimative dropout. If not then the "worst case" or 
day 14 was taken as the censor. Cumulative rates for days on study, days of neutropenia, 
and days of fever were estimated by Kaplan-Meier methods. Groups were compared by 
the generalised Wilcoxon test. Data are reported as median survival and absolute ranges. 
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The risk reduction for assigned study medication with the theoretical discharge from 
hospital as dependent variable was adjusted for influential baseline covariates, chosen by 
step-wise selection, by using. a Cox proportional regression model. The covariates 
selected were more than 11 days after last chemotherapy, solid tumour, and fever of 
unknown origin (FUO). Only variables whose coefficients had P-values of less than 0.05 
were included. Adjusted risk reductions are presented. 
A two-sided probability level of 0.05 or less was considered to indicate statistical 
significance. All analyses were performed using Statistical Analysis System version 6.08 
(SAS Institute, Cary, N.C.). The quality of life items are presented as mean scores. For 
the comparison between items the Mann-Whitney and the Chi-square tests were used. The 
cost of both groups were compared with the Mann-Whitney test (Glantz, 1989). 
10.4 Results 
10.4.1 Patient characteristics 
One hundred and fifty-three patients were entered in the study (Table 10.1). Of these 
patients 74 received GM-CSF and 79 placebo. Nine patients in the GM-CSF group and 10 
patients in the placebo group were excluded from analysis due to ineligibility of main 
entry criteria, e.g. temperature less than 38°C or granulocyte count more than 0.5xlO'/l. 
Table 10.1 Study population 
GM-CSF Placebo 
No. group group 
153 patients randomised 74 79 
I 
'" 
19 ineligibility for entry criteria 9 10 
134 patients ami/able for illtelltion to treat analysis 65 69 
I 
'" 
11 withdrawals before end of follow-up: 
.. incorrect treatment with study 2 3 
medication or concomitant medication 
.. possibility of side-effects 2 
.. withdrawal consent 1 
" 
adverse event 0 
123 patients available for per protocol analysis 60 63 
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Eleven patients (five GM-CSF, six placebo) were withdrawn before study completion and 
were excluded for the per protocol analysis. The reasons for excluding these patients 
were: incorrect treatment with study medication or concomitant medication (1/=5), 
adverse event (/I = I), suspected side-effects of treatment (n=3), and refusal of further 
treatment (/1=2). 
The baseline characteristics of the 134 patients are summarised in Table 10.2. The two 
treatment groups were well matched with regard to age, sex, tumour type and neutrophil 
count. The preceding chemotherapy in the GM-CSF group consisted of a cisplatin 
containing (21 %), anthracycline containing (66%), or a high-dose Ara-C containing 
regimen (10%). In the placebo group comparable treatment schedules were applied: 27% 
cisplatin containing, 57% anthracycline containing, and 2% a high-dose Ara-C containing 
regimen. 
Table 10.2 Baseline characteristics of the study patients 
GM-CSF Placebo 
group group 
(1/=65) (1/=69) 
Median age (years, range) 49 (19-73) 48 (16-70) 
Male sex, n (%) 32 (49) 36 (52) 
Tumour type, n (%) 
- solid 41 (63) 46 (66) 
- lymphoma 18 (27) 21 (30) 
- ALL 6 (9) 2 (3) 
Days since last chemotherapy 12 13 
Baseline leucocyte count, n (%) 
- < O.lxlO'/I 42 (64) 39 (56) 
- 0.1-0.5xlO'/I 23 (35) 30 (43) 
Baseline neutrophil count, n (%) 
- < O.lxlO'/I 42 (64) 39 (65) 
- 0.1-0.5xlO'/I 16 (24) 21 (30) 
Microbiologically or clinical documented infection, n (%) 45 (69) 42 (61) 
- culture positive with bacteraemia 12 (18) 13 (18) 
- culture positive without bacteraemia 24 (36) 19 (27) 
- culture negative but clinically documented 9 (13) 10 (14) 
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With regard to the microbiologically or clinically documented infection no significant 
difference was observed for fever of unknown origin, bacteraemia and culture positive 
infection. The positive blood cultures consisted in 44 % of gram-positive bacteria and in 
56% of gram-negative bacteria in the GM-CSF group. In the placebo group 50% of the 
cultures contained gram-positive and 50% gram-negative bacteria. 
10.4.2 Neutropenia and fever 
GM-CSF enhanced the neutrophil recovery as depicted in Figure 10.1. A significant 
difference in absolute neutrophil count was observed at days 4 and 5 (P<O.OOI). A 
difference was also observed for the numbers of monocytes and eosinophils at last day of 
GM-CSF/placebo treatment in 100 evaluable patients. In the GM-CSF group the median 
number of monocytes was 0.9xlO'/l (range 0-0.4) and of eosinophils 0.5xlO'/l (range 0-
1.2). In the placebo group these values were 1.2xlO'/l (range 0.1-4.9; P<0.03) and 
0.3xlO'/l (0.0-0.5; P=0.45), respectively. However, despite the enhancing effect of GM-
CSF on the neutrophil recovery, no differences were observed in the median days of 
neutrophils less than 0.5xl0'/1 and 1.0x10'/1 (Table 10.3). 
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Figure 10,1 Neutrophil recovery, temperature curve and 
patient number during GM-CSF or placebo treatment 
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No difference was observed in time to resolution of fever. The median temperature curve 
was higher in the OM-CSF group compared to the placebo group during the first 6 days 
of treatment with a significant difference at day 2 (P<O.05, Figure 10.1). 
146 
10 GM-CSF in chemotherapy-related febrile neutropenia 
Table 10.3 Days of neutropenia and fever and days on study 
(hospitalisation) per treatment group (11= 134) 
GM-CSF group Placebo group 
median range median range 
ANC < 0.5xlO'/I (days) 3 1-14 4 1-14 
ANC < 1.0xlO'/i (days) 4 1-14 4 1-14 
ANC at day 4 (xlO'/I) 2.9 0-25 1.3 0-9 
Fever (days) 3 1-14 3 1-14 
Days of hospitalisation 6 3-14 7 4-14 
NS: not significant; ANC: absolute neutrophil count. 
P-value 
NS 
NS 
<0.005 
NS 
NS 
The estimated median survival for the primary end point of the study (Figure 10.2), e.g. 
normalisation of temperature and a granulocyte cOllnt of more than 1.0xlO'/I during 48 hr 
or a leucocyte count of IOxlO'/I or more both followed by a 24 hI' observation period, 
was reached after a median of 6 days (range: 3-14) in the OM-CSF group and 7 days 
(range: 4-14; P=O.27) in the placebo group according to the intention to treat analysis. 
Comparable results were obtained with the per protocol analysis: OM-CSF: 6 days 
(range: 3-14); placebo: 6 days (range: 4-14; P=0.33). 
Figure 10.2 Estimated median survival for the primary end point of the study 
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Finally, the proportion of patients in the GM-CSF and placebo arm was similar with 
regard to the hospitalisation period of more than 10 days; 9% in the GM-CSF group and 
10% in the placebo group. 
10.4.3 Antibiotics and GM-CSF 
All patients were treated with intravenous antibiotics. In the GM-CSF group 15 % 
received imipenem, 23% cefuroxime in combination with an aminoglycoside, 13% 
augmentin in combination with an aminoglycoside and 20% ceftazidime. In the placebo 
group the percentages were 11 %, 14%,23%, and 18%, respectively. Antibiotic treatment 
was changed in 29% of the GM-CSF group and 24% in the placebo group. Six (9%) of 
the patients treated with GM-CSF and three (4%) of the patients receiving placebo were 
given intravenous antifungal therapy. The median duration of GM-CSF and placebo 
application for the total group was 5 days in both the GM-CSF arm (range: 1-14) and 
placebo arm (range: 1-13). However, not in all cases the antibiotic treatment was stopped 
at the same day of GM-CSF/placebo cessation. In the GM-CSF arm 16 patients had a 
prolonged administration of antibiotic treatment between 3-5 days, and three patients 
between 5-10 days. In the placebo arm prolonged antibiotic administration was given in 
eight patients between 3-5 days and in two patients between 7-9 days. 
10.4.4 Subgroup, adjusted and lIIultivariate analysis 
First, it was evaluated whether a difference in response was noticed in patients with 
baseline neutrophils <O.lxlO'/I vs 0.1-0.5xl0'/1. No difference was observed between 
both groups for time to reach a neutrophil count> l.OxIO'!! in combination with time 
for resolution of fever. Secondly, Table lOA shows the result of a Cox proportional 
hazards regression analysis for the primary end point in which the difference between the 
two treatment regimens was estimated after adjustment for the independent associated 
covariates: more than 11 days since last chemotherapy, solid tumour, and fever of 
unknown origin. GM-CSF application did not influence the primary end point signifi-
cantly, but a trend was observed. When all prognostic factors were taken into account 
simultaneously in the Cox regression model, the risk reduction of the primary end point 
due to GM-CSF treatment was 29% (P=0.12). The unadjusted risk reduction of GM-CSF 
treatment was 23 % (P=0.20). 
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Table 10.4 Analysis of the risk of hospitalisation in a Cox regression model 
Analysis Risk reduction P-value 
Unadjusted: GM-CSF treatment 23% 0.200 
Multivariate (Cox regression model) 
Days since last chemotherapy (> II days) 41 % 0.016 
Solid tumour 55% 0.001 
Fever of unknown origin 42% 0.016 
Adjusted: GM-CSF treatment 29% 0.120 
10.4.5 Supportive care 
The median number of red blood cell transfusion was similar in the GM-CSF group 
versus the placebo group, 2 (range: 0-8) vs 2 (range: 0-8), respectively (P=0.50). Plate-
let transfusion was given in a median of 0 patients (range: 0-5) in the GM-CSF group and 
in 0 patients (range: 0-4) in the placebo group (P=O.72). 
10.4.6 Results quality of life analysis 
The results of the quality of life analysis are based on 113 daily data forms and 90 quality 
of life questionnaires. The discrepancy between the numbers of questionnaires and data 
forms is due to a later start of the cost-effectiveness study. The questionnaires and data 
fOlms that are not included are centre related, so it is very unlikely that as a consequence 
of this a bias would have been introduced. 
The results of the patient questionnaires are sunmlarised in Table 10.5. The scores of the 
Karnofsky Perfonnance Index were greater among the placebo group, i.e. a mean value 
of 63 in the GM-CSF group versus 73 in the placebo group (P<0.05). The patients in the 
placebo group reported less complaints on the Nottingham Health Profile than the patients 
who received GM-CSF treatment. The mobility, emotional, and energy problems were 
less pronounced in the placebo group than in the GM-CSF group (P<0.05). No signifi-
cant differences were noticed in the EuroQol scores using patient values. The population 
value was in favour of the placebo group, namely 54 in the GM-CSF ann and 66 in the 
placebo arm (P< 0.05). 
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Table 10.5 Mean scores of quality of life in both treatment arms 
GM-CSF group Placebo group P-value 
(1/=46) (1/ =44) 
Kamo/sky JI/dex' 63 73 0.034 
Nottil/gham Heallh Profile' 
- Mobility 30 16 0.009 
- Emotional reactions 20 9 0.008 
- Energy 57 36 0.014 
- Social isolation II 5 0.128 
- Pain 23 19 0.151 
- Sleep 35 24 0.116 
EuroQol' 
- Patient score 55 57 0.760 
- Population score3 54 66 0.Q25 
Most important symptoms!complainti 
1. Fatigue 2.9 2.5 0.108 
2. Lack of appetite 2.7 2.0 0.006 
3. Lack of energy 2.5 1.9 0.003 
4. Dry mouth 2.4 1.9 0.161 
5. Sweating, perspiring 2.2 1.9 0.555 
6. Sore mouth / pain when swallowing 2.1 2.0 0.776 
, Range 0-100: from worst (0) to best health states (100); 2 Range 100-0: from worst (100) 
to best health states (0); l Utility scores based on the valuations of patients and of a represen-
tative panel of the population; , Answer possibilities: 1 = not at all, 2= a little, 3 = quite a 
bit and 4=very much. The average values are presented. 
The most important complaints and symptoms reported on the Rotterdam Symptom 
Checklist were tiredness, lack of appetite, lack of energy, dry mouth, sweating/perspiring 
and sore mouth and/or pain when swallowing. Patients in the placebo group experienced 
less problems concerning appetite and energy than the patients in the GM-CSF group 
(P<O.OI). Regarding tiredness, dry mouth and sweating no difference was observed. 
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The results of the population scores (data forms) derived from the descriptive part of the 
EuroQol are presented in Figure 10.3. Patients receiving placebo treatment were feeling 
better during the hospitalisation period than the patients in the GM-CSF group. From day 
8, the observations are biased as many patients were already discharged from hospital. 
Figure 10.3 EuroQol population scores in the GM-CSF and in the placebo group 
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10.4.7 Results cost analysis 
The median number of days in hospital in the GM-CSF group was 6 days (mean: 7.25). 
The hospital care was classified as follows: 87% regular oncological or haematological 
care, 11 % protected environment care and 2% intensive care. Patients treated with 
placebo had a median hospital stay of 7 days (mean 8.33). This group was divided into: 
86% regular oncological or haematological care, 13% care in a protected environment 
and 1 % intensive care. 
The median cost of hospitalisation in the GM-CSF group was US$ 2130 (range: 860-
6420) and in the placebo group US$ 2450 (range: 1140-7130). The median cost of 
antibiotics amounted to US$ 630 (range: 130-3790) in the GM-CSF group and to US$ 
580 (range: 144-2930) in the placebo group. The cost of GM-CSF was US$ 1100 (range: 
280-3860). Additional costs included laboratory services, medical procedures, consul-
tations and blood transfusions. The median costs were equal in both anns, namely US$ 
470 (range: 120-2830 in the GM-CSF group and range: 170-2680 in the placebo group). 
The median of all costs was US$ 4140 (mean: 5180; range: 1710-14650) in the GM-CSF 
group and US$ 3590 (mean: 4180; range: 1680-10990) in the placebo group (P<0.05). 
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10.4.8 Adverse events 
The events observed during the treatment period are reported in Table 10.6. A great 
variety in events was observed. Myalgia and lor rash andlor bone pain andlor oedema was 
noticed in 20% of the GM-CSF treated patients and 6% in the placebo treated patients 
(P=NS). No difference was observed in the mortality rate between both groups. In the 
GM-CSF arm one patient died due to acute respiratory distress syndrome. In the placebo 
arm two patients died as a result of pulmonary embolism. 
Table 10.6 Major medical events reported during the 
treatment of antibiotics plus GM-CSF or placebo 
GM-CSF group 
Gastro-intestinal 35% 
Cardiac dysfunction 6% 
Biochemical abnormalities 30% 
Thrombosis 3% 
Myalgia 4% 
Rash 4% 
Bone pain 1% 
Oedema 12% 
Death 1% 
10.4.9 Cylokine analyses 
Placebo group 
23% 
1% 
27% 
0% 
1% 
0% 
1% 
5% 
2% 
Serum cytokine levels were measured at presentation and 24 hr after initiation of therapy 
in 60 patients (28 GM-CSF treated patients and 32 placebo treated patients; Table 10.7). 
The analysis concerned eight patients with bacteraemia, 25 patients with a clinically docu-
mented infection and 27 patients with fever of unknown origin. At presentation high 
levels of Interleukin-6 (IL-6) and G-CSF were observed especially in the patients with 
bacteraemia. During the first 24 hr of treatment no change in the cytokine profile was 
observed due to the administration of GM -CSF, except for significantly higher levels of 
GM-CSF that were measured in the GM-CSF treated group (Table 10.7). 
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Table 10.7 Cytokine profiles on day 0 and I of treatment 
Treatment arm GM-CSF group Placebo group 
day 0 day 1 day 0 day 1 
GM-CSF 28 ± 20 709 ± 126' 13.8 ± 3.9 54 ± 37 
G-CSF 3459 ± 583 2858 ± 604 2897 ± 498 2394 ± 512 
TNF-" 1.0 ± 0.43 0.18 ± 0.77 2.0 ± 1.2 1.25 ± 0.9 
IL-6 304 ± 67 238 ± 57 324 ± 64 262 ± 61 
Cytokine serum levels of G-CSF (mean x ± SE (standard error», pg/ml; GM-CSF (x ± SE) 
pg/ml; Tumour Necrosis Factor-" (TNF-,,), x ± SE nglml and Inlerleukin-6 (IL-6), x ± SE 
pg/ml; , A significant difference was observed al day 1 of treatment (P<O.OOOI). 
10.5 Discllssion 
The present study demonstrates that GM-CSF accelerates the neutrophil recovery in 
patients who received antibiotics for febrile neutropenia after chemotherapy. Enhancement 
of the neutrophil recovery by GM-CSF was irrespective of whether patients presented 
with baseline granulocytes less than O.lxIO'/I or between 0.1-0.5xlO'/l. However, the 
enhancing effect of GM-CSF On the neutrophil recovery did not occur immediately, but 
was observed only 4 and 5 days after start of treatment. 
Despite the faster neutrophil recovery in the GM-CSF group no difference was observed 
in the resolution of fever between the GM-CSF and placebo group. Previous studies 
demonstrated distinct correlation between resolution of fever and neutrophil recovery 
(Bodey el al., 1966). However, these studies were conducted almost entirely in patients 
with a long-lasting neutropenia (Pizzo el al., 1982). The observations apply particularly to 
patients with acute leukaemia who are treated with intensive chemotherapy. The present 
study and other studies in cancer patients show that this correlation is less prominent for 
patients treated with less intensive chemotherapy regimens. In these patients the febrile 
period is usually short and depends on the response to antibiotics. In the placebo group 
the median duration for resolution of fever « 37.5°C) was 3 days, while a granulocyte 
count of more than IxIO'/I was reached after a median of 4 days. A possibility in the 
GM-CSF group could be that GM-CSF negatively affected the days for resolution of 
fever. Phase I-II studies have demonstrated that GM-CSF might induce fever. However, 
this was observed especially in patients treated with a higher dose of GM-CSF (Lieschke 
and Burgess, 1992; Hazenberg el al., 1989). A recent study with G-CSF in febrile 
neutropenia demonstrated that G-CSF hastened the neutrophil recovery, but did not affect 
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the duration of fever (Maher et al., 1994). Since the period of fever and severe granulo-
cytopenia was not reduced by GM-CSF treatment, no difference was observed in the 
duration of hospitalisation. This lack of difference in hospitalisation duration between both 
arms resulted that GM-CSF was not cost-effective for the total group of patients with 
chemotherapy-related febrile neutropenia. Treatment costs were significantly higher than 
those in the placebo group, mainly due to the costs of GM-CSF. In part this is caused by 
the fact that GM-CSF is only available in vials of 300 I,g and 400 I'g. In this study, the 
GM-CSF was administered at a dose of 5.0 I'g/kg/day, implying that a patient of 65 kg 
received 325 I'g GM-CSF. Correcting for this loss of GM-CSF or applying a 300 I,g vial 
only would reduce the costs of GM-CSF by approximately ten percent. 
Adverse events were frequently noticed in this study and can be ascribed to the underly-
ing disorder and treatment. Quality of life analyses demonstrated significant differences in 
favour of the placebo group. However, no increased mortality was observed in the GM-
CSF treated group. 
Different cytokines were measured to analyse whether the GM-CSF application might 
change the IL-6, G-CSF, and TNF-" serum levels during the treatment. Elevated levels 
were measured, but GM-CSF did not modulate these cytokine profiles significantly. 
Recent studies in mice with non-compromised bone marrow have demonstrated that GM-
CSF priming is associated with an enhanced production of cytokines after challenge with 
endotoxin, resulting in an increased mortality (Tiegs et al., 1994). The present study 
revealed no major changes in the cytokine profile during the administration of GM-CSF. 
Four studies have been conducted in patients with febrile neutropenia (Biesma et al., 
1990; Riikonen et al., 1994; Maher et al., 1994; Mayordomo et al., 1993). In three 
studies a significant advantage of GM -CSF or G-CSF treatment was observed (Riikonen 
et al., 1994; Maher et al., 1994; Mayordomo et al., 1993). In the present study only a 
trend for advantage of GM-CSF application is seen. The difference might be ascribed to 
differences in patients categories and treatment protocols. This is supported by the 
multivariate analysis in which tumour type was an independent prognostic factor for the 
success rate of treatment. Furthermore, a remarkable difference is observed in duration of 
antibiotic application between the different studies which seems to be the most relevant 
factor for the hospitalisation period. In the study of Riikonen et al. (1994) antibiotic treat-
ment was continued for a minimum of 5 days while in the study of Maher et al. (1994) 
antibiotic treatment was continued for 4 days after normalisation of temperature. In the 
present study the antibiotic treatment was intended to stop after 2 consecutive days with 
resolution of fever and granUlocytopenia. The differences in antibiotic policy have a great 
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impact on the hospitalisation period. The median number of days in hospital for the GM-
CSF and G-CSF arm of the studies of Riikonen and Maher were 9 and 8 days, respective-
ly. In the present study the median hospitalisation duration while on study was 6 days in 
the GM-CSF arm and 7 days in the placebo arm. 
The results in this study do not exclude that a subgroup of patients, e.g. patients with a 
hospitalisation period longer than 10 days and neutropenia might benefit from the 
application of GM-CSF. In both previous studies (Riikonen ef al., 1994; Maher ef al., 
1994) in febrile neutropenia a significant advantage of HGF application was observed, 
resulting in a significant reduction in hospitalisation duration. However, in the present 
study the follow-up period was only 14 days and prolonged hospitalisation was only 
observed in 10% of the patients which makes further analyses inadequate. Finally, the 
dose of GM-CSF used in this study seems to be adequate. A distinct effect on the 
neutrophil recovery was observed. Moreover, the results obtained for duration of severe 
neutropenia were comparable with the G-CSF study, in which a dose of 12 /lg/kg/day was 
used (Maher ef al., 1994). 
In conclusion the here presented study demonstrates that the application of GM-CSF in 
febrile neutropenia did not result in a significant shortening of the hospitalisation period, 
despite a faster recovery of the neutrophils for the whole group of patients. 
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Part IV 
Implementation of new technologies 

11 
Costs of introducing ABMT in the Netherlands 
11.1 Summary 
In a retrospective study we calculated the costs of introducing ABMT in the treatment of 
patients with malignant lymphoma and acute leukaemia in the Netherlands. The cost 
analysis has been performed in five university hospitals and one cancer centre, in a series 
of patients with intermediate- and high-grade non-Hodgkin's lymphoma (NHL) and 
patients with acute myeloid leukaemia (AML). Conventional treatment consisted of 
chemotherapy. The average costs of the conventional NHL treatment varied from US$ 
3120 to US$ 12900. The costs of ABMT amounted to US$ 40220. In the AML group the 
costs of conventional treatment amounted to about US$ 11040, as only 50% of the 
patients were treated further. The costs of ABMT, including a follow-up period of two 
years, amounted to US$ 55440. In the Netherlands the total number of ABMTs per year 
in these patient groups was estimated at 230; 180 in the NHL group and 50 in the AML 
group. The costs of introducing ABMT in the NHL group will vary between 4.93 and 
6.68 million dollars and for the AML group these costs were estimated at 2.22 million 
dollars. As a result, the total extra costs of introducing ABMTs are expected to be 
between 7.15 and 8.90 million dollars. 
11.2 IntroduClion 
Over the past decade ABMT in combination with high-dose chemotherapy has become a 
widely applied treatment for certain patients with haematological malignancies. The 
number of ABMTs actually carried out is increasing per year (Singer and Goldstone, 
1986; Gorin el al., 1984; Dufoir el al., 1992; Desch el al., 1992). ABMT is currently 
performed more frequently than heart transplantation (Durbin, 1988). 
159 
IV Implementation of new technologies 
In the Netherlands, as in many European countries, little is known about the financial 
consequence of introducing ABMTs to the clinical setting (Durbin, 1988; Lobo et al., 
1991). Furthermore, it has become increasingly apparent, that resources for the provision 
of health care are limited. The Dutch government has already provided an additional 
budget of 3.4 million dollars for ABMT in 11 haemato-intensive care hospitals. In this 
study, we considered the macroeconomic consequences of introducing the use of ABMT 
in the Netherlands in terms of the additional resources required to finance ABMT for 
patients with non-Hodgkin's lymphoma (NHL) and acute myeloid leukaemia (AML). 
11.3 Patients and methods 
11.3.1 Study population 
The NHL group consisted of patients with NHL of intermediate- and high-grade malig-
nancy. These patients had had a previous CR and thereafter a (first or second) relapse. 
They received two reinduction courses of chemotherapy and showed a partial or complete 
response. Data of 50 patients with NHL were examined; 25 patients had ABMT and 25 
received conventional treatment. 
Furthermore, we considered patients with AML in first and second remission. Patient and 
hospital records of 30 patients with AML were studied; 20 patients received ABMT and 
10 conventional treatment. 
11.3.2 Treatment modalities 
A panel of haematologists defined current treatment practice and protocols of the patient 
groups mentioned above. The panel consisted of five haematologists from academic 
institutes with considerable experience with the treatment of lymphoma and aCllte 
leukaemia. 
The conventional treatment of NHL patients differed across patients and centres. 
Chemotherapy regimens administered were, for example, the CHOP, ProMACE-MOPP, 
CAMP, DHAP and the IMVP regimen (Glossary of chemotherapy regimens: page 166) 
(Fisher et al., 1993; Armitage, 1993; Verdonck et al., 1992; Cooleman, 1985). We 
focused on patients receiving ProMACE-MOPP, DHAP, CHOP and IMVP regimens, as 
these regimens were most often used. 
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Some regimens were given as outpatient schedules, other regimens were given on an 
inpatient basis. An abbreviated scheme of the treatment patterns for the NHL group is 
shown in Figure 11.1. 
Figure 11.1: Model of non-Hodgkin's lymphoma treatment 
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In the Netherlands, the alternative to ABMT in the AML group is "no further treatment", 
as according to a currently ongoing prospective randomised study. The best treatment 
option is still subject to debate. As the purpose of this study is to assess the costs of 
introducing ABMT in the Netherlands, we used the "no further treatment" option (= 
option 1) as the alternative to ABMT. Figure 11.2 shows an abbreviated scheme of the 
treatment patterns for the AML group. In the "no further treatment" arm, about 60% of 
the patients will relapse. For these patients, sometimes the decision was to try and 
reinduce a subsequent complete remission, or otherwise to withhold further therapy. In 
the past (situation with no ABMT), many patients did not receive any further therapy due 
to medical complications (about 50%). The other patients received a relapse treatment. 
For the cost analysis, we considered a follow-up period of at the most two years. 
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Figure 11.2 Model of treatment for patients with acute myeloid leukaemia 
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In the treatment of patients with AML in second CR, it is also possible to use ABMT. In 
general, bone marrow (BM) was harvested after first CR (= option 2). About 60% of the 
patients relapsed. These patients received at least I reinduction cycle. Of these patients, 
about 50% attained a second CR. According to the panel, about 15 % of the AML patients 
in second remission would receive an ABMT. Option 3 describes the ABMT application 
in patients in first CR. 
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11.3.3 Cost analysis 
The cost analysis has been performed in five university hospitals and one cancer centre. 
The activities considered were days in hospital, outpatient visits, medical procedures 
(laboratory services, diagnostics), medication (cytostatics, antibiotics, antiemetics, etc.) 
and blood transfusions. These costs were registered through cost registry forms and 
reflect full costs including overheads. Cost price studies, measuring real resource use, 
have been carried out for all costs. The year of study was 1992. 
For the calculation of the total costs of introducing ABMT the expected number of 
ABMTs per year was also estimated. The incidence, remission and relapse rates per 
patient group have therefore been collected. These rates are derived from existing 
registration systems and from the Dutch Working Party on Haemato-Oncology (Medical 
Insurance Board, 1993). The extra costs of introducing ABMT is calculated by sub-
tracting the costs of conventional therapy from the treatment costs of the strategy with 
ABMT. 
1l.4 Results 
1l.4.1 Treatment cost NHL group 
Depending on the chemotherapy regimen the patients were hospitalised or they were 
treated on an outpatient basis. Chemotherapy regimens administered on an outpatient basis 
were CHOP and ProMACE-MOPP. The costs are summarised in Table 11.1. CHOP 
therapy was the cheapest chemotherapy. The average costs of CHOP chemotherapy 
amounted to about US$ 3120. Patients who failed CHOP received ProMACE-MOPP, 
DHAP or IMVP regimens. The patients who were treated with DHAP and IMVP 
regimens were hospitalised. Per chemotherapy cycle, patients spent 5-7 days in the 
hospital and received an average of four cycles. The most expensive treatment was 
estimated at about US$ 12900. 
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Table 11.1 Average cos Is of chemolherapy Irealments in NHL 
COSls of outpatient Costs of inpatienl 
administration administration 
(US$) (US$) 
Regimen I: CHOP Iherapy DHAP Iherapy 
- Hospitalisation I outpatient visits 1070 7088 
- Medical procedures 1355 1740 
- Medication 695 3888 
TOlat 3120 12716 
Regimen 2: ProMACE-MOPP Iherapy IMVP Iherapy 
- Hospitalisation I outpatient visits 1605 9924 
- Medical procedures 1665 1476 
- Medication 695 1500 
TOlat 3965 12900 
Concerning ABMT, a pre-transplantation and a transplantation period were distinguished. 
An additional study was perfonned to assess the average cost of BM harvest, including 
cryopreservation and BM cultures. This cost was estimated at US$ 2042, subdivided into 
personnel US$ 689, operating room US$ 543, medical equipment US$ 436, materials 
US$ 222 and quality control of the BM US$ 152. BM was unpurged. The total expenses 
during the pre-transplantation period were about US$ 5480. However, only 67% of the 
bone marrow harvests actually resulted in a transplantation. Therefore, the mean costs of 
the pre-transplantation period amounted to US$ 8220 (= 1.5x US$ 5480). The transplan-
tation period cos ted about US$ 32000 (range: US$ 23960 - US$ 69100); hospitalisation 
was responsible for 60% of these costs. The total costs of ABMT amounted to US$ 
40220. 
11.4.2 Treallllelll cost AML group 
In general, the AML patients received three induction therapies as first-line treatment and 
1-3 reinduction therapies as second-line treatment. We calculated the average costs of 
these induction therapies (Table 11. 2) and used this calculation as the basis for the re-
induction treatment. 
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Table 11.2, Average costs and days in hospital of induction treatments in AML 
Costs induction Average number 
treatment (in US$) of hospital days 
(range) (range) 
Cycle 1: DNR and Ara-C 30560 (22640 - 42080) 33 (25-44) 
Cycle 2: Ara-C and amsacrine 35040 (22640 - 50540) 36 (25-59) 
Cycle 3: Mitoxantrone and Ara-C 27880 (14590 - 39130) 36 (23-53) 
Average cost/days of 3 induction cycles 93480 105 
Average cost/days per induction cycle 31160 35 
All patients were hospitalised, The mean number of days in hospital amounted to 35 days 
(range: 23-59 days), The average costs of an induction cycle amounted to about US$ 
31160, When patients remained in complete remission, the costs of follow-up only were 
US$ 4220, The average costs of follow-up in the "no further treatment" option amounted 
to approximately US$ 11040 (Table 11.3), 
With ABMT, in option 2 in addition to option 3, BM was harvested after the first CR, 
The same procedure for the BM harvest was accounted for as for the NHL patients, In 
the Netherlands, BM of leukaemia patients is also usually unpurged, Therefore, the same 
costs (US$ 5480) were used, In option 3, about 1.5 of the BM harvests actually resulted 
in an ABMT, Hence, with this treatment option the pre-transplantation costs amounted to 
about US$ 8220, 
Costs of the transplantation period were more expensive than those incurred with the 
lymphoma patients, because the AML patients stayed longer in the hospital and needed 
more antibiotics and blood transfusions, The costs of this period amounted to about US$ 
43000, Costs of hospitalisation were responsible for almost 55% of the total costs, 
medical procedures for 13%, medication for 14% and blood transfusions for 18%, Total 
ABMT costs were about US$ 51220, 
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Table 11.3 Costs of treatment for AML in the Netherlands 
Treatment Average 
cost cost 
(US$) (US$) 
"No jurther treatmelll" (optiolll) 
- 40% no relapse 4220 1690 
- 60% relapse: . 50% re-induction cycle 31160 9350 
. 50% no re-induction cycle 0 0 
Total optioll I 11040 
"No jurther treatmellt" (optioll 2) 
- Bone marrow harvest 5480 5480 
- 40% no relapse -)0 no further treatment -)0 follow up 4220 1690 
- 60% relapse: 
. 90% received 1 re-induction cycle: 31160 16830 
- 50 % second CR: 
. 85% no further treatment 0 0 
.15% ABMT 43000 1740 
- 50 % no second CR -)0 no further treatment 0 0 
10% no further treatment 0 0 
Total optioll 2 25740 
ABMT (optioll 3): 
ABMT 51220 51220 
Follow-up: - 60 % no relapse 4220 2530 
- 40% relapse 4220 1690 
Total optioll 3 55440 
In option 2, the average costs of treatment were approximately US$ 25740. However, as 
the purpose of this study was to assess the costs of introducing ABMT in the Netherlands 
and option 2 included an ABMT option, we cakulated the costs of introduction as the 
difference between option 3 and option I. In the ABMT group, about 40% of the patients 
would develop a relapse and received no further therapy. The costs in the follow-up 
period amounted to about US$ 4220. 
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11. 4. 3 Costs of introducing ABMT 
In the Netherlands, the expected number of ABMTs was 180 for patients with NHL and 
the expected number for patients with AML was estimated at 50 (Medical Insurance 
Board, 1993). The costs of introducing ABMT in both patient groups are summarised in 
Table 11.4. When conventional NHL treatment with chemotherapy is replaced by ABMT, 
the minimum substitution costs amount to about US$ 27430 and the maximum costs to 
about US$ 37120. By multiplying these costs with the expected number of patients, costs 
of introducing ABMT for this patient group will vary between 4.93 and 6.68 million 
dollars. 
Table 11.4. Costs of introducing ABMT in patients with NHL and AML in the Netherlands 
Costs per patient per group Number Average Total costs 
of costs (x 1000) 
patients (USS) (US$) 
NHL group: 
-ABMT 180 40220 7240 
- Chemotherapy on inpatient basis 12900 2306 
- Chemotherapy on outpatient basis 3120 562 
Costs of ABMT introduction 
- Minimum 27410 4934 
- Maximum 37100 6678 
AML group: 
- ABMT 50 55440 2772 
- Conventional treatment 11040 552 
Costs of ABMT introduction 44400 2220 
In the AML group the extra costs of introducing ABMT are assessed at 2.22 million 
dollars, that is US$ 44400 per patient. Combining both patient groups, the total costs of 
introducing ABMTs in the Netherlands are expected to be between 7.15 million and 8.90 
million dollars. 
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11.5 Discussion 
As new treatment modalities become available for patients with haematological malignan-
cies, the additional economic burden raises concern (Weber, 1993). This analysis shows 
that at least some savings from substitution will occur. However, there still remains a 
gap, and hospitals which carry out ABMTs will not be able to finance these additional 
costs from savings elsewhere. 
In the Netherlands ABMT is also used for haematological malignancies, besides for NHL 
and AML, namely patients with Hodgkin's disease and acute lymphoid leukaemia (ALL). 
Patients with Hodgkin's disease are conditioned for transplantation if they do not attain a 
complete remission on first-line chemotherapy or present with relapse following CR 
within 1 year after chemotherapy. Patients with ALL are transplanted if they relapse and 
reach a second remission. According to the panel of haematological experts, the use of 
medical resources by patients with Hodgkin's disease is almost comparable to the NHL 
patients and the use of medical facilities of ALL patients is comparable to that of patients 
with AML. The total number of ABMTs per year is estimated at 50 for Hodgkin's 
disease and 25 for ALL (Medical Insurance Board, 1993). As a result, the total extra 
costs of introducing ABMT for the lymphoma and acute leukaemia patients, including 
these last two categories, are expected to be between 9.63 and 11.86 million dollars. 
In our study, the estimated cost of ABMT was lower than reported in other studies. In the 
literature, the estimated cost of ABMT for lymphoma and breast cancer varied between 
US$ 62200 and US$ 100000 (Desch el al., 1992; Hillner el al., 1992; Gulati and Bennet, 
1992). The cost of salvage therapy was estimated at $ 4000 and $15000. With leukaemia 
patients, Welch and Larson (1989) estimated the ABMT costs at $ 139000 and the chemo-
therapy costs at $ 78000, both during the first 6 months. This high ABMT cost, com-
pared with our results, may be related to the fact that in these studies all patients who 
underwent transplantation, regardless of their medical condition were treated in the 
intensive care unit or in a protected care unit during the entire transplantation period. In 
the study of Dufoir el al. (1992), patients were hospitalised in a protected care unit from 
the date of admission to the end of aplasia. Therefore, the estimated costs of ABMT were 
lower, namely about US$ 72400 (1 FF ~ 0.184 US$). The costs of ABMT were still 
higher than by our calculations, but in this study a number of patients received a double 
transplantation. Conventional chemotherapy (four cycles) amounted to US$ 24000; the 
mean number of days in hospital was 23 days, that is 2-5 days per cycle. The cost 
difference in the various studies are mostly generated by the difference in the ABMT 
procedures. Therefore, it may be advisable to specify the ABMT procedure and to present 
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procedure-specific unit prices in more detail, allowing better comparison of ABMT costs 
between countries. 
The introduction of ABMT has major economic consequences, but it has important 
treatment benefits as well. For the NHL patients mentioned above, the disease-free 
survival (DFS) at 2 years after DHAP varies between 5% and 20% (Velasquez el al., 
1988). ABMT may result in a DFS at 3 years of approximately 50% of all transplanted 
patients and in 25 % of the original number of patients destined to receive ABMT 
(Verdonck el al., 1992). Patients with Hodgkin's disease after a chemotherapy relapse 
were treated with similar, or salvage chemotherapy. Although 35-60% of these patients 
achieve a CR, only 25-35 % are alive at 5 years. ABMT after first relapse frequently 
results in higher CR rates and longer DFS (Desch el al., 1992). According to the panel, 
with no ABMT, patients with AML in first remission have a 40% probability remaining 
in remission. With ABMT this probability is about 60%. These estimates correspond with 
the results of Welch and Larson (1989). Furthermore, Welch and Larson estimated the 5-
years survival at 41 % for the conventional chemotherapy group and at 60% for the 
ABMT group. For ALL patients who relapse, second CRs can be obtained in 10-75% of 
patients depending on the treatment regimens; however the durability of these remissions 
is poor. ABMT in these patients does lead to significant longer DFS (Ball and Rybka, 
1993). 
Currently, additional treatment modalities in these patient groups are being studied 
(Hillner et al., 1992; Velasquez el al., 1988; Uyl-de Groot et al., 199411). Use of colony 
stimulating factors and peripheral stem cell transplantation (PSCT) seem to be alternatives 
to ABMT. Fortunately, it may be expected that these modalities are cheaper than ABMT 
(Nemunaitis et al., 1991). However, in the near future, it is also expected that ABMTs or 
stem cell transplants will be carried out in patient groups not previously treated with 
transplantation (Hillner et al., 1992; Ayash et al., 1994; Ossenkoppele et al., 1994). 
Economic evaluations linked to clinical trials provide information about the cost-effective-
ness of new treatment modalities. In the Netherlands several economic evaluations 
concerning PSCT are being carried out, for example in breast carcinoma and multiple 
myeloma. When these new treatment modalities are implemented in the clinical setting, 
these studies should provide the necessary information on the economic consequences of 
introducing such new technologies. 
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CHOP: 
ProMACE-MOPP: 
CAMP: 
DHAP: 
IMVP: 
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A glossary of chemotherapy regimells 
Cyclophosphamide, doxorubicin, vincristine, prednisone 
Prednisone, methotrexate with leucovorin rescue doxorubicin, 
etoposide. mechlorethamine. vincristine, prednisone, procarbazine 
Cyclophosphamide, adriamycin. mitoxantrone. prednisone 
Dexamethason, cispiatine, Ara-C, prednisone 
Ifosfamide, melholrexale, eloposide (VP-16) 
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Hospital economic model for HGF therapy 
12.1 Summary 
Patients receiving chemotherapy frequently develop fever and neutropenia. Haemato-
poietic growth factors (HGFs) may decrease the duration of such episode or may prevent 
a febrile neutropenic episode. In this study we introduce a Markov type economic model 
for the hospital which calculates all relevant direct costs and savings of HGF therapy and 
may support decisions on HGF administration. A distinction is made between patients 
receiving intensive and standard chemotherapy schedules. Our results indicate that HGFs 
can induce savings in intensive chemotherapy and standard chemotherapy following 
ncutropenic fever. Prophylactic administration of HGF is cost-effective if the risk of 
infection is considerable. The risk of infection depends on underlying malignancy, 
corresponding treatment modalities and the health condition of the patient. The model is 
meant as an analytical framework and should be used carefully, as not all benefits (e.g. 
benefits to the patients) are considered. These benefits may be balanced against the 
additional costs or savings resulting from the economic model. 
12.2 Introduction 
Neutropenia is closely related with the treatment of cancer. The risk of a life-threatening 
infection increases significantly when the neutrophil count falls below O.5xlO'/l and it is a 
major cause of death in cancer patients. Furthermore, the duration of neutropenia has an 
important role in the design, schedule, and dose of cancer treatment regimens (Ant man et 
al., '1988; Pizzo, 1984). Treatment-related neutropenia is highly variable, ranging from 
days to weeks. 
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Neutropenic patients with fever require prompt initiation of early broad spectrum 
antibiotic therapy. Moreover, haematopoietic growth factors (HOFs), such as granulocyte 
colony-stimulating factor (O-CSF) and granulocyte-macrophage colony-stimulating factor 
(OM -CSF) are becoming increasingly important in the treatment of febrile neutropenic 
patients (Lieschke and Burgess, 1992; Metcalf, 1990). HOFs are indicated for rapid 
haematopoietic reconstitution by stimulating the proliferation of neutrophils and could be 
administered during intensive chemotherapy schedules, during standard chemotherapy 
cycles and in patients with chemotherapy-induced fever and neutropenia (Biesma el al., 
1990; Crawford el al., 1991; Bronchud el al., 1987; Estey el al., 1992). 
The administration of HOFs during intensive chemotherapy regimens mainly concerns 
patients undergoing autologous bone marrolY transplantation (ABMT) or peripheral blood 
progenitor cell (pBPC) transplantation and patients with acute myeloid leukaemia (AML). 
These patients remain neutropenic for three to foul' weeks (Estey el al., 1992; Ohno el 
al., 1990; Uyl-de Oroot el al., 1994II). They are all hospitalised and treated with broad 
spectl1lm antibiotics. HOF therapy may reduce the period of neutropenia and may result 
in shortening the period of hospitalisation and antibiotic therapy. 
Prophylactic administration of HOF during and after standard chemotherapy cycles is 
already applied in patients with small cell lung cancer (Crawford el al., 1991; Bronchud 
el al., 1987; Trillet-Lenoir el al., 1993). The standard chemotherapy is mainly given on 
an outpatient basis. When patients become febrile and neutropenic during a given cycle of 
treatment, they are generally hospitalised and receive standard parenteral antibiotic agents 
(Metcalf, 1990; Estey el al., 1992; Riikonen el al., 1994; Oabrilove, 1988). 
At a time of restrained public spending, hospitals are coming under increasing pressure to 
deliver more services with less resources. The main cause of rising hospital dl1lg 
expenditure in leading Western European countries are antibiotics (Thilrmann and Harder, 
1993). The administration of HOFs may lead to less infections and as a result to less 
antibiotic administrations. Furthermore, it could result in a lower risk of hospitalisation 
and a shorter stay in hospital. Thus, the use of HOFs may decrease utilisation of some 
health care resources. Olaspy el al. (1993) developed an economic model to demonstrate 
these savings of prophylactic administration of the haematopoietic growth factor O-CSF 
(filgrastim) in patients with small cell lung cancer. The analysis was conducted in 
conjunction with a phase III clinical trial (Crawford el al., 1991). The data were derived 
from 3 of the 14 hospitals included in the clinical trial. However, the clinical results in 
these 3 hospitals differed from the results of the total study. For example, in the larger 
trial the number of days in hospital and the number of days with antibiotic therapy were 
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similar in both groups once patients were hospitalised, while in the economic model not 
only the number of hospitalisations decreased with almost 50%, but the duration of 
hospital stay decreased with almost 50% as well. Furthermore, Glaspy's study is focused 
on the administration of haematopoietic growth factors in one patient group. 
The aim of this study is to develop an economic model for the hospital, which includes all 
relevant direct costs and savings in relation to chemotherapy-induced fever and neutro-
penia. Three categories of treatment choices will be presented: the first category considers 
a treatment option where HGFs are administered during intensive chemotherapy cycles. 
The second category describes a prophylactic option where HGFs are administered during 
and after standard chemotherapy cycles, which are given on an outpatient basis. When the 
patients become febrile and neutropenic, they are hospitalised and treated with broad 
spectrum antibiotics. The aim of HGF administration in this second category is to prevent 
patients from developing fever and neutropenia. It may be applied during the first 
chemotherapy cycle or during consequent cycles. The third category concerns a treatment 
option in for example solid tumour patients and patients with non-Hodgkin's lymphoma. 
These patients receive standard chemotherapy cycles again on an outpatient basis and 
subsequently may develop fever and neutropenia. The purpose of administering antibiotics 
in combination with HGFs is to shorten the period of fever and neutropenia. 
The model is meant for hospital pharmacists, doctors and hospital management. The 
perspective of the study is that of the hospital and therefore only the direct costs of 
outpatient and inpatient treatment are considered. 
12.3 Approach and method 
12.3.1 Development of the model 
The costs of the treatment alternatives will be compared by subtracting the estimated total 
costs used for the group treated with conventional therapy from the estimated total costs 
for the group treated with HGF therapy. For all categories, the following formula is used 
to calculate the cost or benefit of the HGFs therapy: 
where ~ C = differential treatment cost, E C, = total treatment costs of convential 
therapy without HGF and E C, = total treatment costs of HGF therapy. 
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This formula implies that if '" C is positive, the conventional therapy is more expensive 
than HGF therapy. The situation with'" C = 0 marks the break-even point, and if'" C 
< 0 than the administration of HGFs does not lead to savings. 
Figure 12.1 shows the three categories in the hospital economic model. In category I, all 
patients are treated with intensive chemotherapy and stay in hospital for a few weeks. 
During and after the administration of cytostatics they are treated either with antibiotics or 
with antibiotics in combination with HGF therapy. The relevant cost items are days in 
hospital, days with antibiotics and, if applicable, the number of days with HGF. This 
results in the following formula: 
'" C, = {(HD" x HC,) + (AD" x AC,)} -
{(HD" x HC,) + (AD" x AC,) + (HGFD, x HGFC)}. 
where t. C, = differential costs in category I, HD, = number of hospital days, HC, = 
cost per hospital day, AD, = number of days with antibiotic therapy, AC = antibiotic 
cost per day, HGFD, = number of days with HGF therapy and HGFC = cost of HGF 
per day. 
Category II concerns patients who receive standard chemotherapy. These patients may be 
treated with HGF on a prophylactic basis. This means that all patients receive HGF 
directly after completing their chemotherapy. When the HGF is not applied, the so called 
"wait and see" option, there is a probability that fever and neutropenia develop (PFN1). 
Once this event has set in, antibiotics or antibiotics plus HGFs are administered (category 
III). Delay of administration of the following chemotherapy cycle may occur, resulting in 
extra outpatient visits. The relevant cost items are days in hospital, days with antibiotics 
and HGF, and number of extra outpatient visits. For this category the following formula 
applies: 
t. CII {P(FNl) X «HDm x HCII) + (ADm X ACII)+ (P(EOm) x EOm x OCII»} -
{(P(FN2) X «HD", x HCII) + (AD", x ACII) + (P(EOIl1) X EO", x OCII))) + 
(HGFDII x HGFC)} 
where t. CII = differential costs in category II, P(FN) = probability to develop fever and 
neutropenia, HDII = number of hospital days, HC" = cost per hospital day, AD" = 
number of days with antibiotics, AC" = antibiotic cost per day, P(EOII) = probability of 
extra outpatient visits, EO" = number of extra outpatient visits, OCII = cost of an 
outpatient visit, HGFD" = number of days with HGF, and HGFC = HGF costs per day. 
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Figure 12.1 Hospital economic model 
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Category III handles patients who develop fever and neutropenia due to standard chemo-
therapy. The chemotherapy is administered on an outpatient basis, but the patients are 
hospitalised in case of fever and neutropenia. Delay of chemotherapy administration may 
happen in both groups. The formula is the same formula as for category I. 
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Default values of the probability to develop fever and neutropenia, the hospitalisation 
risk, the number of days in hospital, the number of extra outpatient visits, the number of 
days with antibiotics and the number of days with a HOFs are based on literature review. 
Cost prices are derived from previous Dutch studies on the cost-effectiveness of cancer 
treatment in the relevant patient groups (Uyl-de Oroot et al., 19941 and 199411). 
Sensitivity analyses are carried out to provide insight into the effect of changes in the 
probability to develop fever and neutropenia, days in hospital and cost per hospital day on 
the total treatment costs. 
We specified a Markov model to estimate the consequences of HOF administration when 
more (standard) chemotherapy cycles are given and possible combinations of category II 
and III are considered. Patients treated with antibiotics or HOF therapy in the previous 
cycle are assumed to receive the same treatment in the following cycles. 
We used the computer programme Quattro Pro for Windows. 
12.3.2 Default values 
Category I: In the study of Nemunaitis et al. (1991), the median duration of the initial 
hospital stay was 27 days in the HOF group as compared to 33 days in the placebo group. 
This is a reduction of almost 20% and is consistent with results reported elsewhere (Oorin 
et al., 1992). The number of days with antibiotics was about 82% of the days in hospital 
in the placebo group. This percentage was 89% in the HOF group. For the formula, this 
implies that: HD" = 0.8 x HD", AD" = 0.82 x HD" and AD" = 0.89 x HD". 
In category II, the conventional therapy is the "wait and see" option. Patients only receive 
antibiotics when they develop fever and neutropenia. The default values will be similar as 
in category III. The other option is that all patients receive HOF therapy. HOFs are given 
on average 10 days (range 7-14 days) (Crawford et al., 1991; Bronchud et al., 1987; 
Gerhartz et al., 1993). Crawford et al. (1991) and Bronchud et al. (1987) reported a 
reduction of the event rate for fever and neutropenia by 50% in the HGF group as 
compared with the "wait and see" option. The average duration of the individual episodes 
of antibiotic use and hospital stay in case of fever and neutropenia, were similar in both 
treatment groups. In the study of Gerhartz et al. (1993) the event rate decreased with 
40%. The reduction in infection distributed equally through all six cycles of chemothe-
rapy. Patients receiving HGF stayed shorter in hospital than the patients treated with 
placebo. The percentage of chemotherapy cycles finished on time was 54 % in the HGF 
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group and 34 % in the placebo group. However, data on the average number of delayed 
chemotherapy schedules per patient were not showed. To simplify the models these 
probabilities are set to zero. The assumptions made are P(FN2) ~ 0.5 x P(FNI), HGFDn 
~ 10 and once the event has set in: HDJII ~ HD"" ADJII ~ AD", and P(EOJII) ~ 
P(EO",) ~ o. 
Category III: In the study of Mayordomo ef al. (1993), patients treated with antibiotic 
therapy had a median hospital stay of 8 days (range: 5-34) and patients treated with anti-
biotic therapy in combination with HGF had a median hospital stay of 5 days (range: s-
IS). This implies a reduction of 37% in hospital days. In the study of Maher ef al. 
(1994), the median number of days in hospital amounted to 8 days in both groups, while 
the mean number of days in hospital amounted to 10.0 days in the antibiotic group and to 
8.7 days in the HGF group. The difference in hospital stay between the studies of 
Mayordomo and Maher could be explained by differences in definition of fever and 
neutropenia and differences in doses of HGF administration. In the model we assume that 
the hospital stay in the antibiotic group is 10 days and 8 days in the antibiotics with HGF 
group, implying a reduction with 20%. The antibiotic therapies consisted of piperacillin 
and tobramcyin, ceftazidim and amkacin or tobramycin and cefuroxime (Biesma ef al., 
1990; Gerhartz ef al., 1993; Mayordomo ef al. 1993). The antibiotic therapy and/or HGF 
therapy was stopped about 2 days before hospital discharge. This implies that: HDIII2 ~ 
0.8 X HDIII1 , ADl111 ~ (HDnn - 2) and ADIII2 ~ HGFDIII ~ (HDIII2 -2). 
For the Markov model all default values will apply. Data on patients developing FN in 
subsequent cycles are not available. According to interviews with clinical experts, we 
made the assumption that patients with a previous FN have a 95 % chance of FN in the 
next cycle and that patients with no previous FN have a 5% chance of FN in the next 
cycle. 
12.3.3 Ullif prices 
In the Netherlands, the cost of hospitalisation amounts to about US$ 350 per day for 
normal haematological care, to about US$ 536 per day for a stay in a protected environ-
ment and to about US$ 1223 per day for a stay on an intensive care ward (Uyl-de Groot 
ef al., 19941 and 1994II). These costs do not include the costs for laboratory services and 
medical procedures. The laboratory services mainly consist of routine haematological 
laboratory services and cultures. The medical procedures include X-rays and ECGs. We 
estimate these costs at US$ 50 per hospital day. 
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The patients who receive intensive chemotherapy stay more frequently and longer in a 
protected environment andlor on an intensive care ward. Furthermore, in the Netherlands 
these patients are treated in haemato-intensive care hospitals, thus the hospital costs are in 
this case higher than in the standard chemotherapy strategies. We use US$ 600 as an 
estimation for the average cost of a day in hospital for the patients receiving intensive 
chemotherapy schedules. The costs for laboratory services and medical procedures are 
included in this price. For the patients who receive standard chemotherapy, we estimated 
a cost price of US$ 450 for a hospital day in a regional hospital. The costs of antibiotic 
therapy are estimated at US$ 100 per day. The recommended amount of HGF varied 
from 3.5 I'glkg to 12 I'g/kg per day. In the model, we use a unit price of US$ 138, that 
is the cost of a 300 I'g vial G-CSF or GM-CSF. 
12.4 Results 
Category I: Group receiving intensive chemotherapy. 
The results of the costs of convential antibiotic treatment and antibiotic plus HGF therapy 
are summarised in Table 12.1. The antibiotic therapy costs are about US$ 22510 and the 
antibiotic plus HGF therapy cost about US$ 21550. The model suggests that antibiotic 
plus HGF therapy results in a saving of US$ 960 in comparison with a therapy with 
antibiotics alone. 
In Figure 12.2 the number of days in hospital when no HGF is given (= HOn) is varied 
from 25 to 40 days. The model shows that the level of savings varies from US$ 28 (HOn 
= 25 days) to US$ 1780 (HOn = 40 days) (Figure 12.2). For this range the conventional 
therapy is more expensive than the antibiotics plus HGF therapy. 
Sensitivity analyses were perfOlmed to assess the effect of changes in the number of days 
in hospital and the cost per hospital day. The cost per hospital day is varied from US$ 
400 to US$ 800. When the hospital cost is lower than the default value of US$ 600, the 
savings decrease obviously. For example, when the hospital cost is US$ 400, the savings 
range from US$ -870 (HOn = 25 days) to US$ 340 (HOn = 40 days). The break-even 
point, i.e. no cost difference between the two treatment groups, is at 35.8 days. 
When the hospital costs are higher than the default value, for example US$ 800, the 
savings are higher and range from US$ 930 (HOn = 25 days) to US$ 3220 (HOn = 40 
days). When the number of days in hospitals decreases with a smaller percentage due to 
HGF therapy than the default value of 20% reduction, the savings are smaller. 
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Table 12.1 Costs of conventional and HGF therapy per category (in US$) 
Costs of Costs of Cost 
antibiotic antibiotic- difference 
therapy + HGF-
Categories therapy 
Category I (illlensive chemotherapy group) 
- Hospital costs 19800 16240 3560 
- Costs of antibiotics 2710 2410 300 
- Costs of HGFs - 2900 -2900 
Total costs 22510 21550 960 
Category II (standard chemotherapy group) 
- Hospital costs 2565 1280 1285 
- Costs of antibiotics 455 230 225 
- Costs of HGFs - 1380 -1380 
Total costs 3020 2890 130 
Category 1lI (standard chemotherapy group) 
- Hospital costs 4500 3600 900 
- Costs of antibiotics 800 600 200 
- Costs of HGFs - 828 -828 
Total costs 5300 5028 272 
Assumptions: P(FNI) = 57%; HDnulli = 10; default values. 
Category II: Group receiving standard chemotherapy ± prophylactic HGF therapy. 
Now the cost of fever and neutropenia treatment with and without a HGF depend on the 
probability to develop fever and neutropenia (= P(FN». The chance of savings increases 
with the risk of fever and neutropenia. A relatively small risk of fever and neutropenia 
results in ineffective HGF administration in many patients and leads to additional net 
costs. Taking into account the default values and a P(FN1) of 57% (Crawford et al., 
1991) there will be a saving of the HGF therapy of US$ 130 (Table 12.1). 
A sensitivity analysis was performed to assess the impact of varying the risk of develop-
ing fever and neutropenia from 0% to 100% (Figure 12.3). When the hospital cost is US$ 
450, the savings varied from US$ -1380 to US$ 1470. The break-even point is at 52%, 
implying that below this level the HGF strategy is more expensive than the conventional 
antibiotic treatment. 
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Figure 12,2 Group receiving intensive 
chemotherapy (category I) 
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Furthermore, we varied the price of a hospital day with US$ ISO. The a priori chance of 
P(FN2) still is 0.5 x P(FNI). When the hospital cost is as low as US$ 300, the savings 
vary from US$ -1380 to US$ 520. The break-even point is at about 72.7 %. In case the 
price of a bed day is US$ 600, the savings range from US$ -1380 to US$ 2220 and the 
break-even point is at 38.4%. 
When P(FN2) decreases to less than 50% of P(FNI), the savings are smaller. A more 
than 50% reduction of P(FN I) results in more savings. 
Category III: Group receiving standard chemotherapy, developing fever and lIelllropenia. 
In this group the average duration of the hospitalisation period is shorter than in the group 
receiving intensive chemotherapy. Furthermore, the cost per day in hospital will be 
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lower. Taking into account the default values, the costs in the antibiotic group amount to 
US$ 5300 and in the HGF group US$ 5028 (Table 12.1). This results in a saving of US$ 
272 in favour of the HGF therapy. Figure 12.4 shows that in this case the outcomes are 
not very sensitive for changing the number of days in hospital. The savings range from 
US$ 274 to US$ 270. 
When the hospital cost amounts to US$ 300, the savings range from US$ 124 (HD\ = 5 
days) to US$ -180 (HD\ = 15 days). The break-even point is at 9.0 days. Hospital cost 
of US$ 600 per day always result in savings (range: US$ 424 - US$ 720). 
Markov model. 
Considering category III over 3 chemotherapy cycles and the default values, the cumula-
tive costs amount to US$ 8955 in the conventional antibiotic therapy group. When HGF is 
used as treatment option in case of fever and neutropenia, the cost amounts to US$ 8496. 
Prophylactic use of HGF over 3 cycles results in cost of US$ 9002. This implies that 
HGF as a treatment option in fever and neutropenic patients produces the lowest costs. 
However, this option is accompanied by having fever and neutropenia and its associated 
risks of (fatal) complications. Furthermore, it could result in dose reduction and delay of 
chemotherapy administration. The latter frequently requires extra outpatient visits. In the 
Netherlands, an outpatient visit costs approximately US$ 90 (Uyl-de Groot el al., 1994II). 
Assuming that one delay of chemotherapy administration requires one extra outpatient 
visit, it already implies that a 50% delay of chemotherapy administration results in equal 
costs in the prophylactic strategy and the "wait and see" strategy with conventional 
antibiotic treatment. 
Another option is to give HGF only prophylactic when patients had previous fever and 
neutropenia. The patients received HGF plus antibiotic therapy for their first febrile 
neutropenic episode. We assumed that probability of fever and neutropenia in the next 
cycle will be reduced with 50%. Fever and neutropenia after prophylactic HGF therapy 
will be treated with antibiotics. Taking into account the default values and a P(FNI) of 
57% the cumulative costs of this option amount to US$ 7975. 
A sensitivity analysis is performed to demonstrate the effect of changing the probability of 
developing fever and neutropenia. Figure 12.5 shows that when the probability of fever 
and neutropenia is lower than 80%, prophylactic administration of HGF when patients 
had previous fever and neutropenia produces the lowest cost. Probabilities above 80 % are 
in favour of the prophylactic HGF therapy during all cycles. 
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12.5 Discllssion 
The administration of HGF is adding considerably to the cost of medication (Finley, 
1991), but this hospital economic model indicates that the administration of HGF may 
lead to savings in the daily hospital practice. In the intensive chemotherapy and the "wait 
and see" option, HGF is cost-effective for almost all basic assumptions. However, 
standard chemotherapy is often administered in regional hospitals, where the cost of a 
hospital day is lower than in the haemato-intensive care hospitals. When patients stay 
longer than 9.0 days in hospital and lor the hospital cost are below US$ 300, the HGF 
administration does not result in savings. 
Concerning the prophylactic administration of HGF, whether or not there are savings, 
largely depends on the probability of developing fever and neutropenia. This probability 
differs between underlying malignancies, corresponding treatment modalities and the 
health condition of the patients. In our model, the administration of HGFs in patients with 
a high risk of infections leads to savings. This suggests that it is worthwhile to identify 
other determinants of high risks of infections, such as the prior patient history (infection 
at previous cycles) or other patient or hospital specific factors thought to influence the 
risk of infection. 
This hospital economic model is meant as an analytical framework to assess the savings 
from a clinical application of HGFs. It is applicable to any hospital in any country, 
regardless of practice patterns as hospital andlor country specific data can be used. It may 
support decision making about the treatment of certain patient groups as well as negotiat-
ing budget transfers with hospital management. It only requires a few relatively simple 
data from the hospital accounting system and the medical registration system. One of the 
available spreadsheet programmes may be used to quickly calculate the differential costs 
given hospital and patient characteristic data. 
However, the model should be used carefully, as the benefits to the patients, such as 
improved quality of life as a result of shorter stay in hospital and less infections are not 
considered. Other benefits may be less delay of chemotherapy administration, less distress 
to the patient and less travel costs. There may also be indirect savings (decreased loss of 
productivity). These benefits may be balanced against the additional costs (or added to the 
savings) resulting from the economic model. 
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13.1 General issues 
Economic evaluation is intended to support health policy at different levels of decision 
making. In cancer treatment, health policy concerns both preventive, curative and 
palliative strategies and decisions are often made at the micro and macro level. Economic 
evaluation can provide essential information on the costs and benefits of each option and 
consequently on the optimal policy mix, and thus support decisions on the adoption and 
utilisation of new treatment strategies. Such information may assist policy makers in 
formulating regulatory policies and legislation, industry in developing products, health 
professionals in treating and serving patients, and consumers in making personal health 
decisions. Examples of situations in which economic evaluation can playa valuable role 
are: 
Research and developmelll decisions: The results of economic evaluation may be used for 
"go/no go" decisions at critical points in the development process of new treatment 
modalities. Infonnation can be used both by university hospitals and pharmaceutical 
firms. 
Pricing decisions: Economic evaluation can help to establish an appropriate price for a 
treatment modality. This infonnation can be used both by government regulators and 
pharmaceutical firms. 
Reimbursemelll decisions: Government, hospitals, insurers, and other payers can use the 
results of economic evaluation in their reimbursement policies. For instance, the results of 
economic evaluation could influence decision making on whether or not to include new 
technologies in the package of (social) health insurance. 
183 
Discussion 
Clinical guidelines: Hospital budgets are limited and doctors face financial restrictions. 
The results of economic evaluation may support the choice of treatment strategy and the 
selection of patients at the micro level, as well as negotiating budget transfers with 
hospital management. While developing clinical guidelines for providers not only the 
efficacy and effectiveness of treatment alternatives need to be considered, but also their 
cost -effectiveness. 
However, decisions should not be based on the results of economic evaluation alone. 
Economic evaluations are used to inform decision making, not to replace it. Using results 
of economic evaluations requires that these are reliable and unambiguous and that the 
evaluation is can-ied out in a rigorous manner. The methods used and the way in which 
costs and consequences are measured and valued must be made clear, in order to help 
policy makers to determine whether the study's results are relevant to their policy 
context. The following sections deal with specific issues concerning measuring and 
valuing outcome and resources and the generalisability of study results. 
13.2 Measuring and valuing outcollle 
In clinical studies in cancer the main end points used are sUfvival fates, response rates 
and response duration. To improve results in tenos of incremental survival and less 
morbidity and suffering, physicians and nurses are now paying more attention to 
supportive care. Quality of life studies may give insight into the burden of cancer and its 
treatment for patients. Thus, quality of life is becoming an important end point in cancer 
research. 
To incorporate quality of life aspects in economic appraisal, the use of a generic, a 
disease-specific, and a valuation instrument is advisable. In this respect standardisation is 
essential, so that different health care interventions can be compared. At the moment, in 
the Netherlands there is growing consensus among researchers which instruments should 
be used. In this thesis, the quality of life studies used the Karnofsky Performance Index 
and the Nottingham Health Profile as generic instruments, the Rotterdam Symptom 
Checklist as cancer-specific instrument and the EuroQoL as valuation instrument. The 
choice of instruments was based on the relatively good psychometric features, on their 
opportunity to capture specific patient features and their good feasibility record. 
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Concerning the generic instruments, there is a tendency to use the Short-Form 36 instead 
of the Nottingham Health Profile. The Short Form-36 may be regarded as an extension of 
the RAND-MOS 20 (Ware ef al., 1993); Anderson ef al., 1993). It includes multi-item 
scales measuring eight health concepts (physical functioning, role limitations due to 
physical health problems, bodily pain, general health, vitality (energy/fatigue), social 
functioning, role limitations due to emotional problems, and mental health (psychological 
distress and psychological well-being), and a single item on change in health. The Short 
Form-36 has good psychometric features and the administration time is approximately 10 
minutes (Ware ef al., 1993). It is the only generic quality of life instrument reviewed that 
is currently undergoing international adaptation (Anderson ef al., 1993). In the past, the 
use of Short-Form-36 was restricted, but recently it has become available for broader use. 
However, written approval of the Medical Outcome Trust is still required. In new eco-
nomic appraisals concerning cancer treatments, for example in patients with renal cancer, 
in patients with multiple myeloma and in lymphoma patients undergoing stem cell 
transplantation, we used the Short-Form 36 in stead of the Nottingham Health Profile. A 
disadvantage of the Short-Form 36 is that this instrument has no validated Dutch popula-
tion references. In the near future these reference values will be provided. 
The use of a cancer-specific questionnaire (for all cancers) or a specific-cancer question-
naire (for one type of cancer) is to monitor the reactions of patients to cancer and cancer 
treatment. The Rotterdam Symptom Checklist is a suitable cancer-specific instrument to 
be used in economic evaluation. However, this questionnaire is mainly applied in patients 
receiving standard chemo- and/or radiotherapy (De Haes ef al., 1990). Patients undergo-
ing stem cell transplantation receive high-dose chemotherapy and sometimes total body 
irradiation. Stem cell transplantation is a very intensive treatment modality, that will be 
applied in many new patient groups. The sensitivity of the Rotterdam Symptom Checklist 
to monitor the burden of this treatment modality to patients requires further study. 
Alternatives for the Rotterdam Symptom Checklist are for example the European 
Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire 
(EORTC QLQ-C30) (Aaronson ef al., 1988; Aaronson ef al. 1993) and the Functional 
Assessment of Cancer Therapy Scale (FACT-scale, Cella ef al., 1993). The QLQ-C30 is 
a 30-item instrument consisting of five functional scales (physical, role, emotional, social 
and cognitive functioning), three symptom scales (fatigue, nausea/vomiting, and pain), a 
global quality of life scale, and a number of single items assessing additional symptoms 
(dyspnoea, sleep disturbance, constipation, and diarrhoea) and perceived financial impact 
of the disease and its treatment. It has been demonstrated to have good validity and 
reliability (Aaronson ef al., 1993; Anderson ef al., 1993), and is currently being 
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employed in a large number of clinical trials of the EORTC, other clinical trial groups, 
and the pharmaceutical industry. The QLQ-C30 is a core instrument that is intended to be 
supplemented by more specific subscales (modules) to assess aspects of quality of life of 
particular importance to specific subgroups of patients (Sprangers el al., 1993). A module 
is a set of items assessing quality of life issues not (sufficiently) covered by the core 
questionnaire, and considered to be relevant for the target population and the research 
question at hand. This set of items may refer to disease symptoms related to tumour site 
(e.g. breast cancer), or stage within tumour site (e.g. local vs metastatic breast cancer), 
side-effects of treatment (e.g. chemotherapy-induced neutropenic fever), or other quality 
of life dimensions such as fatigue and fear of disease recurrence. At the moment, three 
site-specific modules have been developed, Le. head and neck cancer (Bjardal el at., 
1993), breast cancer (Sprangers et al., 1992) and lung cancer (Bergman el al., 1994). 
The average time to complete the QLQ-C30 and a supplementary questionnaire specific to 
lung cancer patients was 11 minutes (Sprangers el al., 1993). Furthermore, most patients 
could complete the questionnaire without assistance. As the number of modules is 
increasing the EORTC has developed guidelines to standardise the module development 
process (Sprangers el al., 1993). The EORTC QLQ-C30, including the modules, is 
available for use on a no-cost basis for academic researchers and those working in non-
profit seltings. Industry users are required to complete a licensing agreement. 
The FACT-scale is a validated, 33-item scale, developed for evaluating the quality of life 
of patients receiving cancer treatment (Cella et al., 1993). It can easily be completed in 5 
minutes, usually without assistance. The instrument is widely used in the United States, 
but no validated Dutch translation is available. 
The EuroQol is a suitable valuation instrument to be used in economic evaluation of 
cancer treatments. It is a simple health status measurement instrument designed to allow 
valuation of health status in terms of utilities (EuroQol study group, 1990). As the 
EuroQol consists of 5 dimensions with 3 answer categories, 243 health states are possible. 
About 40 states have empirically estimated values or utilities; the other health states are 
estimated using a model (Van Hout and McDonnell, 1991). However, the validity of 
using mathematical models is questionable, as only a slllall number of health states have 
been empirically valued. An iMTA research project has been initiated to get valuations of 
health states from the general population. Furthermore, an organisation has been built to 
provide official translations of the EuroQol and a professional user guide. 
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A problem in the standardisation of instruments is that different instruments are used in 
Europe and in the United States. For example, the Rotterdam Symptom Checklist and the 
EuroQol are applied in many European studies, but are rarely used in the United States 
and conversely the Sickness Impact Profile is often used in the United States but to a 
much lesser extent in Europe. Furthermore, for a number of English! American question-
naires there are no validated Dutch translations available (e.g. the Torrance's Health 
Status Classification (Torrance et al., 1982) and the Functional Assessment of Cancer 
Therapy Scale (FACT-scale, Cella et al., 1993). At the moment, there is not enough 
empirical data to assess decisively the comparative advantages of the several measurement 
and valuation instruments. However, for achieving world wide standardisation, coopera-
tion, not only between researchers in Europe but with researchers in the United States as 
well, is necessary. The development of the Short-Form 36 and the EORTC QLQ-C30 and 
its different translations are examples of such overseas cooperations. 
The administration of both a generic, a cancer specific and a valuation instrument 
appeared to be too much of a burden for some of the elderly patients with AML. Reasons 
were the duration of the questionnaire and motivation (assistance of a nurse was some-
times necessary). These problems appear specific to this aged category of patients and 
resulted in refusals to further cooperate in the quality of life study. For future research 
we would like to pay more attention to alleviate the burden of completion of the question-
naires, especially for the elderly. A solution may be to make different questionnaires for 
the short- and long-term quality of life measurement. It is possible to use for the short-
term quality of life measurement a cancer-specific questionnaire (e.g. the Rotterdam 
Symptom Checklist or the EORTC QLQ-C30) in combination with the EuroQol. Before 
the start of the treatment and for the long-term quality of life a generic instrument (e.g. 
the Nottingham Health Profile or the Short-Form 36) in combination with the EuroQol 
may be used. 
13.3 Measllring and valuing resources 
In economic evaluation, a distinction is made between direct medical costs, direct non-
medical costs, indirect medical costs and indirect nonmedical costs. The direct costs 
concern the costs of operating a treatment programme. Direct nonmedical costs are for 
example patient's travel costs and housekeeping costs. The indirect medical costs concern 
the costs of medical consumption during life years saved. The indirect nonnledical costs 
relate to production losses in society as a consequence of illness or treatment. The 
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importance of nonmedical costs varies between treatments and patient groups. The studies 
in this thesis are mainly focused on direct medical costs. 
In the Dutch hospitals most information systems do not contain relevant data on direct 
medical costs. Thus, studying patient files was the only way to collect all relevant cost 
data. This method of data collection is very time consuming. Inclusion of the most 
important cost items in case registry forms may simplify the data collection. For example, 
data on type of hospital care, consultations, medication, blood transfusions and outpatient 
visits may be added to the case registry forms. Before starting an add-on economic 
evaluation, the possibilities of such an inclusion may be considered. 
In the near future other methods of data collection will become available. In the future 
hospitals will face more incentives to collect information about the input, process and 
output of treatment programmes. This implies that more attention will be paid to patient 
oriented information systems. These information systems may contain data on number of 
activities and unit prices relevant for economic evaluations. 
Concerning the valuation of resources a clearing house for data on unit prices of the most 
relevant activities in cancer treatment (real prices and/or tariffs) may be helpful. Such a 
database necessitates a yearly update and may be used for several studies. Concerning the 
unit prices, the existing tariffs may be used as far as they represent the real cost price. 
For the most important activities separate cost price studies may have to be carried out. 
From the studies described in this thesis the following cost prices are available: cost of a 
stay on a haematological-, oncological-, isolation care- and intensive care ward per day, 
cost of treatment in a day care department, cost of a haematological outpatient visit, cost 
of bone marrow harvest, cost of the insertion of a catheter and the costs of total body 
irradiation (Appendix A4.3). The results of other cost price studies may be added to such 
database. 
When comparing alternative health care programmes the pattern of costs and benefits may 
differ significantly between options under review. For example, health promotion (e.g. to 
reduce smoking by young people) and preventive health care programmes (e.g. screening 
for breast cancer) produce immediate costs, but benefits will only be realised many years 
later. ABMT may induce high treatment costs, but, if successful, it gives immediate 
benefits to the patient. Long-term maintenance or palliative drug therapy may have 
relatively low annual costs, but in spite of that it may build-up to a substantial amount 
over a lifetime. 
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When long-term costs and consequences are taken into account, simply adding total costs 
and benefits over time is not adequate because people have a time preference for delaying 
costs and bringing forward benefits. There is a consensus that both costs and outcomes 
should be discounted at the appropriate rate when they are measured in monetary terms. 
However, there is a debate currently on-going whether non-monetary benefits, such as life 
years gained, should be discounted at the same rates as costs, not be discounted at all or 
discounted at a reduced rate. In our studies we have discounted both the costs and 
consequences at a discount rate of 5 %. 
The introduction of new technologies often leads to additional costs. The introduction of 
ABMT for patients with haematological malignancies shows that at least savings from 
substitution will occur. At the moment, additional treatment modalities in these patient 
groups are studied. The application of PBPC transplantation seems to be a cheaper 
alternative to ABMT. In the near future, it is also expected that ABMT and PBPC 
transplantations will diffuse across other patient groups. This will lead to additional costs, 
but savings from substitution as well as economies of scale may occur. Scale effects are 
likely if care is standardised and provided on a centralised basis, as is the case with 
ABMT and PBPC transplantation. 
13.4 Gelleralisabilily of results 
The generalisability of our results is somewhat limited due to several reasons. Clinical 
trials attempt to demonstrate validly the efficacy of a technology. Therefore, a long list of 
inclusion and exclusion criteria is proposed and treatment guidelines are described in 
detail. The more specifically these criteria are defined, the better the study will be 
accepted from the viewpoint of reproducibility and reliability, but these criteria may drive 
a clinical trial far from the average clinical practice. Another aspect is the location where 
the trial is carried out. All studies have been carried out in a selective environment, 
namely in haematological intensive care hospitals. In general, such a selective environ-
ment makes it impossible to generalise study results to the average clinical practice. How-
ever, stem cell transplantations and intensive chemotherapy in patients with AML will not 
be carried out in each hospital and treatment protocols are rather standardised in the 
haematological intensive care hospitals. Thus, the costs of these treatments will hardly 
differ between these hospitals and therefore the results can be generalised to all 
haematological intensive care hospitals. 
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The generalisability of the results of GM-CSF administration in patients with chemo-
therapy-induced fever and neutropenia may cause more problems, as these patients are 
also treated in regional hospitals. Treatment protocols, criteria for discharge from hospital 
and antibiotic regimes vary considerably between hospitals. Moreover, the prices of 
health care services, especially the hospital cost, will vary between the centres participat-
ing in the study and the regional hospitals. Through sensitivity analyses the impact of 
such variation on the cost-effectiveness of the treatment has been demonstrated. 
Some problems with the generalisability of the results are not specifically related to our 
studies. For example, it is possible that patients participating in clinical trials may be 
more compliant than their counterparts in daily life. Furthermore, clinical researchers 
usually are more competent concerning the specific treatment issues than their colleagues 
in smaller hospitals. Rapid change of costs and benefits over time may invalidate 
conclusions by the time they appear. Moreover, generalisation of the results to other 
countries is not straightforward. Health care organisation and prices will differ, and 
valuation of health care benefits may depend on cross-cultural differences (Van Ineveld et 
al., 1993). In the end, the appreciation of the resulting cost-effectiveness ratio depends on 
the country specific opportunity cost of introducing the new technology. Therefore, in all 
published studies, the patient selection criteria, the treatment modalities, the methods used 
in the measurement and valuation of all costs and consequences must be made clear. Only 
then, policy makers can determine whether the study's results are applicable to their 
policy context, can it help other researchers to avoid duplication of research and can it 
facilitate the extrapolation of the study's results to other settings. 
13.5 Epilogue 
In a recent editorial in the New England Journal of Medicine, it was stated that cost-
effectiveness analyses are usually performed by developing a model of the outcomes of 
alternative treatments (Kassirer and Angell, 1994). Such a model is usually based on 
published data. In contrast, this thesis reports three prospective economic appraisals 
linked to phase III, randomised clinical trials. In our experience, these "piggyback" 
economic analyses in cancer research are very well feasible. 
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Additional modelling has been applied, because in economic evaluation all consequences 
regardless of the time frame of the study should be considered. Lifelong costs and 
consequences will not be observed, except for patients with either complete disease-free 
survival or death within the study follow-up period. Therefore, modelling approaches are 
often required to calculate lifelong costs and consequences. 
In the editorial mentioned above, it was further stated that the model specifications vary 
substantially. Standardisation of methods used, specification of the assumptions made and 
detailed presentation of costs and corresponding unit prices, will minimise the most 
important sources of bias. In the hospital economic model, the treatment modalities, 
probabilities, treatment outcomes and unit costs are described in detail and can be applied 
to any hospital in any country, regardless of practice patterns as hospital and lor country 
specific data could be used. "Piggyback" economic analyses have great potential to reduce 
bias due to patient selection and selection of methods when these are a priori specified in 
a protocol for both the clinical and economic data collection and analysis. 
Another source of bias may be caused by contlict of interest. Conflict of interests may 
arise as professional judgements concerning a primary interest (for example patient's 
welfare, validity and integrity of research) tend to be unduly intluenced by a secondary 
interest, for example financial gain or a desire for prestige and power (Thompson, 1993). 
However, the secondary interest is not iIlegimate in itself. One should prevent these 
secondary factors from dominating the relevant primary interest. Therefore, clinical- and 
economic investigators must have independence regarding methodological considerations 
at all stages of the study, and must have freedom of publication at all time. 
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Summary 
This thesis aims at contributing to decision making concerning the introduction of new 
technologies in cancer treatment through economic evaluation. Economic evaluation is a 
comparative analysis of alternatives in te1ms of both their costs and consequences. 
Therefore, the basic task of economic evaluation is to identify, measure, value and 
compare the costs and effects of the alternatives being considered. In Part I, the metho-
dology of economic evaluation in general and of economic evaluation in cancer in specific 
is reviewed and practical issues are illuminated. Chapter 2 discusses basic methods of 
economic evaluation, the way of measuring and valuing effectiveness and resources and, 
finally, current practice of economic evaluation by reviewing screening and lung cancer. 
Chapter 3 also concerns methodological and practical issues, but it focuses on economic 
evaluation alongside cancer trials. In the treatment of cancer patients not only survival 
and disease-free survival are important outcome parameters, but also the quality of years 
alive. In Chapter 4, specific attention is given to the measurement and valuation of quality 
of life. 
Subsequently, economic evaluation is applied in several new cancer treatment modalities. 
In Part II the results of three retrospective cost-minimisation analyses are presented. 
Chapter 5 deals with autologous bone marrow transplantation (ABMT) in patients with 
non-Hodgkin's lymphoma (NHL) and acute leukaemia. The cost of ABMT in patients 
with NHL amounted to about US$ 35220. Patients with acute leukaemia stayed longer in 
hospital and needed more supportive care. ABMT in this patient group cos ted about US$ 
48000 per patient. 
Chapter 6 concerns patients with haematological or oncological malignancies. The patients 
received either ABMT with granulocyte colony-stimulating factor (G-CSF; filgrastim; 
Neupogen"') or without G-CSF or alternatively, peripheral blood progenitor cell (PBPC) 
transplantation mobilised by G-CSF. The accelerated haematopoietic recovery in the 
193 
Summary 
PBPC group as compared with the ABMT groups, was associated with a reduction in 
blood transfusions, with a reduction in episodes of fever and with earlier discharge from 
the hospital. This resulted in the average costs per treatment of the PBPC group amount-
ing to US$ 21197 and in the ABMT groups to US$ 30593 (without G-CSF) and to US$ 
32443 (with G-CSF). 
In Chapter 7, the treatment costs of patients with multiple myeloma were calculated. The 
patients received either high-dose melphalan combined with or without G-CSF afterwards, 
or alternatively, PBPC mobilised by G-CSF following high-dose melphalan. Compared to 
the conventional treatment with melphalan, the PBPC group showed a shortening of the 
pancytopenic period and platelet recovery. This resulted in a cost reduction of 44 % when 
changing to PBPC reinfusion (on average US$ 32223 in the control group and US$ 17908 
in the PBPC group). 
Part 1II discusses the results of three prospective cost-effectiveness studies. Chapter 8 
deals with a prospective randomised clinical trial with simultaneous data collection for an 
economic appraisal. The study concerns patients with intermediate and high-grade 
malignant NHL, who attained a partial response after three cycles of chemotherapy and 
who had no evidence of bone marrow involvement of NHL. The standard chemotherapy 
group continued with cyclophosphamide, doxorubicin, vincristine and prednisone 
(CHOP). The ABMT group was treated with high-dose chemo-radiotherapy followed by 
ABMT. The overall and disease-free survival at 3 years were 61 % and 60%, respective-
ly, in the ABMT group, and 85% and 77% in the CHOP group (P~NS). In addition, 
there were more (severe) complaints and symptoms in the ABMT group than in the 
CHOP group. Regarding treatment costs, it was shown that the average costs of CHOP 
chemotherapy were significantly lower than the average costs in the ABMT group 
(CHOP: US$ 3118 versus ABMT: US$ 34447). Considering long-term consequences the 
ABMT group was more expensive (US$ 34580) and patients experienced 0.14 life years 
and 0.22 quality adjusted life years less than the CHOP group (discount rate 5%). Based 
on these results, changing therapy from CHOP to ABMT, as primary treatment in slow 
responders to CHOP, should not be recommended. 
Chapter 9 deals with a prospective, randomised clinical trial comparing the costs and 
effects of granulocyte-macrophage colony-stimUlating factor (GM-CSF; molgramostim; 
Leucomax®) as an adjunct to intensive chemotherapy in elderly patients with acute 
myeloid leukaemia (AML). The study was a combined study of the EORTC Leukaemia 
Group and the Dutch HOVON Haemato-Oncology Group. The patients were randomised 
to either daunomycin-cytosine arabinoside (control arm) or daunomycin-cytosine ara-
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binoside wiIh GM-CSF (GM-CSF arm). GM-CSF was given to the second group of 
patients during chemotherapy as well as during the phase of bone marrow suppression 
post chemotherapy. The patients were treated with one, or in case of a partial response, 
wiIh two remission induction cycles, and when a complete remission was attained, they 
received one additional course of consolidation therapy. Complete remission was achieved 
in 46.2% (after induction cycle J) and 57.9% (after cycle II) of the patients in the control 
group and in 50.0% (after the first chemotherapy cycle) and 54.9% (after cycle II) of the 
patients in the GM-CSF group (P=NS). The duration of survival and disease-free 
survival, at 2 years after randomisation were estimated at 26 % and 19 % for the control 
group and 23% and 11% for the GM-CSF group (P=NS). Concerning the time of 
recovery of neutrophils there were significant differences in favour of the GM -CSF 
group. However, the administration of GM-CSF resulted in moderate to severe toxicities 
attributed to GM-CSF. The quality of life analysis showed more problems wiIh regard to 
depressed mood, diarrhoea and rash/eczema. Considering the long-term quality of life 
there were no significant differences between the two groups. Considering a follow-up 
period of 2 years, the cumulative, discounted survival amounted to 0.979 life years for 
the control group and to 1.007 for the GM-CSF group. The quality adjusted survival was 
0.800 for the control group and 0.816 for the GM-CSF group. The average costs of the 
primary treatment were higher in GM-CSF treated patients than in the control group, i.e. 
US$ 40782 and US$ 34465, respectively (P<O.OI). The costs during the follow-up 
period did not differ between the two groups. They averaged about US$ 11000 during the 
first year of follow-up and about US$ 6000 during the second year. The results of this 
randomised clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is 
not a cost-effective treatment strategy as compared wiIh daunomycin-cytosine arabinoside 
alone. 
The third study focuses on patients with chemotherapy-related fever and neutropenia 
(Chapter 10). Neutropenia is a frequent and serious complication of cancer chemotherapy. 
When present in combination with fever, neutropenia often becomes life-threatening, and 
requires additional health care resources. Haematopoietic growth factors (HGFs) reflect a 
new and effective means of treating chemotherapy patients to prevent fever and neutrope-
nia. The use of HGFs may reduce the duration and/or severity of neutropenia. Also, the 
administration of HGFs may lead to significant cost savings, by reducing the stay in 
hospital, and may produce quality of life benefits. However, the administration of GM-
CSF did not produce quality of life benefits as compared with placebo. The median 
hospitalisation period of the patients who received GM-CSF was 6 days (mean: 7.25; 
range: 3-14). The patients treated wiIh placebo had a hospital stay of 7 days (mean: 8.33; 
range: 4-14). The median total treatment costs amounted to US$ 4140 (mean: US$ 5180; 
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range: US$ 1710 - US$ 14270) in the GM-CSF group and to US$ 3590 (mean: 4180; 
range: US$ 1680 - US$ 11450) in the placebo group. This difference is significant 
(P<0.05) and mainly due to the additional cost of GM-CSF. 
The implementation of ABMT and HGFs in the clinical practice may have major macro-
and microeconomic consequences. In Chapter 11, the extra costs of introducing ABMT in 
the treatment of patients with malignant lymphoma and acute myeloid leukaemia in the 
Netherlands are assessed. In the Netherlands, the total number of ABMTs per year in 
these patient groups was estimated at 230; 180 in the NHL group and 50 in the AML 
group. The extra costs of introducing ABMT in the NHL group will vary between 4.94 
and 6.68 million dollars and in the AML group these costs were estimated at 2.95 million 
dollars. As a result, the total extra costs of introducing ABMTs are expected to be 
between 7.89 and 9.63 million dollar. 
The costs of introducing HGFs in the clinical practice are presented by a Markov type 
economic model for the hospital, which calculates all relevant direct costs and savings of 
HGF therapy and may support decisions on HGF administration (Chapter 12). Three 
categories of treatment choices are presented: a. a treatment option where HGFs are 
administered during intensive chemotherapy schedules, b. a prophylactic option where 
HGFs are administered during and after standard chemotherapy cycles, and c. HGF 
therapy in patients with chemotherapy induced fever and neutropenia. Our results indicate 
that HGFs can induce savings in intensive chemotherapy and standard chemotherapy 
following neutropenic fever. Prophylactic administration of HGF is cost-effective if the 
risk of infection is considerable. The risk of infection depends on underlying malignancy, 
corresponding treatment modalities and the health condition of the patient. The model is 
meant as an analytical framework and should be used carefully, as not all benefits (e.g. 
benefits to the patients) are considered. These benefits may be balanced against the 
additional costs or savings resulting from the economic model. 
Chapter 13 concludes with a discussion and with reconunendations for further research. 
Economic evaluation is intended to support health policy at different levels of decision 
making. Using results of economic evaluations in health policy requires that the methods 
used and the way in which costs and consequences are measured and valued must be 
made clear. In this respect standardisation of methods is important. Finally, issues 
concerning the generalis ability of the study results are described. 
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Samenvatting 
Dit proefschrift heeft als doe I een bijdrage te leveren aan besluitvonning omtrent de 
introductie van nieuwe kankerbehandelingen door middel van economische evaluatie. 
Economische evaluatie is een vergelijkende analyse in termen van kosten en opbrengsten. 
Hiervoor is identificatie, meting, waardering en vergelijking van de kosten en effecten 
noodzakelijk. In deel I wordt de me thodologie van economische evaluatie in het algemeen 
en van kankerbehandelingen in het bijzonder uiteengezet en worden practische problemen 
beschreven. Hoofdstuk 2 beschrijft de verschillende method en van economische evaluatie, 
welke kosten en effecten in een dergelijke evaluatie meegenomen dienen te worden, hoe 
de kosten en effecten gewaardeerd dienen te worden en vervolgens de toepassing bij 
screening en longkanker. In hoofdstuk 3 worden eveneens methodologische en practische 
issues behandeld. In dit hoofdstuk ligt de nadruk echter meer op economische evaluaties 
die gekoppeld zijn aan klinische studies. Bij het behandelen van kankelpatienten is 
behalve (ziektevrije) overleving ook kwaliteit van leven een belangrijke uitkomstmaat. In 
hoofdstuk 4 wordt hier speciale aandacht aan geschonken. 
Vervolgens is een aantal economise he evaluaties van kankerbehandelingen uitgevoerd. In 
dee I II worden de resultaten beschreven van drie retrospectieve kosten-minimeringsanaly-
ses. Hoofdstuk 5 heeft betrekking op patienten met non-Hodgkin's lymphoma en acute 
leukemie die een autologe beenmergtransplantatie (ABMT) ondergaan. De kosten van een 
ABMT bij patienten met non-Hodgkin's lymphoma bedroegen US$ 35220 per patient. De 
kosten van ABMT's bij acute leukemie patienten lagen beduidend hoger. Deze patienten 
lagen in het algemeen langer in het ziekenhuis en behoefden meer isolatie, meer transfu-
sies en meer antibiotica. De kosten voor deze groep werden geschat op US$ 48000. 
Hoofdstuk 6 heeft betrekking op patienten met een hematologische- of oncologische 
maligne aandoening. De behandelingsmodaliteiten waren ABMT met of zander granulocyt 
kolonie-stimulerende factor (G-CSF; filgrastim; Neupogen®) en perifere stamceltransplan-
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tatie (PSCT) in combinatie met G-CSF. Het hematologische herstel in de PSCT groep in 
vergelijking met de beide ABMT groepen, ging gepaard met een reductie in bloedtransfu-
sies, koorts episoden en verpleegdagen. Dit resulteerde in significant lagere gemiddelde 
kosten in de PSCT groep. De gemiddelde kosten in de PSCT groep bedroegen US$ 
21197, in de ABMT groep zonder G-CSF US$ 30593 en in de ABMT groep met G-CSF 
US$ 32443. 
In hoofdstuk 7 zijn de behandelingskosten van patienten met mUltiple myeloma berekend. 
Deze patienten werden behandeld met hoge dosis melphalan soms in combinatie met G-
CSF of met PSCT plus G-CSF na hoge dosis melphalan. De PSCT groep had in vergelij-
king met de conventionele behandelingsmethode een beduidend kortere pancytopenische 
periode en een sneller hers tel van de bloedplaatjes. Dit resulteerde in een kostenreductie 
van 44% van PSCT ten opzichte van de conventionele behandeling met melphalan. De 
gemiddelde kosten in de conventionele groep bedroegen US$ 32223 en in de PSCT groep 
US$ 17908 . 
Deel III behandelt de resultaten van drie prospectieve kosten-effectiviteitsstudies. 
Hoofdstuk 8 beschrijft een prospectief gerandomiseerd klinisch onderzoek waaraan een 
economische evaluatie is gekoppeld. De studie heeft betrekking op patienten met non-
Hodgkin's lymphoma van hoge en intermediaire maligniteitsgraad die na drie kuren 
conventionele chemotherapie (CHOP) een partiele remissie hebben bereikt en wier 
beenmerg tumorvrij is. Het doel van deze studie is het bepalen van de kosten en effecten 
van ABMT en intensieve chemotherapie in vergelUking met de conventionele behandeling 
bij patienten lijdend aan NHL. De conventionele behandeling bestond uit cyclofosfamide, 
doxorubicin, vincristine en prednison (CHOP). De ABMT groep werd behandeld met 
hoge dosis chemo-radiotherapie gevolgd door ABMT. De drie-jaars overleving in de 
ABMT groep bedroeg 60% en in de CHOP groep 77%. Drie jaar na de randomisatie 
bedroeg de ziektevrije overleving 61 % in de ABMT groep en 85%% in de CHOP groep. 
De verschillen zijn niet significant. In het algemeen hadden de ABMT patienten meer 
klachten en symptomen dan de patienten die met CHOP werden behandeld. Met betrek-
king tot de kosten van beide behandelingen was de ABMT groep significant duurder dan 
de CHOP groep. De ABMT groep kostte gemiddeld US$ 34447 en de CHOP groep US$ 
3118. Indien een follow-up van twee jaar en een disconteringsvoet van 5% in ogenschouw 
worden genomen, dan was de ABMT groep gemiddeld US$ 34580 per patient duurder 
dan de CHOP groep. Tevens hadden de ABMT patienten 0.14 levensjaren en 0.22 voor 
kwaliteit gecorrigeerde levensjaren minder dan de CHOP patienten. Samenvattend kan 
geconcludeerd worden dat de CHOP behandeling de meest kosten-effectieve behandeling 
is voor patienten met non-Hodgkin's lymphoma van hoge en intermediaire maligni-
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teitsgraad die na drie kuren conventionele chemotherapie (CHOP) een partiele remissie 
hebben bereikt. 
Hoofdstuk 9 behandelt een prospectieve, gerandomiseerde klinische studie die de kosten 
en effecten van granulocyt-macrofaag kolonie-stimulerende factor (GM-CSF; molgra-
mostim; Leucomax"') gedurende en na intensieve chemotherapie bij oudere patienten met 
acute myelolde leukemie (AML) onderzoekt. De studie was een gecombineerde studie van 
de EORTC Leukaemia Group en de HOVON. De patienten werden gerandomiseerd voor 
daunomycine-cytosine arabinoside (controle arm) of daunomycine-cytosine arabinoside 
met GM-CSF (GM-CSF arm). GM-CSF werd toegediend gedurende de chemotherapie en 
gedurende de aplastische fase. Aile patienten kregen een remissie inductie kuur en indien 
ze een partiele respons hadden twee remissie inductie kuren. Indien een complete remissie 
werd bereikt, kregen de patienten een extra consolidatie kuur. Een complete remissie 
werd bereikt in 46.2% (na inductie kuur I) en 57.9% (na kuur II) in de controle groep en 
in 50.0% (na de eerste inductie kuur) en 54.9% (na kuur II) van de patienten in de GM-
CSF groep (P=NS). De twee-jaars overleving en ziektevrije overleving na de random is a-
tie bedroegen respectievelijk 26% en 19% in de controle groep en respectievelijk 23% en 
11 % in de GM-CSF groep (P=NS). Met betrekking tot het hematologisch herstel waren 
er significante verschillen ten gunste van de GM-CSF toediening. Verder leidde de GM-
CSF toediening tot meer toxiciteit. De kwaliteit van leven analyse toonde meer problemen 
met betrekking tot neerslachtigheid, diarree en huiduitslag in de GM-CSF groep dan in de 
controle groep. Ten aanzien van de kwaliteit van leven op de lange termijn waren er geen 
verschillen tussen de beide groepen. De twee-jaars, cumulatieve overleving bedroeg 0.979 
levensjaren in de controle groep en 1.007 in de GM-CSF groep. De voor kwaliteit 
gecorrigeerde levensjaren waren 0.800 in de controle groep en 0.816 in de GM-CSF 
groep (disconteringsvoet = 5%). De gemiddelde behandelingskosten lagen hoger bij de 
met GM-CSF behandelde patienten dan bij de controle groep, te weten respectievelijk 
US$ 40782 en US$ 34465 (P<O.OI). De kosten gedurende de follow-up periode 
verschilden niet tussen de beide groepen. In het eerste jaar bedroegen de kosten van 
follow-up gemiddeld US$ 11000 en gedurende het tweede jaar ongeveer US$ 6000. 
Geconcludeerd kan worden dat daunomycine-cytosine arabinoside plus GM-CSF geen 
kosten-effectieve behandeling is in vergelijking met aileen daunomycine-cytosine arabino-
side bij oudere patienten met AML. 
Hoofdstuk 10 beschrijft patienten met chemotherapie gerelateerde koorts en neutropenie. 
Neutropenie is een frequent voorkomend en ernstige complicatie van chemotherapie. 
Indien de neutropenie gepaard gaat met koorts dan kan het een levensbedreigende 
complicatie zijn en vereist additionele behandeling met antibiotica. Hematopoietische 
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groeifactoren zijn nieuwe middelen voor chemotherapie patienten om febriele neutropenie 
te voorkomen. HGF's kunnen de duur van de neutropenie verkorten. Derhalve kan HGF 
toediening leiden tot kostenbesparingen ten gevolge van een korter verblijf in het 
ziekenhuis en kan het "kwaliteit van leven" verbeteren. Het onderzoek is uitgevoerd bij 
patienten met koorts en neutropenie na chemotherapie die opgenomen moesten worden 
voor deze complicatie. De behandeling bestond uit het geven van breedspectrnm antibioti-
ca en de hematopoietische groeifactor GM-CSF of placebo. Dit werd minimaal 4 en 
maximaal 14 dagen toegediend. De behandeling werd gestaakt als gedurende 48 uur de 
temperatuur genOlmaliseerd was « 37.5°C) en het neutrofielen aantal gestegen was tot 
IxlO'/! of hoger. Vervolgens zijn de patienten 24 uur geobserveerd waarna ontslag 
volgde. Eveneens werd de behandeling met GM-CSF of placebo gestaakt als patienten een 
leucocyten aantal van IOxIO'/! of hoger ontwikkelden. In deze situatie werd de antibiotica 
behandeling gecontinueerd tot het moment dat de koorts gedurende 48 uur genormaliseerd 
was. De mediane opnameduur bedroeg 6 dagen in de GM-CSF groep (gemiddelde: 7.25; 
range: 3-14) en 7 dagen in de placebo groep (gemiddelde: 8.33; range: 4-14). De 
mediane totale behandelingskosten bedroegen US$ 4140 (gemiddelde: US$ 5180; range: 
US$ 1710 - US$ 14270) in de GM-CSF groep en US$ 3590 (gemiddelde: US$ 4180; 
range: US$ 1680 - US$ 11450) in de placebo groep. Dit verschil is significant en in het 
voordeel Van de placebo behandeling. Het verschil wordt echter hoofdzakelijk veroorzaakt 
door de additionele kosten van GM-CSF. 
Deel IV beschrijft de implementatie van ABMT en HGF's. De implementatie van deze 
twee technologieen in de klinische praktijk kunnen belangrijke macro- en microeconomi-
sche gevolgen hebben. De extra kosten die de introductie van ABMT in de behandeling 
van patienten met maligne lymphoma en acute myeloide leukemie in Nederland met zich 
meebrengt, zijn berekend (Hoofdstuk 11). In Nederland worden jaarlijks ongeveer 230 
ABMT's uitgevoerd: 180 bij patienten met non-Hodgkin's lymfoma en 50 bij patienten 
met acute myeloide leukemie. De extra kosten die de introductie van ABMT bij de NHL 
patienten genereren varieren tussen de 4.94 en 6.68 miljoen dollar. Deze kosten bedragen 
ongeveer 2.95 miljoen dollar in de AML groep. Dit resulteert in extra kosten ten gevolge 
van de introductie van ABMT's van 7.89 tot 9.63 miljoen guldens voor deze patienten-
groepen. 
De kosten van de introductie van HGF's in de klinische praktijk worden beschreven aan 
de hand van een Markov-achtig ziekenhuis economisch model (Hoofdstuk 12). Dit model 
berekent de belangrijkste directe kosten en besparingen die ten gevolge van HGF therapie 
optreden en kan besluitvomling met betrekking tot de toepassing van HGF therapie 
ondersteunen. Hierbij wordt onderscheid gemaakt tussen drie categorieen, te weten a. een 
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behandeloptie waarbij HGF's na hoge dosis chemotherapie worden toegediend, b. een 
profylactische behandeloptie waarbij HGF's na standaard ehemotherapie worden toege-
diend, en c. HGF therapie bij patienten met een febriele neutropenie. De resultaten geven 
aan dat HGF therapie besparingen kunnen opleveren bij patienten die intensieve chemo-
therapie ontvangen en bij patienten die chemotherapie gerelateerde koorts en neutropenie 
hebben. In de profylactische strategie was de HGF therapie kosten-effeetief, indien de 
kans op koorts en neutropenie hoog is. De kans op infeetie hangt onder andere af van de 
onderliggende maligniteit, de daarmee samenhangende behandelingsmodaliteiten en de 
gezondheidstoestand van de patient. Het model is bedoeld als analytisch kader en dient 
zorgvuldig gebruikt te worden, aangezien niet aile baten (denk bijvoorbeeld aan baten 
voor de patient) in acht genomen worden. Deze baten dienen afgewogen te worden tegen 
de additionele kosten of besparingen die het model berekent. 
Hoofdstuk 13 besluit met een discussie en aanbevelingen voor toekomstig onderzoek. 
Economische evaluatie heeft als doel het ondersteunen van besluitvorming. Om de 
resultaten van economise he evaluaties te kunnen gebruiken voor gezondheidszorgbeleid is 
het van belang dat de gehanteerde methaden tel' berekening van de kosten en opbrengsten 
duidelijk zijn. Standaardisatie van methoden om kosten en opbrengsten te meten en te 
waarderen is hierbij van belang. Tot slot wordt ingegaan op de mogelijkheden en 
beperkingen am de resultaten van de genoemde onderzoeken te generaliseren. 
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ABMT 
AML 
Ara-C 
BM 
CBA 
CCT 
CEA 
CHOP 
CMA 
CR 
CVA 
DNR 
EE 
G-CSF 
GM-CSF 
hr 
HGF 
HOVON 
NHL 
p 
PBPC 
PSCT 
PO 
PR 
QALY 
QoL 
At 
List of abbreviations 
Autologous bone malTow transplantation 
Acute myeloid leukaemia 
Cytosine arabinoside 
Bone marrow 
Cost-benefit analysis 
Controlled clinical trial 
Cost-effectiveness analysis 
Cyclophosphamide, doxorubicin, vincristine, prednisone 
Cost-minimisation analysis 
Complete remission 
Cost-utility analysis 
Daunomycin 
Economic evaluation 
Granulocyte colony-stimulating factor 
Granulocyte-macrophage colony-stimulating factor 
hour 
Haematopoietic growth factor 
Dutch Cooperative Group on Haemato-Oncology 
Non-Hodgkin's lymphoma 
probability 
Peripheral blood progenitor cell 
Peripheral stem cell transplantation 
Progressive disease 
Partial remission 
Quality adjusted life year 
Quality of life 
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se 
SCT 
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standard error 
Stem cell transplantation 
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Quality of life questionnaires: 
A.3.1 
A.3.2 
A.3.3 
A.3.1 
Nottingham Health Profile 
EuroQol 
Rotterdam Symptom Checklist 
Nottingham Health Profile 
A3 
Quality of life questionnaires 
Listed below are some problems which people may have in their daily life. Look down the list and 
put a tick in the box under yes for any problem you experienced during the last week. Tick the 
box under no for any problem you didn't experience. The problems may resemble each olher, but 
there are different nonetheless. Will you please answer every question. If you are not sure 
whether to say yes or no, tick whichever answer you think is more true at the moment. 
Yes No 
I'm tired all the time 0 0 
2 I have pain at night 0 0 
3 Things are getting me down 0 0 
4 I have unbearable pain 0 0 
5 I take tablets to help me sleep 0 0 
6 I've forgotten what it's like to enjoy myself 0 0 
7 I'm feeling on edge 0 0 
8 I find it painful to change position 0 0 
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Yes No 
9 I feel lonely 0 0 
10 I can only walk about indoors 0 0 
11 I find it hard to bend 0 0 
12 Everything is an effort 0 0 
13 I'm waking up in the early hours of the morning 0 0 
14 I'm unable to walk at all 0 0 
15 I'm finding it hard to make contact with people 0 0 
16 The days seem to drag 0 0 
17 I have trouble getting up and down stairs and steps 0 0 
18 I find it hard to reach for things 0 0 
19 I'm in pain when I walk 0 0 
20 I lose my temper easily these days 0 0 
21 I feel there is nobody I am close to 0 0 
22 I lie awake for most of the night 0 0 
23 I feel as if I'm losing control 0 0 
24 I'm in pain when I'm standing 0 0 
25 I find it hard to dress myself 0 0 
26 I soon run out of energy 0 0 
27 I find it hard to stand for long 0 0 
(e.g. at the kitchen sink, waiting for a bus) 
28 I'm in constant pain 0 0 
29 I feel I am a burden to people 0 0 
30 It takes me a long time to get to sleep 0 0 
31 Worry is keeping me awake at night 0 0 
32 I feel that life is not worth living 0 0 
33 I sleep badly at night 0 0 
34 I'm finding it hard to get on with people 0 0 
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A3 Quality of life questionnaires 
Yes No 
35 I need help to walk about outside 0 0 
(e.g. a walking aid or someone to support me) 
36 I'm in pain when going up and down stairs or steps 0 0 
37 I wake up feeling depressed 0 0 
38 1'm in pain when I'm sitting 0 0 
Now we would like you to think about the activities in your life which may be affected by health 
problems. 
In the list below, tick yes for each activity in your life which is being affected by your state of 
health. Tick no for each activity which is not being affected. 
When you are not sure or when you do not want to answer the question ... please tick the box 
under the question remark ... ("?") 
Is your present state of health causing problems with your ... 
Yes ? No 
39 Job or work (that is, paid employment) 0 0 0 
40 Looking after the home (examples: cleaning & 0 0 0 
cooking, repairs, odd jobs around the home) 
41 Social life 0 0 0 
42 Home life (that is, relationships with other 0 0 0 
people in your home) 
43 Sex life 0 0 0 
44 Interests and hobbies (sports etc.) 0 0 0 
45 Holidays 0 0 0 
A.3.2 EuroQo/ descriptive part 
By placing a tick in one box in each group below, please indicate which statements best describe 
your own health state during the last week. 
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46 Mobility 
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed 
47 Self-care 
I have no problems washing or dressing myself 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
48 Usual aClh'ilies (e.g. work, study, housework, 
falllily or leislire activities) 
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
49 Paill/Discolllfort 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
50 Amiety/Depressioll 
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
A,3,3 Rotterdalll SYlllptolll Checklist 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
In the list below you will be asked about your symptoms, Would you please, for all symptoms 
mentioned, indicate to what extent you have been bothered by it, by circling the answer most 
applicable to you, The questions are related to the past week, 
Have you, during the past week, been bothered by 
Not at all 
51 Lack of appetite 
52 Irritability 
53 Tiredness 
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o 
o 
o 
A little 
o 
o 
o 
Quite a bit 
o 
o 
o 
Very much 
o 
o 
o 
A3 Quality of life questionnaires 
Not at all A Iitlle Quite a bit Very much 
54 Worrying 0 0 0 0 
55 Sore muscles 0 0 0 0 
56 Depressed mood 0 0 0 0 
57 Lack of energy 0 0 0 0 
58 Low back pain 0 0 0 0 
59 Nervousness 0 0 0 0 
60 Nausea 0 0 0 0 
61 Desperate feelings 0 0 0 0 
about the future 
62 Difficulty sleeping 0 0 0 0 
63 Headaches 0 0 0 0 
64 Vomiting 0 0 0 0 
65 Dizziness 0 0 0 0 
66 Decreased sexual interest 0 0 0 0 
67 Tension 0 0 0 0 
68 Abdominal aches 0 0 0 0 
69 Anxiety 0 0 0 0 
70 Constipation 0 0 0 0 
71 Diarrhoea 0 0 0 0 
72 Shivering 0 0 0 0 
73 Tingling hands or feet 0 0 0 0 
74 Difficulty concentrating 0 0 0 0 
75 Sore mouth/ pain when 0 0 0 0 
swalJowing 
76 Loss of hair 0 0 0 0 
77 Burning/sore eyes 0 0 0 0 
78 Shortness of breath 0 0 0 0 
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Not at all A little Quite a bit Very much 
79 Dry mouth 0 0 0 0 
80 Constipation 0 0 0 0 
81 Painful joints" 0 0 0 0 
82 Palpitations . 0 0 0 0 
83 Rash, eczema 0 0 0 0 
84 Sweating, perspiring . 0 0 0 0 
Finally, a number of activities is listed below. We do not want to know whether you actually do 
these, but only whether you are able to perform them presently. 
answer that applies most to your condition of the past week, 
unable only with 
help 
85 Care for myself (wash etc.) 0 0 
86 Walk about the house 0 0 
87 Housekeeping 0 0 
88 Climb stairs 0 0 
89 Odd jobs 0 0 
90 Walk out of doors 0 0 
91 Shopping 0 0 
92 Go to work 0 0 
Would you please check whether you answered all questions? 
Thank you for your help. 
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Would you please mark the 
without without help 
help, 
with 
difficulty 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
A4 
Unit prices 
A4.1 Costs of the pre-trallsplalllatioll period (ill US$) 
Pre~transplantation period Costs 
BM harvest 
- Personnel 689 
- Operating room 543 
- Medical equipment 436 
- Materials 222 
- Quality control BM 152 
Total BM harvest 2042 
Hospitalisation 1367 
Visits 98 
Laboratory services 691 
Diagnostics 714 
Medication 420 
Transfusions 149 
Total pre-trallsplalllatioll 5481 
A4.2 COsis of total body irradiatioll (ill US$) 
TBI Costs 
Per session (10 minutes) 
- Personnel 81 
- Medical equipment 26 
- Other capital expenditures 12 
- Exploitation 28 
SlIbtotal 147 
TB1 = 6 sessiolls (abollt 1 hOllr) 882 
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A4.3 Ullit prices (ill US$) 
Items Unit cost 
Hospital stay: 
~ regular oncological care 290 
- regular haematological care 350 
- protected environment 536 
- intensive care 1223 
Outpatient visit 87 
Day-care departlllelll 134 
Laboratories: 
- Haematology lab (haemoglobin,haematocrit,leucocytes, platelets) 3.58 
_ Biochemistry lab (sodium, potassium, creatinin, glucose) 10.58 
- Urine 1 (pH,glucose,albumin,uro,bilirubin,sediment) 12.47 
- Urine 2 (creatinin,sodium,albumin,tot.protein) 8.71 
- Cultures (blood/urine/sputum) 20.50 
- Virology tests 72.94 
- Cytology (BM/bronchus) 42.59 
Diagnostics: 
- X-ray chest 31 
- X-ray sinus 37 
- EKG 22 
- CT scan 220 
Catheter procedure (Hickman) 504 
Total Parenteral Nutrition 83 
Platelet transfusions 74 
Red cell transfusions 110 
Drugs: 
- CHOP (one course) 258 
_ G-CSF (Neupogen") 300 ~g; GM-CSF (Leucomax") 300 ~g 138 
- G-CSF (Neupogen") 480 I'g 220 
- GM-CSF (Leucomax") 400 ~g 184 
- Antibiotics and other medication: 
e.g. Ceftazidine 2000 mg iv 162 
Ciproxin 400 mg iv 77 
Ciproxin 500 mg oral 7 
Tienam 1500 mg iv 71 
Teicoplanin 400 mg iv 139 
Vancomycin 1000 mg iv 66 
Zofran 8 mg iv 35 
Zovirax 800 mg oral 6 
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